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ABSTRACT 
Fungal infections now contribute significantly to microbe-related morbidity and mortality due 
to there being a limited number of available antifungal agents and limited modes of delivery. 
Over the past two decades, many pathogenic fungi have developed various modes of 
resistance to commonly used antifungals. Thus there is a need for novel antifungal agents 
with novel mechanisms of action. Inhibition of the essential plasma membrane (PM)                   
H+-ATPase of fungi is a potentially effective therapeutic approach in antifungal drug discovery. 
In order to investigate this, three series (A-C) consisting of a total of thirty-three symmetrical 
1,4-diene-3-one (22a-v, 23a-h and 24a-c) compounds have been synthesized.  
In vitro macro-broth susceptibility testing of 1,4-diene-3-ones showed wide range of 
inhibition against Saccharomyces cerevisiae (0.2 - 99%) and Candida albicans (0 - 99%). 
Compounds 22f, 22m, 22n and 22s exhibited highest potency then other compounds from 
the library against S. cerevisiae (IC50 = 1.21, 2.22, 0.62 and 1.87 μM), however these 
compounds demonstrated limited activity against C. albicans (IC50 = 114, 525, 474 and 666 
μM). In contrast, compounds 23f, 23g and 23h exhibited a higher degree of antifungal activity 
against C. albicans (IC50 = 68.5, 57.6 and 50.7 μM) and these compounds also showed good 
potency against S. cerevisiae (IC50 = 8.46, 5.52 and 6.25 μM).  
To gain an understanding about the mechanism of action of 1,4-diene-3-ones, the H+-ATPase 
mediated proton pumping by S. cerevisiae was investigated by measuring the pH of the 
glucose-induced acidification of the external medium. The bis-pyridylidene derivatives of N-
methylpiperidin-4-one (23a-c, 60 µM) were determined to be the most potent inhibitors of 
H+ efflux from S. cerevisiae and the steady state of proton flux from S. cerevisiae was achieved 
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within 10 minutes of medium acidification. A similar result was observed with N-
ethylmaleimide (NEM, 60 µM, positive control). Additionally, 23a, 23b and 23c have shown 
good potency in the macro broth susceptibility assay of S. cerevisiae (IC50 = 12.6, 8.84 and 
9.45 µM). Moreover, the most potent compounds 22n and 23h in macro broth susceptibility 
assay against S. cerevisiae and C. albicans exhibited limited activity to inhibit the proton efflux 
from S. cerevisiae.  
To further elucidate the mechanism of action, preliminary structure-activity relationship 
(SAR) studies was performed. SAR of bis-benzylidene derivatives of N-methylpiperidin-4-one 
displayed reasonable correlation coefficient (R2 = 0.6746) between the inhibitory activity 
expressed as log (1/IC50) and an electronic parameter, the 1H-NMR δ-values of proton on the 
β-carbon. Conversely, SAR of log (1/IC50) and a lipophilic parameter, calculated logP (clogP) of 
bis-benzylidene derivatives of N-methylpiperidin-4-one showed R2 of 0.4138. This indicates 
that the inhibitory activity of compounds is due to the influence of electronic property rather 
than the lipophilic property. In conclusion, the inhibitory action of 1,4-diene-3-ones on yeast 
suggests a membrane-bound enzyme target for its action. It is hypothesized that these 
compounds form a covalent C-S thio-ether bond with cysteine residues of proteins of the 
plasma membrane and eventually inhibit the H+-ATPase. 
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1 General introduction 
1.1 Introduction 
In the recent years, the P-type H+-ATPase enzyme has received significant interest as a target 
for the discovery and development of novel antifungal agents (Monk & Perlin, 1994; Tung et 
al., 2017; Ottilie et al., 2018). The P-type H+-ATPase exhibits a vital role in the maintenance of 
the electrochemical proton gradient which facilitates the uptake of nutrients and ions into 
fungal cells (Monk et al., 1995). The PM H+-ATPase is restricted to fungi, plants, protists (Monk 
et al., 1995) and bacteria such as Lactococcus lactis and Pseudomonas aeruginosa (Andrés & 
Fierro, 2010); which makes this enzyme a potential target for drug discovery and the 
development of novel drugs. The essential role of this enzyme in cell growth and division was 
demonstrated using a Glucose-Galactose promoter exchange experiment by Portillo & 
Serrano, (1989). Additionally in various research articles it has been mentioned that                
α,β-unsaturated carbonyls inhibited the PM H+-ATPase (Manavathu, Vashishtha, Alangaden, 
& Dimmock, 1998; Dao et al., 2016; Kjellerup et al., 2017). In this research work, the 
benzylidene/pyridylidene/thienylidene derivatives of N-methylpiperidin-4-one and 
cycloalkanones were synthesised and tested for their antifungal activity. 
1.2 Fungi 
There are estimated to be more than 1.5 million fungal species in the world (Hawksworth, 
2001). However, only a few hundred are considered pathogenic to humans. Fungi can be 
identified based on their shape, size, structure and nutritional requirements. They are often 
visible as their mature (fruiting) forms such as found in moulds (Moore, 2003). Fungi may be 
either single-celled or multicellular. Unicellular fungi are the yeasts which exist in a planktonic 
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form. However, multicellular fungi comprise networks of long hollow tubes termed hyphae. 
Hyphae are elongated, branched filamentous structures of fungi. Some species of pathogenic 
fungi are dimorphic exhibiting both yeast and mycelial forms of growth e.g. Candida spp. 
whilst other human pathogenic fungi only exist in mycelial form e.g. Aspergillus spp.  (Moore, 
2003).  
In the current taxonomic arrangement, fungi are classified into several phyla based on their 
sexual reproduction, these being Ascomycota, Basidiomycota, Chytridiomycota, 
Deuteromycota and Zygomycota. However in this chapter, only Ascomycota is described 
because the majority of pathogenic fungi belong to this phylum, which is characterised by the 
key structure the ascus, a sac like structure which contains haploid ascospores (Deacon, 
2013). Many ascomycetes (e.g. Saccharomyces species) are used commercially in 
fermentation process to produce bread, beer or wine (Walker et al., 2014) and some are used 
in the production of antibiotics (e.g. Penicillium species) to treat various bacterial infections 
(Li et al., 2019). However, some ascomycetes are pathogenic, which can cause infections e.g. 
species of Candida, Aspergillus, and Trichoderma (Deacon, 2013). Additionally, some species 
of ascomycetes are used as model organisms in laboratory research including S. cerevisiae 
(example of non-pathogenic yeast) and C. albicans (pathogenic yeast). Therefore, in the later 
section the genera Saccharomyces and Candida are describe in more detail.  
1.2.1 The genus Saccharomyces  
The genus Saccharomyces contains several species of yeasts including S. cerevisiae               
(Figure 1.1), S. pastorianus, S. eubayanus, S. cariocus, etc. (Buckley, 1989). Although non-
pathogenic some of these are opportunistic pathogens, particularly in individuals who are 
significantly immunocompromised (Pérez-Torrado & Querol, 2016). S. cerevisiae is the most 
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extensively studied yeast in terms of both its molecular and cell biology, and biochemistry. 
The yeast S. cerevisiae can easily be grown, and the maintenance of mutant strains is also 
relatively easy compared to other fungi (Cherry et al., 2012). A significant reason for the use 
of S. cerevisiae is that it is available in both haploid and diploid variants. Thus the generation 
of mutant strains is relatively simple unlike other yeasts such as Candida spp., which are 
generally believed to be obligate diploid (Odds, 1988).   
 
Figure 1. 1. Electron micrograph view of S. cerevisiae cells. 
The cells of S. cerevisiae are round or ovoid in shape with their size being about 5-10 μm in 
diameter. S. cerevisiae cells reproduce by the budding process. Cytokinesis facilitates                           
S. cerevisiae cells to divide into two daughter cells by producing bud scars. Image is taken 
from Milo & Phillips, (2015). 
 
Model organisms are useful for research since they offer a framework on which methods can 
be developed and standardized. Karathia, Vilaprinyo, Sorribas, & Alves, (2011) have compared 
S. cerevisiae with 704 other organisms from various phyla and suggested that S. cerevisiae is 
a good model organism to study various biological processes. Study using a model organism 
can provide a framework on which methods can be developed and standardised and 
compared to species, which are difficult to study. Additionally, model organisms are chosen 
as they are often considered representative of living beings. S. cerevisiae is one of the most 
commonly used eukaryotic model organisms and has been used in studies of the regulation 
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of gene expression, cell ageing, signal transduction, metabolism, cell cycle activity, apoptosis 
and various other biological processes (Karathia et al., 2011).  
1.2.2 The genus Candida 
The genus Candida is composed of a diverse group of species of yeast in which the cells 
commonly vary in shape. There are presently 166 species allocated to the genus Candida 
(Sullivan et al., 1996) although this number continues to rise. The different species of Candida 
can be characterised on the basis of their biochemical, physiological or morphological 
properties (Lehmann, Lin, & Lasker, 1992). Identification of the genus Candida by physical 
profile includes analysis of cell wall properties, the ability to produce: germ tubes, true hyphae 
or pseudohyphae, chlamydospores; and by physiological profiles such as the capacity to 
consume a range of compounds as a single source of nitrogen or carbon (Kim et al., 2002). 
Candidal species can also be differentiated based variously on DNA fingerprinting, DNA-DNA 
re-association, and Southern blot analyses (Lehmann et al., 1992). 
In the 1990s, several research groups studied diverse features of yeasts such as C. albicans. 
By 1996, the genomic sequence of this pathogen was completed with more than 80% of             
C. albicans genes being similar to S. cerevisiae (Kabir, Hussain, & Ahmad, 2012). A eukaryotic 
pathogen, in nature C. albicans exists genetically as a diploid, and exhibits morphologically 
dimorphic forms of growth in response to diverse environmental conditions and signals 
(Moore, 2003). C. albicans is generally a harmless endosymbiont of human epithelial tissues. 
However it can rapidly adapt to changes in the host’s environment even though nutrient 
bioavailability may be  limited and develop into a significant pathological infection (Sexton, 
Brown, & Johnston, 2007).  
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1.3 Fungal infections  
In recent years, the incidence of fungal infections has increased significantly particularly in 
immunocompromised patients such as individuals on prolonged cancer chemotherapy or 
patients having undergone organ transplantation surgery (Neelofar et al., 2011; Brown et al., 
2012). Such fungal infections can be described as either superficial or invasive (Parker, 2009). 
Fungal infections have become widespread in immunocompromised patients and have 
become a significant problem in disease management (Sardi, Scorzoni, Bernardi, Fusco-
Almeida, & Mendes Giannini, 2013). Additionally infections of the bloodstream caused by 
Candida spp. termed candidaemia, is the fourth most recurrent infection in hospitalized 
patients in the USA (Edmond et al., 1999) and the sixth leading cause of bloodstream 
infections in Europe (Canela et al., 2018). It has been reported that more than 90% deaths 
related to fungal infections are due to species belonging to the genera Aspergillus, Candida 
and Cryptococcus (Cowen, Sanglard, Howard, Rogers, & Perlin, 2015).   
During the past 20 years, there has been an expansion of diagnostic methods including the 
immunoassay of specific antigen detection in clinical samples or polymerase chain reaction in 
molecular diagnostics. This had led to better diagnosis of both species and strain identification 
of Candida species and  new strategies to counteract candidaemia (Kozel & Wickes, 2014). 
However, the incidence of candidaemia continuous to increase due to reduced susceptibility 
to azoles and echinocandins in Candida species caused by an increase incidence of resistance 
(Guinea, 2014). 
Species of Candida often cause gastrointestinal, subcutaneous or nasal infections especially 
in immunocompromised individuals (Richardson & Warnock, 2012). Candidal infections in 
immunocompromised individuals can give rise to mortality rates of about 30% (Sexton et al., 
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2007). Certain species of the genus Candida (C. albicans, C. tropicalis, C. glabrata,                             
C. gullemondii, C. krusei and C. parapsilosis) are the most common cause of yeast infections 
worldwide accounting for 62% of cases (Dadar et al., 2018). Although other species are 
increasing in their incidence e.g. Candida auris. Out of the 62% of cases, about 80% of 
Candidal infections are due to C. albicans (because C. albicans is part of our natural 
microflora), whilst a further 12% is accounted for by C. tropicalis. The remaining 8% of fungal 
infections are due to C. krusei and various other species of Candida (Di Santo, 2010).  
1.3.1 Superficial fungal infections 
Superficial fungal infections (SFIs, Figure 1.2) includes superficial candidiasis and 
dermatophytosis which affects tissues such as skin or mucous membranes. Dermatophytic 
fungi usually digest keratin (Ameen, 2010). Infections of the skin, hair or nails caused by the 
genera Trichophyton, Microsporum or Epidermophyton is termed ‘dermatophytosis’ (Hay, 
2017). SFIs can be diagnosed and usually treated with ease using currently available antifungal 
drugs such as (tri)-azoles or allylamines although treatments may require long term (3 – 10 
months) treatment depending on the severity of the infections. Such SFIs affect up to 25% of 
the world’s population and the incidence of such SFIs continues to increase (Ameen, 2010).  
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Figure 1. 2. Various examples of superficial fungal infections. 
Examples of superficial fungal infections. Oral thrush (a) commonly due to Candida spp. 
appears as white spots on the tongue. Ringworm (b) appears as round scaly, swollen, red 
patch on the body due to C. albicans. Nail infection (c) and athlete’s foot (d) infections develop 
due to the moist and warm environment and are commonly caused by Trichophyton spp.  
 
The most common mucosal infection caused by Candida is thrush (which is the appearance 
of white spots on the infected membranes) and is generally observed on oropharyngeal 
mucosa, vaginal mucosa or gastrointestinal epithelial cells (Richardson & Warnock, 2012). 
Oral thrush (Figure 1.2a) is caused by elevated levels of C. albicans that appears as white spots 
on an erythematous background. SFIs also include ringworm of the body (Tinea corporis), nail 
infections (Tinea ungulum), athlete’s foot (Tinea pedis) and ringworm of the groin (Tinea 
cruris). Several topical antifungal drugs are available for the treatment of superficial fungal 
infections including amorolfin or terbinafine (from the allylamine class), and clotrimazole, 
econazole, miconazole or ketoconazole (from the azole class). Fungal nail infections require 
long-term treatment with amorolfin as a topical application normally applied weekly as a 
(a) (b) 
(c) (d) 
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lacour (which may require 6 – 9 months treatment) or systemic treatment with terbinafine 
250 mg daily for 6-12 weeks (Hay, 2017). 
1.3.2 Invasive fungal infections 
The occurrence of opportunistic invasive fungal infections has gradually increased in China 
(Liao, Chen, Thomas, Yang, & Liao, 2013) and across the world predominantly due to 
infections with Candida species (McCarthy, Kontoyiannis, Cornely, Perfect, & Walsh, 2017; 
Pemán & Zaragoza, 2010). Invasive fungal infections (IFIs) have high levels of mortality and 
morbidity, often exhibiting greater than 50% morbidity especially in immunocompromised 
patients, individuals on long-term steroid therapy or chemotherapy and those undergoing 
organ transplantation or blood transfusions (Manavathu, Dimmock, Vashishtha, & 
Chandrasekar, 1999). These individuals are at high risk for many opportunistic fungal 
infections such as aspergillosis, candidiasis, cryptococcosis and pneumocystosis  (Chakrabarti, 
2011).  
IFIs are most commonly caused by species of Candida or Cryptococcus followed by Aspergillus 
or Mucor spp (Kjellerup et al., 2017). The infections caused by C. neoformans, Pneumocystis 
jiroveci, Histoplasma capsulatum and Penicillium marneffei are most commonly reported in 
Africa, Southeast Asia and South America. Individuals suffering from these infections are 
difficult to diagnose and treat due to lack of specificity and sensitivity in the diagnostic 
methods (Kozel & Wickes, 2014). H. capsulatum is the causative agent of a globally distributed 
systemic disease that affects lungs of humans (Mora-Montes & Gacser, 2016). C. neoformans 
often affects immunocompromised individuals whereas Cryptococcus gatti can affect healthy 
individuals however demonstrated a diminished reaction to the central nervous system 
(Mora-Montes & Gacser, 2016). 
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C. auris an emerging fungal pathogen, is responsible for nosocomial invasive infections 
(Bidaud, Chowdhary, & Dannaoui, 2018). A significant outbreak of C. auris infection was 
reported in London’s Cardio-thoracic Center between April 2015 and July 2016 (Schelenz et 
al., 2016). It is difficult to detect C. auris using conventional biochemical methods of detection 
hence its incidence and prevalence rate is not yet available. Due to this, infection with C. auris 
is difficult to treat. Additionally C. auris is resistant to commonly used anti-fungal agents such 
fluconazole. Additionally C. auris has shown variable susceptibility to both amphotericin and 
echinocandins (Chowdhary, Voss, & Meis, 2016). Yeast identification methods currently in use 
in clinical laboratories include molecular matrix-assisted laser desorption/ionisation – time of 
flight mass spectrometry (MALDI-TOF MS), polymerase chain reaction (PCR), sequencing 
analysis and DNA fingerprinting (Bidaud et al., 2018). 
Other diseases such as asthma, an inflammatory disease of the airways, can be aggravated by 
Aspergillus spp. especially Aspergillus niger (Agarwal & Gupta, 2011). In recent years, there 
has been an increase in the incidence of invasive infections caused by filamentous fungi (both 
Aspergillus and non-Aspergillus spp.), particularly in patients suffering from cystic fibrosis 
(Sudfeld, Dasenbrook, Merz, Carroll, & Boyle, 2010). Invasive aspergillosis, usually caused by 
A. fumigatus, which is most commonly reported in patients with compromised immune 
system (Mora-Montes & Gacser, 2016).  
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1.4 Background to antifungal agents and drug targets 
The structure of the fungal cell and the potential sites of action of available antifungal agents 
is shown in Figure 1.3. 
 
Figure 1. 3. Structure of a fungal cell with various antifungal drug targets. 
Schematic outlining the topology of a fungal cell, cell membrane and cell wall. The fungal cell 
wall is composed of chitin, mannoproteins, β-1,3-glucan and β-1,6-glucan. Fungal cell 
membrane composed of a phospholipid bilayer, which contains ergosterol. Ergosterol plays 
an essential role in membrane fluidity and sterol biosynthesis in fungi. Ergosterol and its 
precursor are the key targets for many of the currently available antifungals. Image taken 
from (Ashley, Lewis, Lewis, Martin, & Andes, 2006). 
  
Ergosterol is a sterol found specifically in fungi, particularly (but not exclusively) in the plasma 
and vacuolar membranes of fungi, and is responsible for stabilizing these membranes (Zhang 
et al., 2010) which is in contrast to cholesterol the main steroid found in animal cells, whereas 
phytosterols, brassicasterols and stanosterols, which are found in plant cells. Animal and plant 
sterols have a similar role in membranes to ergosterol in fungi which is to stabilise and 
increase or control the membrane’s rigidity. The biosynthetic pathway of ergosterol is 
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presented in Figure 1.4. Thus the enzymes involved in ergosterol synthesis represent an 
excellent target for the development of anti-fungal drug therapies since most of the enzymes 
involved in the synthesis of ergosterol are unique to fungi (Bhattacharya, Esquivel, & White, 
2018). 
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Figure 1. 4. Biosynthetic pathway of ergosterol. 
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1.4.1 Overview of the classes of currently available antifungal agents 
1.4.1.1 Polyenes and macrolides 
Polyenes are antifungal agents that bind to ergosterol resulting in the destabilisation of the 
fungal plasma membrane. This destabilisation results in the consequent leakage, especially of 
Na+, K+ and H+ ions, which eventually leads to cell death (Sheehan, Hitchcock, & Carol, 1999). 
Examples of polyenes include amphotericin B and nystatin. Since the 1950s, Amphotericin B 
(1) has been considered to be the ‘gold standard’ antifungal therapy when treating severe, 
life-threatening, fungal infections (Groll, De Lucca, & Walsh, 1998). Amphotericin B, originally 
isolated from Streptomyces nodosus, possesses a wide spectrum of antifungal activity. 
Nevertheless, the use of amphotericin B is limited due its narrow therapeutic index, poor oral 
absorption and notorious nephrotoxicity. Consequently the preferred route of administration 
is clinically controlled intravenous infusion (Sheehan et al., 1999).   
 
Figure 1. 5. Structure of Amphotericin B (1). 
 
In the 1950s, nystatin was identified as a further polyene antifungal. Nystatin works in a 
similar fashion to amphotericin B by causing the leakage of ions such as Na+, K+ or H+ ions, 
leading to cell death. Nystatin is not absorbed after oral administration. However it is very 
effective in the treatment of oropharyngeal candidiasis (Kathiravan et al., 2012). Systemic use 
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of nystatin is limited due to adverse effects including itching, burning, irritation, nausea and 
diarrhoea. Other macrolides, such as Candicidin, are used in the topical treatment of 
vulvovaginal candidiasis (Ghannoum & Rice, 1999).  
Until the 1970s, treatment options for systemic fungal infections were limited to either 
griseofulvin or amphotericin B. For invasive fungal infections, the treatment option was 
limited to amphotericin B until 1979. However Flucytosine, a pyrimidine analog originally 
developed as an anti-cancer agent, was introduced in the late 1970s and early 1980s, which 
acts as a prodrug by blocking cell division (Sheehan et al., 1999). Flucytosine is converted to 
5-fluorouracil which is able to inhibit the enzyme thymidylate synthase an enzyme involved 
in the replication of DNA in the fungal cell (Polak & Scholer, 1975). However, flucytosine is 
rarely used due to it rapidly giving rise to drug resistance. It does however continue to be used 
in combination therapies of various types of fungal infections. 
1.4.1.2 Azoles and triazoles 
In the 1970s it was observed that alkyl imidazoles had an antifungal effect, leading to the 
development of various azole containing drugs. The first systemic azoles for the treatment of 
systemic infections were introduced clinically in the 1980s including ketoconazole (2), which 
include two nitrogens in the azole ring and itraconazole which include three nitrogens in the 
azole ring (Groll et al., 1998). Subsequently the azole ring was substituted by a triazole ring, 
the first-generation tri-azoles included itraconazole and fluconazole. Ketoconazole shows a 
wide spectrum of antifungal activity against blastomycosis, candidiasis, coccidioidomycosis, 
paracoccidioidomycosis and histoplasmosis (Shao, Huang, & Hsueh, 2007). Conversely 
itraconazole is effective against Aspergillus spp (Groll et al., 1998). However, there are 
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significant adverse side effects reported with some (tri)azoles such as ketoconazole including 
fatal toxic hepatitis (Kathiravan et al., 2012).  
Cytochrome P450 is found in all biological kingdoms and it is the most commonly 
disseminated CYP gene family (Lepesheva & Waterman, 2004). However therapeutic 
concentrations of azoles have a greater affinity towards fungal P-450DM (cytochrome P-4540-
dependent 14α-sterol demethylase enzyme) than the mammalian sterol-demethylating 
enzyme (Sheehan et al., 1999). Many azoles/triazoles does not cause major problems with 
mammalian CYP although reversible male impotence has been reported in some cases 
(Zakhem, Goldberg, Motosko, Cohen, & Ho, 2019).  
Antifungal azoles inhibit various enzymes in (pathogenic) fungi involved in ergosterol 
synthesis especially the cytochrome P450 enzymes 4α–demethylase, 14α–demethylase and 
sterol-C-24-methyltransferase (Kathiravan et al., 2012). Inhibition of one or more of these 
enzymes leads to the impairment of ergosterol synthesis in fungi (resulting in the 
destabilization of various ionic gradients such as ΔpH, ΔK+ or the electrochemical potential 
due to the protons ΔΨH+). In the 1990s further azole analogues were introduced including 
clotrimazole (3), miconazole (4), econazole (5), fluconazole, voriconazole, posaconazole, 
isavuconazole and ravuconazole (Sheehan et al., 1999). Fluconazole and itraconazole are the 
only two azole drugs which are currently available as oral formulations. Fluconazole has both 
a high water solubility and low affinity for plasma proteins, which makes it a unique antifungal 
agent in the azole class (Andriole, 2000). Fluconazole is used in the treatment of both 
superficial and invasive Candida infections. 
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Figure 1. 6. Structures of azole antifungal agents that includes ketoconazole (2), 
clotrimazole (3), miconazole (4) and econazole (5). 
 
Second-generation triazoles include voriconazole, posaconazole, isavuconazole and 
ravuconazole. Voriconazole is a low molecular weight, water-soluble triazole having a wide 
spectrum of activity and is effective against Aspergillus spp, Candida spp, Fusarium spp. and 
Scedosporium infections (Pemán & Zaragoza, 2010). Posaconazole is a lipophilic antifungal 
triazole, which is effective against Aspergillus, Candida spp, Cryptococcus spp and 
Histoplasma spp. However, there are various common side effects reported with the use of 
posaconazole including: headache, nausea, abdominal pain, vomiting and skin rashes 
(Kathiravan et al., 2012). Ravuconazole has shown a broad spectrum of antifungal activity 
even against some isolates that displayed resistance to fluconazole (Kathiravan et al., 2012). 
The development of this class of antifungal continues with other molecule of this type in 
clinical development. 
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1.4.1.3 Allylamines 
In 1981 the first allylamine, Naftifine (6), underwent clinical trials (Sheehan et al., 1999). 
Allylamines are highly effective against dermatophytic infections. They act by inhibiting the 
enzyme squalene epoxidase, which is required to convert squalene to squalene-2,3-epoxide 
in the ergosterol synthesis pathway. Inhibition of the squalene epoxidase or cyclase system 
results in the cellular concentration of squalene increasing to toxic levels. This results in the 
collapse of the plasma membrane ΔpH. Examples of clinically used allylamines include 
naftifine, terbinafine (7), amorolfine and butenafine.  
 
Figure 1. 7. Structures of allylamines that includes naftifine (6) and terbinafine (7). 
 
Terbinafine exhibited its effectiveness against Aspergillus spp, Fusarium spp and other 
filamentous spp. However it exhibited variable activity against yeasts (Kathiravan et al., 2012). 
Terbinafine is commonly used to treat infections such as ringworm, athlete’s foot or infection 
of toes or fingernails. Terbinafine is currently available as either an oral preparation or as a 
cream or ointment for topical application. Amorolfine is very effective against superficial 
mycosis and is currently available as a nail lacquer. Naftifine was withdrawn from clinical use 
and is not currently available due to its adverse side effects such as stinging, burning or skin 
irritation. 
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1.4.1.4 Echinocandins 
In 2001, a novel class of antifungal agent, first echinocandin, Caspofungin, was introduced 
(Ashley et al., 2006). Subsequent addition to this class includes micafungin, anidulafungin and 
echinocandin-B (8).  
 
Figure 1. 8. Structure of Echinocandin B (8). 
 
Echinocandins inhibit the synthesis of glucan by targeting the enzyme β-(1,3)-glucan synthase, 
a major component in the fungal cell wall. Inhibition of this enzyme leads to disruption of the 
cell wall of the growing cell, causing osmotic instability leading to lysis of susceptible yeast 
cells (Ashley et al., 2006).  This class of compounds were a significant addition to the 
antifungal armoury due to their inhibiting a different enzyme system compared to the (tri)-
azoles. 
Caspofungin is very effective against Aspergillus spp. However it has only moderate activity 
against B. dermatitidis, H. Capsulatum and C. immitis, and has no activity against Fusarium 
spp, Trichosporon spp, C. neoformans, Hyalohyphomycetes or Zygomycetes (Akins, 2005). In 
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addition, they are ineffective against pseudo-fungi due to the different components of the 
cell walls where many pseudo fungal cell walls are made from cellulose (Akins, 2005). A study 
conducted by van Burik et al., (2004) demonstrated that prophylactic treatment with 
micafungin in stem cell transplantation patients during neutropenia displayed better potency 
compared to fluconazole. Additionally, micafungin is very effective in the treatment of 
candidiasis (Kathiravan et al., 2012). 
Echinocandins are considered an effective alternative to azole antifungals due to their 
different mode of action, decreased side effects and having higher fungicidal activity against 
many species of Candida. The fungicidal activity of echinocandins against several Candida 
species makes it an effective alternative for the treatment of azole-resistant strains (Cannon 
& Holmes, 2015).  
Additionally the toxicity profile of echinocandins is significantly lower than many of the 
(tri)azoles (Cannon & Holmes, 2015). This may be due, in part, to the fact they target the 
enzyme involved in the cell wall synthesis and mammalian cells do not contain a homologue 
of this enzyme whereas (tri)azoles may interact with a variety of P450 type enzymes in 
mammalian cells and tissues. Unfortunately, echinocandin has poor oral bioavailability partly 
due to its high molecular weight. Consequently, it can be used only via intravenous 
administration. In addition, there are some side effects associated with echinocandins 
including fever, nausea, vomiting, diarrhoea, rash, phlebitis, headache, hypotension, 
leukopenia and hypokalemia. The use of echinocandins is also limited due to both cost and 
their interactions with antihistamine medications such as diphenhydramine (Ashley et al., 
2006).  
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1.4.1.5 Other antifungal agents 
Other agents having antifungal activity include griseofulvin, nikkomycin, polyoxins, ciclopirox, 
sordarins, tolnaftate and benzoic acid. Griseofulvin inhibits the formation of mitotic spindles 
by inhibition of microtubule polymerization and is effective in the treatment of cutaneous 
mycoses (Sheehan et al., 1999). The main adverse effect of griseofulvin is a headache, 
although it may also cause aplastic anaemia or liver toxicity (Odds, Brown, & Gow, 2003). 
Other compounds under development as clinical agents include nikkomycin and polyoxins 
which are inhibitors of chitin synthesis. Nikkomycin is effective when used in combination 
with caspofungin against A. fumigates. Polyoxins are effective against phytopathogenic fungi 
(Kathiravan et al., 2012). The Sordarins are a group of inhibitors of protein synthesis which 
act by inhibiting fungal translation by impairing the function of the fungal elongation factor 2 
(eF2) (Kathiravan et al., 2012; Chakraborty, Sengupta, & Mukherjee, 2013). 
Ciclopirox is a broad-spectrum antifungal medication, available as a topical solution, which 
exhibits both fungistatic and fungicidal activities due to its high affinity for trivalent cations 
such as Fe3+ or Al3+ (Ghannoum & Rice, 1999). Ciclopirox inhibit the availability of important 
mineral co-factors for proteins or enzymes such as iron for cytochromes or P450 type 
enzymes involved in ergosterol biosynthesis. Ciclopirox thus causes instability in the fungal 
membrane and interferes with amino acid transport across the cell membrane (Piraccini & 
Tosti, 2019). However there are some adverse effects associated with the use of ciclopirox 
including redness of the skin, burning, irritation and swelling at the site of application 
(Ghannoum & Rice, 1999). 
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1.5 Drug resistance in fungi 
Antifungal drug resistance is an ongoing problem in the fight against invasive fungal infections 
(Chakrabarti, 2011). Antifungal resistance is a major concern in individuals with suppressed 
immune system due to extensive use of antifungals, antibiotics and chemotherapy (Sardi et 
al., 2013). The extensive use of antifungal agents and growing numbers of individuals with 
opportunistic infections has led to the development of resistance to currently available 
antifungals (Scorzoni et al., 2017).  Evolution of organisms resistant to multiple example and 
classes of antifungal drugs  especially among Candida species (Cowen et al., 2015). Resistance 
can be categorised in two ways; clinical resistance and in vitro resistance. Clinical resistance 
is defined as the progression of the fungal infection even after administration of adequate 
doses of antifungal drugs. Conversely, in vitro resistance is a laboratory measurement, which 
relates to clinical involvement and the range of fungal species are resistant to antifungal drugs 
(Rogers, 2006).  
In vitro resistance may be sub-divided into primary and secondary resistance. In primary 
resistance, fungi are intrinsically resistant prior to drug exposure, an example of which is          
C. auris, which is intrinsically resistant to many clinically used antifungal agents (Chowdhary 
et al., 2016) whereas in secondary resistance fungi develop resistance following exposure to 
the drug (Rogers, 2006). Such resistance may be due to environmental or genetic changes in 
the fungal cell. It is difficult to manage infections caused by certain fungi such as C. auris,           
C. krusei, C. parapsilosis and C. glabrata due to their inherent drug resistance (Rogers, 2006; 
Schelenz et al., 2016). C. auris shows high level of resistance against azoles, echinocandins 
and amphotericin (Schelenz et al., 2016). The mechanism of resistance in C. auris is still 
unclear. However, it is possible that the occurrence of resistance is due to enzymes being 
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intrinsically resistant due to poor binding of the drug or the drug being taken up slowly or the 
efflux pumps being very effective against these drugs even in the wild type strains of C. auris 
(Chowdhary et al., 2016). 
Molecular mechanisms of resistance in fungi may also be associated with the formation of 
biofilms. Overexpression or increased expression of drug target metabolising or transporting 
enzymes (e.g. 4α–demethylase, 14α–demethylase). Due to changes in the efflux pumps such 
as the ABC transporters (ATP-binding cassette transporter) or MFS pump (major facilitator) 
both result in a reduction of intracellular drug levels (Cowen et al., 2015). Certain fungi (e.g. 
C. albicans, C. tropicalis, C. krusei, C. parapsilosis and C. glabrata) develops resistance by the 
formation of biofilms on synthetic or natural surfaces (Emami, Ghobadi, Saednia, & Hashemi, 
2019). Biofilms are a thick layer of cells (i.e. cells are clumped together), which form a physical 
barrier thus making it difficult for a drug to penetrate into the cells (Cowen et al., 2015). 
It has also been shown that C. parapsilosis develops resistance to fluconazole by 
overexpression of efflux pumps encoded by multidrug resistance regulator 1 (MRR1) that 
alongside cause overexpression of cerebellar degeneration related protein (CDR1) and the 
multidrug resistance gene 1 (MDR1) (Zhang et al., 2015). 
 Genetic factors associated with a resistance in certain fungal strains such as genetic 
modification of enzymes in the targeted biosynthetic pathway give rise to structural, kinetic 
and/or drug binding changes in the target enzyme (Sangamwar, Deshpande, & Pekamwar, 
2008). Additionally environmental factors affect the inability of antifungals to effectively treat 
diseases (Scorzoni et al., 2017).  
The occurrence of azole resistance in certain fungi (e.g. C. albicans) may also be due to 
degradation of the drug, a decrease in drug import or an alteration of ergosterol biosynthesis 
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associated with molecular changes in the ERG11 gene (Cannon & Holmes, 2015). Additionally 
azoles not only interact with CYP51 but also affect xenobiotic-metabolizing CYP enzymes in 
mammals which may affect the pharmacodynamics or pharmacokinetics of a wide range of 
the (tri)azole drugs (Mishra et al., 2007). 
Even though there has been an increase in the number of antifungal drugs, the choice of 
different classes of antifungal drug remains limited. Additionally, variations in drug 
bioavailability and drug toxicity in immunocompromised individuals compared to the normal 
individual are known (Chakrabarti, 2011). Furthermore, many agrochemically relevant fungi 
some of which are opportunistic human pathogens have become resistant to various 
antifungal drugs and agrochemicals. There is thus an increased interest and need for the 
identification of novel clinical drug and agrochemical targets within the mycota. 
1.6 Identification of novel antifungal drug target 
Identification of appropriate novel enzyme or receptor targets is necessary in order to 
develop new antifungal agents with improved absorption, distribution, metabolism and 
excretion (ADME) profiles along with reduced toxicity and the ability to overcome resistance 
in drug resistance strains (Scorzoni et al., 2017). Therefore, when selecting a drug target, one 
of the most important factors to consider is that the synthesized compounds should 
selectively target fungal cells without causing any damage to the host organism or cell. 
However the antifungal market is relatively small and there are many azoles/tri-azoles 
available (Chakrabarti, 2011). Pharmaceutical companies commonly expand their range of 
antifungals by looking at X-ray structures and computer-generated models of proteins 
involved in the pathway for ergosterol synthesis and expanding existing drug structures along 
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the azole binding groove in e.g. 14α–demethylase enzyme rather than identifying novel 
enzyme target (Scorzoni et al., 2017).  
To bring new antifungal drugs into development, academic researchers have focused on 
finding new lead molecules targeting novel target enzymes. High throughput screening (HTS) 
is a discipline used by pharmaceutical companies as part of effective drug discovery 
programmes (Pouliot & Jeanmart, 2016). It is predictable that hits from HTS campaigns 
include many false positives among the real hits. The activity of many hits does not depend 
on a specific drug-like interaction between the molecule and protein (Baell & Holloway, 2010).  
In recent years many researchers have published papers claiming their compounds have good 
antifungal property but many of them act as either pan-assay interference compounds 
(PAINS) or promiscuous aggregating compounds (Pouliot & Jeanmart, 2016). Where 
molecules commonly form dimers or higher multimer complexes, one key reason for PAINS 
compounds is the inadequate quality of the data for some of these new inhibitors reported 
in the antifungal literature. Many of them contain undesirable structural features such as the 
presence of 1,2-dihydroxyl groups, which can be oxidise to a 1,2-di-carbonyl structure which 
is able to react with arginine (Murakami et al., 1990). 
Also some covalent modifier compounds which are able to produce hydrogen peroxide, which 
inactivates the target protein in a non-specific fashion (Baell & Walters, 2014). Examples of 
covalent modifiers includes 1,3-dicarbonyls such as curcumin, enones, ene-rhodanine, 
isothiazolones, hydroxyphenyl hydrazones, quinones and catechols. “Most PAINS works as 
reactive chemicals rather than discriminating drugs” (Baell & Walters, 2014). However many 
researchers have been attracted by the activity of certain PAINS compounds and continue 
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their work although it has been published in some reports that covalent modifiers may 
interfere with assays (Baell & Walters, 2014).  
However a review by De Cesco et al., (2017) mentioned that about 30% of marketed drugs 
which target enzymes act as covalent inhibitors. One such example is omeprazole, which was 
discovered in the 1970s and subsequently, in 1988, licenced for use as a H+/K+-ATPase 
inhibitor for the treatment of ulcerative disease. In 1986, Lindberg, Nordberg, Alminger, 
Brandstrom, & Wallmark found that omeprazole acts as a pro-drug and that, in its acid 
activated form, is a sulfinamide, a molecular class that Baell suggested should not be 
developed as drugs (De Cesco et al., 2017). Therefore, it is suggested that this class of 
compounds and other compounds having similar modes of action may be reassessed 
considering the historic achievements of covalent drugs in becoming clinically useful agents.  
The binding of covalent drugs to the target enzyme has significant consequences for their 
efficacy such as prolonged duration of action, increased potency and decoupled 
pharmacokinetic and pharmacodynamics profiles (Singh, Petter, Baillie, & Whitty, 2011). 
Although some companies and lead investigators had concerns over the last 20 years 
targeting drugs to the nucleotide binding sites of various enzymes such as protein kinases, 
this has not stopped the development of various compounds that covalently modify the target 
at nucleotide binding sites and which have been licensed in recent years for clinical use. 
Reviews by various authors have commented in favour of the development of novel covalent 
drugs, especially targeting the ATP binding site of protein kinases (Singh et al., 2011; Barf & 
Kaptein, 2012; Jackson, Widen, Harki, & Brummond, 2017; Dalton et al., 2018). Although ATP 
binding sites have been disparaged as target sites due to the high cellular concentration of 
ATP and relatively high Km and Keq values and there has been a resurge of interest in targeting 
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such sites in recent years (Škedelj, Tomašić, Mašič, & Zega, 2011). In recent years there has 
been an increase in the study and development of covalent modifiers as drugs, resulting in 
the development and licensing of various irreversible protein kinase inhibitors (Barf & 
Kaptein, 2012). Greater efficacy and functional selectivity of irreversible protein kinase 
inhibitors makes them popular over reversible drugs (Barf & Kaptein, 2012). The covalent 
conjugation of a drug molecule with lysine is less common due to the protonation of the side 
chain NH2 under physiological conditions. Therefore kinome-conserved lysine residues are 
considered to be a good alternative target to cysteine (Dahal et al., 2016). Dalton et al., (2018) 
described a novel approach to accomplish irreversible kinase inhibition by targeting the 
preserved catalytic lysine residue. By this method, selective covalent chemical probes can be 
created for selected kinases at the nucleotide (ATP) binding site. 
Using various molecular biological techniques, it has been identified that the plasma 
membrane H+-ATPase of fungi and plants could be a potential new antifungal drug target due 
to its genetic and biochemical properties, and the fact that this enzyme is absent from 
mammalian cells (Serrano, 1980; Monk et al., 1995; Portillo, 2000). The fungal plasma 
membrane (PM) is composed of phospholipids and sterols as their main lipid constituents, 
which acts as a permeability barrier to transport molecules across the membrane. Chemical 
modification of membrane-embedded PM proteins could lead to the disruption of cellular 
functions and thus cell death, thus potentially acting as a new drug target (Sangamwar et al., 
2008; Ottilie et al., 2018).  
1.6 ATPase and ATP synthase enzymes 
ATPases (adenosine triphosphatases) are a class of enzymes that catalyze the hydrolysis of 
ATP to ADP and free phosphate (Pi). The FoF1 ATP synthase is found in the inner membrane of 
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mitochondria in eukaryotes, and the plasma membrane of many prokaryotes, and is involved 
in the synthesis of ATP using the (mitochondrial) proton electrochemical potential composed 
of a proton gradient (ΔpH) and electrical potential (ΔΨH+). The electrical field influences the 
movement of protons and a higher concentration of protons present on one side leads to 
higher driving force for the transport of protons across the membrane. In the past 60 years, 
various membrane bound ATPases from various classes have been discovered and studied to 
solve the specific demands of the cells.  The different types of ATPases discovered include F-, 
A-, V-, P- and E-ATPases based on their cellular function and location (Becher & Muller, 1994). 
1.7.1 Types of ATPases 
1.7.1.1 F-type ATPases 
F-type ATPases, more commonly termed ATP synthases are found in (eu)bacteria, 
chloroplasts and mitochondria. F-ATPases are composed of two multi-protein complexes, 
these being: Fo which is present in the membrane and F1 which is present in the 
lumen/cytoplasm and is attached to the Fo sector. F1 is responsible for the hydrolysis or 
synthesis of ATP, whilst the Fo complex facilitates the translocation of protons. In eukaryotes, 
the F-ATPase transports three or four protons into mitochondria for each ATP synthesized. In 
bacteria, the F-ATPase pumps three to four H+ or Na+ in (or out) of the cell for each ATP 
synthesized or hydrolyzed (Becher & Muller, 1994).  
Eukaryotic and prokaryotic classes of F-ATPases can be differentiated based on their 
sensitivity towards inhibitors such as oligomycin. The bacterial FoF1-ATPase is not sensitive to 
oligomycin whereas eukaryotic FoF1-ATPases are very sensitive to oligomycin                          
(Perlin, Latchney, & Senior, 1985). In other inhibitor studies undertaken by Gledhill, 
Montgomery, Leslie, & Walker, (2007) it has been shown that resveratrol and related stilbene 
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polyphenols inhibit the F1 ATPase from bovine heart mitochondria. Resveratrol blocks the 
synthesis and hydrolysis of ATP by the ATP synthase (F1Fo-ATPase) enzyme found in 
mitochondria (Gledhill et al, 2007). The inhibitors bind to the F1-ATPase and act as non-
competitive inhibitors. The stilbene nucleus found in molecules such as resveratrol, binds via 
hydrophobic interactions whilst the substituents on the benzene rings of the stilbene such as 
hydroxyl (-OH) may bind via H-bonds (Gledhill et al, 2007). Additionally, stilbenes such as 
resveratrol also block the transport of H+ through the Fo channel (Dadi, Ahmad, & Ahmad, 
2009). 
1.7.1.2 A-type ATPases 
A-type ATPases (AoA1) are found in archaea and function in a similar fashion to the F-type 
ATPases. Some of the A-type ATPases are known to utilize Na+ rather than H+ gradients 
(Becher & Muller, 1994). 
1.7.1.3 V-type ATPases 
Vacuolar (VoV1) or V-type ATPases act as proton pumps in eukaryotic vacuolar membranes. A 
V-type ATPase is found in various eukaryotic vacuolar membranes including the human 
lysosomal and fungal membranes. Similar enzymes are also found in neuronal synaptic 
vesicles of humans and plasma membranes of plants (Becher & Muller, 1994). The V-ATPase 
is comprised of a V0 complex consisting of six different types of subunit and is responsible for 
proton translocation. V1 is a soluble complex composed of eight types of subunit that 
hydrolyses ATP. This enzyme is linked to controlling the uptake and concentration of various 
neurotransmitters in vesicles in mammalian cells (Becher & Muller, 1994).  
In fungal cells, V-ATPases acidify vacuoles by hydrolysing ATP, with the consequent pumping 
of protons from the cytoplasm into the vacuole, the Golgi body or endosomes (Becher & 
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Muller, 1994). Treatment of the V-ATPase with β-methylcyclodextrin showed a loss of 
vesicular acidification in mammalian cells (Yoshinaka, Kumanogoh, Nakamura, & Maekawa, 
2004). The ergosterol synthesis inhibitor, fluconazole has also been shown to decrease 
vacuolar acidification in both C. albicans and S. cerevisiae (Zhang et al., 2010). Vesicular 
ergosterol thus appears to be important for optimal functioning of the V-ATPase (Zhang et al., 
2010). Fluconazole thus appears to reduce the flow of cytosolic H+ and Ca2+ ions and impairs 
the storage of Ca2+ ions in purified vacuolar vesicles (Zhang et al., 2010). 
1.7.1.4 E-type ATPases 
Ecto, or E-type, ATPases are membrane-associated proteins found in many eukaryotic cells 
(Zhong & Guidotti, 1999). They play an essential role in many biological processes such as 
prevention of intravascular thrombosis, glycosylation of proteins or modulation of neural cell 
activity. E-ATPases have the ability to hydrolyze both di- or tri-phosphate nucleotides when 
activated by Mg2+ or Ca2+ ions (Zhong & Guidotti, 1999).  
1.7.1.5 P-type ATPases 
P-type ATPases (Figure 1.9) are found in both plasma and endoplasmic reticulum membranes 
of eukaryotes such as fungi, plants, protists and in the cytoplasmic membrane of prokaryotes. 
(Monk et al., 1995). Their function is to transport a wide variety of ions such as H+, Ca2+, Cu2+, 
K+, Na+, NH4+, Zn2+ and heavy metals or phospholipids across membranes with the associated 
hydrolysis of ATP.  
Axelsen & Palmgren, (1998) classified P-ATPases into five classes. P-type ATPases are grouped 
together in a phylogenetic tree according to their substrate specificities regardless of the 
evolutionary distance between the parental species (Axelsen & Palmgren, 1998). Type I 
ATPases includes those pumping heavy metals and other potentially toxic ions out of cells 
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such as Cu2+, Cd2+, Pb2+ and Zn2+. The type II family includes the Na+/K+-ATPase, Ca2+-ATPase 
(both plasma membrane and endoplasmic reticulum) and the H+/K+-ATPase and relates to 
mammalian ATPases, which are the most extensively studied P-type ATPases. Type III P-type 
ATPases includes the H+-ATPase that appears in fungi and plants, and Mg2+ pumps. The type 
IV P-type ATPases include the aminophospholipid pumps and are also involved in the 
transport of other hydrophobic compounds. Type V P-type ATPases includes a group of pumps 
with no known substrate specificity (Lecchi & Slayman, 2004). 
 
Figure 1. 9. The structural organization of P-type ATPases. 
P-type ATPases contains five domains, two of these are membrane-embedded domains (S–
class specific support domain and T–transport domain) and along with other three other 
cytoplasmic domains (A-actuator, N–nucleotide binding and P-phosphorylation). The P-
domain is phosphorylated by the activity of the N-domain which is then dephosphorylated by 
the A-domain during each catalytic cycle. In this system, the P-domain acts as the site for both 
phosphatase and kinase activities, whereas the N-domain acts as a protein kinase and the A-
domain acts as a protein phosphatase. Image is taken from (Palmgren & Nissen, 2011). 
 
The plasma membrane (PM) H+-ATPase belongs to the type III P-type ATPase family of ion 
translocating ATPases. The PM H+-ATPase is encoded by the genes PMA1 and PMA2 in                             
Chapter 1: General introduction 
 
32 
 
S. cerevisiae and other fungi, and AHA1 to 10 in plants such as Arabidopsis thaliana. Some 
species of fungi contain only one PMA gene. The PM H+-ATPase is an essential enzyme for the 
growth of fungi where it generates an electrochemical proton gradient across the fungal 
plasma membrane that drives the uptake of nutrients such as amino acids, sugars, ions, etc. 
by secondary transporters and to regulate the intracellular pH (Portillo, 2000). Both glucose 
and pH are responsible for the regulation of the PM H+-ATPase (Mazon, Eraso, & Portillo, 
2015). 
Mammalian type II P-type ATPases are involved in the exchange of various cations such as the 
Na+/K+ or H+/K+-ATPases but fungal and plant P-type H+-ATPases (type III ATPases) are not 
involved in the cation exchange process. P-type ATPases particularly the H+, Na+/K+ and Cu2+ 
play an important role in the regulation of cell metabolism in their respective organisms, such 
that their malfunctioning could potentially cause number of diseases or cell death. The P-type 
ATPase enzymes such as the Na+/K+-ATPase and H+/K+-ATPase are well-defined targets for 
surface-active cardiac glycosides such as digitoxin and anti-ulcer treatments such as 
omeprazole (Monk & Perlin, 1994). In view of the proton ATPase being present in fungi and 
not in animals, the PMA P-type ATPase is considered as a useful target for the development 
and identification of new classes of antifungal agent (Kongstad et al., 2014).  
It has been shown that vanadate is a potent inhibitor of many P-type ATPases (Clausen et al., 
2016). Nevertheless, the structural details of its inhibitory action have remained elusive 
although it is believed to act as a transition state analogue of phosphate (Clausen et al., 2016). 
Clausen et al., (2016) have solved the crystal structure of the sarcoplasmic reticulum (SERCA) 
Ca2+-ATPase bound to vanadate. The Ca2+-ATPase is inhibited by decavanadate competing 
with TNP-8N3-ATP at the nucleotide binding site whereas orthovanadate is characterised as a 
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trigonal bipyramidal transition state intermediate of the SERCA Ca2+-ATPase 
dephosphorylation process (Clausen et al., 2016). 
Many studies have been conducted using a wide variety of inhibitors to elucidate the 
structure, organisation and mechanism of Pma1 (Monk et al., 1995; Petrov & Slayman, 1995; 
Dao et al., 2016; Ottilie et al., 2018). To date, only ebselen and the peptide BM2 have been 
shown to inhibit fungal growth in the low micromolar range (Kjellerup et al., 2017).  
1.7.1.5.1 Reaction mechanism of the plasma membrane H+-ATPase 
The P-type H+-ATPase pumps protons out of the cell which results in an increase in the internal 
pH (pHi) causing cytoplasmic alkalization which stimulates cell growth (Serrano, 1993; 
Kjellerup et al., 2017) The H+-ATPase acts as a master transporter to facilitate uptake of 
nutrients such as sugars, amino acids or mineral ions into the cells via series of ‘slave’ 
transporters. These ‘slave’ transporters require energy which is supplied from the plasma 
membrane ∆pH much of which is generated by the master transporter H+-ATPase (Palmgren 
& Nissen, 2011).  
The P-type H+-ATPase undergoes covalent trans-phosphorylation via the formation of an 
aspartyl phosphate intermediate during each catalytic cycle hence the term phosphorylated 
ATPase or P-type ATPase, also known as E1-E2 ATPases. This formation of a near 
thermodynamically neutral phospho-carboxyl mixed anhydride intermediate is the key 
mechanism that separates P-type ATPase from the other A-, E-, V- or F-type ATPases (Yatime 
et al., 2009). The reaction mechanism of P-type H+-ATPase in Figure 1.10 is described by the 
Post-Albers scheme (Lecchi & Slayman, 2004). This mechanism describes two conformational 
states, E1 and E2 (later sometimes called open and closed states) associated with either ATP 
or the phosphate ion. 
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Figure 1. 10. Reaction cycle of P-type ATPases according to Post-Albers scheme. 
(Lecchi & Slayman, 2004). 
 
ATP first binds to the E1 form of the enzyme in the nucleotide-binding domain which is then 
followed by the binding of intracellular H+ ions to E1ATP as shown in figure 1.10. Following 
binding of the hydronium ion, the transfer of the γ-phosphate from ATP to the enzyme 
produces a ‘high-energy’ β-aspartyl phosphate intermediate (E1PH+). The phosphorylated 
carboxylated group then undergoes hydrolysis with concomitant transfer of a proton through 
the enzyme to the extracellular space. In the process of exporting the H+, the E1P form shifts 
to the E2P conformation. However, the protein remains phosphorylated. The enzyme then 
dephosphorylates to form the E2 state to which ATP binds thus re-generating the E2-ATP 
conformational state (Lecchi & Slayman, 2004; Yatime et al., 2009; Palmgren & Nissen, 2011). 
1.8 Compounds known to react with cellular thiols 
Over the last 50 years, researchers have shown interest in compounds which are known to 
react with cellular thiols particularly compounds containing an α,β-unsaturated carbonyl 
group (Manavathu et al., 1999). Compounds containing an α,β-unsaturated carbonyl group 
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markedly inhibit the plasma membrane H+-ATPase and exhibited antifungal activity (Dimmock 
et al., 1998; Manavathu et al., 1999; Nakhjiri et al., 2012). Such activities are of interest since 
α,β-unsaturated carbonyl groups may not cause any genotoxic effects since thiols are not 
present in nucleic acids. However sulfhydryl reactive compounds react with a wide variety of 
proteins which contain reduced cysteine residues (Winslow, 1981).  
Several studies have demonstrated that inhibition of Na+/K+, Ca2+ and H+/K+-ATPase can be 
achieved by a covalent interaction with group-specific chemical probes such as sulfhydryl 
reagents (Katz & Sussman, 1987). The PM H+-ATPase enzyme has been shown to be inhibited 
by maleimides (9) (e.g. N-ethyl maleimide, which binds to Cysteine 532), sulphinimides (e.g. 
omeprazole (10)), curcumin (11), chalcones (12),  caffeic acid (13), ebselen (14) and α,β-
unsaturated carbonyls such as 1,4-diene-3-ones (Figure 2.6) (Manavathu et al., 1999).  
1.8.1 Maleimides 
A series of N-substituted imides were synthesized by Zentz et al., (2002) who demonstrated 
that N-substituted maleimides (Figure 1.11) were highly active against various bacterial 
species including Escherichia coli, Enterococcus faecalis, Staphylococcus aureus and 
Pseudomonas aeruginosa.  
 
Figure 1. 11. General N-substituted maleimide structure (9) and N-ethyl maleimide (9a). 
 
Maleimides (9) have also been shown to inhibit mitosis in fungal cells (Brooker & Slayman, 
1982). They also demonstrated that N-ethyl maleimide (NEM) (9a) inhibits the H+-ATPase of 
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Neurospora crassa and that it can be used as a probe to examine the nature of enzyme-ligand 
interactions in PMA1. NEM binds to cysteine-532 in the cytoplasmic region causing inhibition 
of the PM H+-ATPase. NEM, a covalent modifier of protein sulfhydryl groups also exhibited 
inhibitory activity against the PM H+-ATPase (AHA) of Avena sativa root cells (Katz & Sussman, 
1987). 
1.8.2 Omeprazole 
The PM H+-ATPase is a critical target that has been studied using the sulfhydryl-reactive 
reagent omeprazole (Seto-Young, Monk, Mason, & Perlin, 1997). Omeprazole (10) is used 
clinically as an anti-ulcerative drug, which following acid activation, is known to inhibit the 
gastrointestinal H+/K+-ATPase by reacting with a protein SH/thiol to form an asymmetric 
disulphide (Schultz et al., 2007). The structure of acid-activated omeprazole is shown in Figure 
1.12. 
 
Figure 1. 12. Structure of acid-activated omeprazole (10). 
Omeprazole has also shown inhibitory activity against the fungal plasma membrane                    
H+-ATPase by the formation of a covalent (disulfide) bond within the first two transmembrane 
segments M1 & M2 in Figure 1.13 (Monk et al., 1995). Specifically, acid activated omeprazole 
reacts with PMA1 to form a disulphide S-S bond between omeprazole and cysteine-148 in the 
M2 loop. 
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Figure 1. 13. The topology of the yeast plasma membrane H+-ATPase with 
extracytoplasmic and cytoplasmic binding sites. 
The yeast plasma membrane H+-ATPase contains three cysteine residue in the 
transmembrane segment (C-148, C-312 and C-867) and six-cysteine residue in the cytoplasmic 
segment (C-221, C-376, C-409, C-472, C-532 and C-569). Omeprazole binds at the TM2 region 
whereas N-ethyl maleimide binds in the N-domain region of the plasma membrane                     
H+-ATPase. Image is taken from Petrov & Slayman, 1995. 
 
Seto-Young et al., (1997) have also studied the molecular interaction of omeprazole with the        
H+-ATPase of various S. cerevisiae pma1 mutants. They have identified that modification of 
amino acid side groups (e.g. cysteine) at various positions in the membrane sector shown 
little effect. Site directed mutations at M128C and D140A or D140C enhanced the sensitivity 
of cells to omeprazole whilst G158D and G156C shown insensitivity to omeprazole. They have 
also shown that M128C, D140A or D140C did not show direct interaction with omeprazole. It 
Tentative omeprazole binding site (TM2) 
N-domain (Nucleotide binding) 
(Fluorescein isothiocyanate) 
(N-ethyl maleimide) 
P-domain (phosphorylation) 
A-domain 
(Actuator) 
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thus appears likely that inhibition by omeprazole is the result of some form of disruptive 
conformational changes following formation of the disulfide adduct. 
1.8.3 Curcumin 
Curcumin (11a and b) is a natural product obtained from the rhizome of the plant Curcuma 
longa and is most commonly used in Asian cooking. In solution curcumin commonly adopts a 
‘carbonyl and keto-enol’ (11b) form rather than the di-carbonyl or di-keto form (11a). Many 
studies have shown that curcumin exhibits a wide range of biological activities including 
antifungal activity (Martins et al., 2009), antioxidant, anti-tumour and anti-mutagenic 
(Neelofar et al., 2011), antimicrobial, and anti-HIV protease activity (Sahu, Sahu, Gupta, 
Thavaselvam, & Agarwal, 2012).  
Recent investigations concerning the antifungal activity of curcumin have shown that 
curcumin is more effective than fluconazole against various Candida species (Martins et al., 
2009). Curcumin has also shown inhibitory activity against the Ca2+-ATPase (Logan-Smith, 
Lockyer, East, & Lee, 2001) and Na+/K+-ATPase (Mahmmoud, 2005) and therefore it may be 
expected to have activity against the fungal plasma membrane H+-ATPase. 
 
Figure 1. 14. Structure of curcumin (11). 
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Commercially available curcumin preparations contain several curcuminoids including 
curcumin (80%), demethoxycurcumin (15%) and about 5% of bisdemethoxycurcumin with 
various others being present in small amounts (Dao et al., 2016). According to Dao et al., 
(2016) demethoxycurcumin was an effective non-competitive ATP inhibitor of the fungal         
P-type ATPase (Pma1p; H+-ATPase). Additionally, it was also identified to be non-toxic to 
mammalian cells. However in vivo testing has shown that curcumin has very low 
bioavailability especially over the medium to long term. 
1.8.4 Chalcones 
Chalcones (12) are precursors of flavonoids, which are polyphenolic antioxidants found in 
many fruits, vegetables, nuts and red wine. Chalcones (Figure 1.15) contain two aromatic 
rings linked by a three-carbon α, β-unsaturated carbonyl structure and have been shown to 
inhibit the growth of C. albicans based on their ability to interact with sulfhydryl groups 
(Batovska et al., 2007). They are also known to inhibit the synthesis of the fungal cell wall by 
inhibiting the β(1,3)-glucan synthase enzyme (Lopez et al., 2001; Chen, Zheng, Sun, and Piao, 
2010). 
 
Figure 1. 15. Structure of chalcone (12). 
 
1.8.5 Ebselen 
Ebselen (14) is a selenium-containing compound, known for its anti-oxidative, anti-
inflammatory and anti-atherosclerotic properties (Figure 1.16). It has also been shown to 
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have antifungal properties (Soteropoulos et al., 2000). More specifically ebselen has been 
shown to inhibit the H+-ATPase in S. cerevisiae in a concentration-dependent manner by 
interacting with a sulfhydryl group of cysteine (Chan, Hardej, Santoro, Lau-Cam, & Billack, 
2007). Medium acidification by S. cerevisiae Pma1 appears to be blocked by ebselen in both 
haploid and diploid strains (Chan et al., 2007). 
 
Figure 1. 16. Structure of ebselen (13). 
 
1.8.6 Caffeic acid 
Other α,β-ketones exhibiting antimicrobial activities include caffeic acids (14a). Sardi et al., 
(2016) investigated their antifungal activity against Candida species and identified structure-
activity relationships derived from various caffeic acids derivatives.  
 
Figure 1. 17. Structure of caffeic acid (14a) and its oxidised form (14b). 
 
However, it is also the case that oxidation of caffeic acids by cytochrome P450 may lead to 
the formation of various enzyme inhibitors. Since caffeic acids contains a 1,2-dihydroxy or 
catachol structure it is possible that caffeic acids may oxidise to 1,2-diones (14b) which will 
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react non-specifically with arginine residues. Such 1,2-diones structure of caffeic acid have 
been shown to be potentially toxic (Murakami et al., 1990). 
1.8.7 Other sulfhydryl reactive natural products 
Other natural products found in vegetables and soft fruits such as the plant phenols ellagic 
acid (15), salvianolic acid (16) and plectrinone A (17) have been shown to inhibit the gastric 
H+/K+-ATPase (Figure 1.18). Ellagic acid blocks the formation of phosphoenzyme in the             
H+/K+-ATPase by competing with ATP at the ATP hydrolysis site (Murakami et al., 1990). A 
study conducted on Plectranthus barbatus leaves has shown that the molecule Plectrinone A 
is also capable of inhibiting the gastric H+/K+-ATPase acting as both an antiulcerative and 
antisecretory molecule (Schultz et al., 2007). However, Plectrinone A also contains a quinoid 
sub-structure which may be associated with the generation of toxic free radicals such as 
hydroxyl or peroxy. 
 
Figure 1. 18. Structures of ellagic acid (15), salvianolic acid (16) and plectrinone A (17). 
The gastric H+/K+-ATPase inhibitors such as ellagic acid, salvianolic acid and plectrinone A. 
These three compounds have ortho-catechol structure and a poly hydroxyl stilbene structure 
both of 1,2-dihydroxy moiety. However, salvianolic acid also contains an α,β-unsaturated 
carbonyl group which may interact with H+/K+-ATPase. 
 
Although containing α,β-unsaturated ketones the phenolic hydroxyl groups of both ellagic 
and salvianolic acids appear to be essential for their interaction with the ATPase (Murakami 
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et al., 1990). Salvianolic acid A  and ellagic acid binds to the ATPase on the cytosolic side and 
inhibits the synthesis of the phosphoenzyme intermediate thus inhibiting the H+/K+-ATPase 
(Murakami et al., 1990). As indicated for caffeic acid all of the compounds salvianolic acid, 
ellagic acid and plectrinone A contain an ortho catecholic structure which may possibly be 
oxidised to a 1,2-dicarbonyl. Such 1,2-dicarbonyls are well known to be toxic due to non-
specific interactions with protein arginine residues (Murakami et al., 1990). 
Recently an article published by Tung et al., (2017) demonstrated that benzo[d]thiazoles 
containing a 3,4-dihydroxyphenyl moiety acts as a potent inhibitors of PM H+-ATPase. 
However, their synthesized compounds are unlikely to be drugable due to the presence of 
the 3,4-dihydroxybenzene moiety, present within the whole structure which will probably 
oxidise to the arginine reactive 3,4-dicarbonyl structure. Alternatively it may be methylated 
via catechol-O-methyltransferase (COMT) which has a low substrate specificity regarding 
methylation of the hydroxyl (-OH) group probably at ring position-3, or alternatively sulphated 
by phenol-o-sulphatase (Tung et al., 2017). 
In a recent review on drug development, curcumin was classified as a pan-assay interference 
compound (PAINS) and invalid metabolic panaceas (IMPS) based on the presence of a reactive 
Michael acceptor, its susceptibility to aggregation and its fluorescence activity (Nelson et al., 
2017). Furthermore, curcumin itself is not considered as a potential drug candidate due to its 
toxic effects under certain circumstances, low efficacy in several disease models, poor 
solubility and low bioavailability (Nelson et al., 2017).  
Similarly due to the requirement for prior acid activation and pH dependence of omeprazole 
action (Monk et al., 1995; Tung et al., 2017), its  weak inhibitory effect against the plasma 
membrane H+-ATPase, the general toxicity of ebselen makes all of these molecules poor 
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starting points for developing novel anti-fungal drugs targeting the H+-ATPase (Tung et al., 
2018). Hence, these compounds are not considered for further investigation in the discovery 
and development of H+-ATPase inhibitors as new antifungal agents. 
Studies have shown that α,β-unsaturated ketones (chalcones, acrylic acid, etc) undergo 
Michael reactions with protein thiols such as cysteine (Pati et al., 2009). The nucleophilic 
attack would be anticipated to occur on the β-carbon of the enones due to the electron-
withdrawing effect of the carbonyl group (Manavathu et al., 1999). However various drugs 
containing this enone structure have been licensed in recent years for the treatment of 
various diseases, which are regulated by ATP binding proteins such as protein kinases (Chène, 
2002; Barf & Kaptein, 2012; Haruta, Gray, & Sussman, 2015). 
1.9 Structure-activity relationship (SAR) 
One of the first examples of the development of a structure-activity relationship is the 
established work of Meyer and Overton. They investigated the physiochemical and structural 
parameters that lead them to predict potencies of anaesthetics (Meyer, 1901; Overton, 
1991). From various in vivo and in vitro experiments, they were able to plot anaesthetic 
potency against the same consistent set of octanol/water partition coefficients (logP). The 
results proposed that the potencies of anaesthetics were due to their lipophilic properties 
(Schwilden & Schuttler, 2008).  
Subsequently in the 1930s Hammett introduced the concept of substituent constants (σ) to 
predict how the introduction of either electron withdrawing groups or electron donating 
groups onto a benzene ring would alter the rate constants of chemical reactions using a linear 
free-energy relationship (Mager, 2006). In this work Hammett characterised the electronic 
influence of the various substituent groups in a series of benzoic acids on the reaction 
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equilibrium dissociation constant (Mager, 2006). This constant now termed the Hammett 
substituent constant (σ) is one of the best-known and utilised parameters used to measure 
electrostatic interaction forces between molecules. It provides a quantitative assessment of 
the electron-withdrawing or -donating properties of different functional groups relative to 
hydrogen.  
In the 1960s, Hansch & Fujita, (1964)  developed a Quantitative structure-activity relationship 
(QSAR) model. They correlated structure and biological activity based on the concept of linear 
free energy relationship by incorporating the Hammett constant (σ) and the lipophilicity index 
(π), a term derived from the water/octanol partition coefficient, a descriptor in the Hansch 
equation (Hansch & Fujita, 1964). This (now called) Hansch equation is used to analyze 
chemical and biological data using linear regression or pattern recognition techniques. 
General practice in the drug discovery process is to optimize the SAR of functional groups with 
regard to their role in biological activities and perform analyses using complex computer-
based techniques involving multivariate analysis.  
Modern technique in QSAR may use up to six different physicochemical descriptors, from then 
now more than one thousand properties that may be measured or calculated to analyze the 
relationships between chemical and biological activities for small data sets or more 
descriptors for large datasets. A QSAR model provides information about the correlation of 
physiochemical and structural properties of compounds with their biological properties, such 
as protein binding, or enzyme or receptor affinity. This relationship is then used to estimate 
and predict the biological properties of new molecules prior to their chemical synthesis.  
A modification in the chemical structure of a compound may result in changes in its properties 
and thus a change to its biological activity. By comparing the molecular properties with the 
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biological activity of the compounds, QSAR modelling predicts the most promising structural 
derivatives that might be synthesized to obtain the greatest efficacy for a potential drug. 
Additionally, there is no totally accurate or definitive method for predicting ADME properties 
such as binding of novel molecules or drugs to plasma proteins. However, it is possible to 
measure protein binding using techniques such as Surface Plasmon Resonance (SPR) or 
fluorescence (polarisation) using a fluorescently labelled analogue of the molecule set in 
order to investigate binding (Giannetti, Koch, & Browner, 2008; Leonova et al., 2013; Tung et 
al., 2017). 
In order to analyse the data resulting from such experiments, sets of inhibitor molecules are 
analysed using QSAR. This methodology is used to determine which combinations of a wide 
variety of molecular descriptors may be used to construct a mathematical relationship using 
the statistical algebraic technique of regression analysis to biological activity. Such techniques 
include multi variate and non-linear regression analysis. By using commercial statistical 
software packages for QSAR modelling it is possible to obtain either a two or three-
dimensional (2D or 3D) arrangement of chemical groups that are potentially involved in 
defining the biological response to a given molecule. Such analyses may be used to optimise 
or maximise biological responses including ADME, pharmacokinetics and pharmacodynamics, 
etc (Yap & Chen, 2005).  
In the early stages of QSAR, modelling was used in the analysis of chemical structures in order 
to determine any relationships between properties such as lipophilicity (logP, 
(octanol/water)); π, the Hammett substituent constant (σ) and the Taft steric parameter (Ts) 
and biological responses such as inhibition of growth or enzyme/receptor binding. Molecular 
structures could be then devised prior to their synthesis that would hopefully have a set of 
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desired properties such as target binding, residency time, plasma half-life, etc. that could be 
further modified to produce drug candidates optimised in terms of their structure and 
mapping to the probable drug binding site(s). Such modelling would potentially optimise and 
minimise the number of molecules required to be synthesized. 
Therefore, QSAR modelling is used as a guide to modify the molecular structures of potential 
drugs in order to alter their physiochemical properties in some defined fashion. There are 
now in excess of 1202 physicochemical and molecular descriptors of which some 284 
descriptors are listed in the computer programme MOE that may be used to correlate with 
some response or (bio) assay (e.g. dose required to elicit 50% of the maximum activity, EC50, 
IC50, Ki, MIC, etc).  
Many reviews and articles have been published regarding QSAR modelling and antifungal 
activity. However most researchers have focused on ligand-receptor interactions. For 
example Caballero & Fernández, (2006) predicted the antifungal activity of 96 heterocyclic 
ring derivatives against C. albicans using Bayesian-regularized neural networks along with 
multiple linear regression of 2-substituted benzothiazoles, 2,5-disubstituted benzimidazoles, 
2,5,6-trisubstituted benz-oxazoles and 2-substituted oxazole(4,5-b)pyridines. They have 
shown that the molecular mass, polarizability and compound volume have an important 
relationship with the potency of compounds.  
In other studies a QSAR model for antifungal activity of heterocyclic compounds was 
developed by using principal component analysis (PCA) and multiple regression analysis 
(MRA) on benzoxazoles, benzimidazoles, benzothiazoles and oxazolo[4,5-b]pyridines against 
C. albicans (Ursu, Costescu, Diudea, & Parv, 2006). A further study conducted by Duchowicz, 
Vitale, Castro, Fernández, & Caballero, (2007) described how QSAR modelling using linear 
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regression analysis on 1202 descriptors, including electronic, geometrical or topological 
parameters was used on a library of heterocyclic compounds in order to determine optimal 
structures for antifungal activity. 
In yet a further study, Katritzky, Slavov, Dobchev, & Karelson, (2008) used a set of measured 
antifungal activities of a library of disparate molecular structures in order to determine the 
best physicochemical descriptors in order to develop a general QSAR for antifungal activity. 
They have generated a QSAR using CODESSA PRO software to generate descriptors 
(electronic, topological, geometrical and hybrid) and subsequently correlated them with the 
MIC values of a diverse set of 83 compounds obtained from susceptibility assay on C. albicans. 
They have seen an increase in the antifungal activity when a molecule acts as a stronger 
electrophile and identified that generated models showed a fundamental influence of 
electrostatic properties over both steric and transport abilities. The presence of heteroatoms 
in a molecule is usually related to their electronegativity or electron pairing which is often 
responsible for the surface recognition and creating acceptor-donor bonds. They have also 
shown that proposed molecules with higher logP values tends to show a decrease in the 
antifungal activity. The models generated by Katritzky et al., (2008) shows similar trend 
between individual and general model indicating the main influence was due to the 
electrostatic effects compared to the steric effects or transport abilities. 
Based on this theory it is believed it would be useful to synthesize a library of molecules 
containing electrophiles containing the 1,4-diene-3-one pharmacophore which contains the 
α,β-unsaturated carbonyl and determine their ability to act as antifungal agents. 
Subsequently in silico SAR could be used to analyse the possible relationships between 
mechanism(s) of action of such compounds or structures and biological activity. The 
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synthesized compounds should have a noticeable affinity or reactivity towards thiols, but not 
for hydroxyl or amino groups such are found in nucleic acids.  
Other potential SH reactive pharmacophores could include sulphenamide (Yatime et al., 
2009) or R-substituted acyloxy methyl ketone (Figure 1.19) (Krantz, Copp, Coles, Smith, & 
Heard, 1991). Where R is a fragment that may have an affinity for docking to the nucleotide-
binding site or the omeprazole binding site of PMA1. By targeting specific binding sites and 
generating molecules of high (nanomolar to low micromolar) affinities along with them being 
reactive to cysteine residues within or close to the binding site they are less likely to have 
carcinogenic or mutagenic effects.  
 
Figure 1. 19. Mechanism of cysteine proteinase inactivation with acyloxy methyl ketone. 
Such compounds could potentially react with PMA1 cysteines if designed correctly. 
 
It is anticipated that the synthesized compounds will react with either the sulfhydryl-
containing region (S- or SH) of the PM H+-ATPase either in the extra-cytoplasmic region i.e the 
omeprazole binding region or alternatively the cysteine present in the nucleotide binding site 
in the cytoplasmic region where NEM has been shown to bind (Brooker & Slayman, 1982). 
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1. 10 Aims and scope 
The plasma membrane H+-ATPase is an essential fungal protein and an anticipated 
therapeutic target for the discovery of novel antifungal agents. Cysteine reactive 
pharmacophores may prove useful in PMA-targeted drugs as many of the nucleotide-binding 
sites of protein kinases lack cysteine residue (Krishnan et al., 2014). This lack of cysteine 
potentially gives the drugs a higher degree of selectivity if targeting ATP binding sites in fungi 
along with lower toxicities or side effects (Zhao, Liu, Bliven, Xie, & Bourne, 2017). It was 
believed that derivatives of bis-benzyldienones might be useful bio-chemical probes to 
determine some of the structural requirements for drugs targeted to cysteine residues found 
in transmembrane segments M1 and M2 or in the nucleotide-binding (N) domain of the 
cytoplasmic site of PMA1. Given the generally accepted safety of benzylidenes, chalcones and 
related compounds, a library of 1,4-diene-3-ones containing an α,β-unsaturated carbonyl 
group has been synthesised using standard synthetic procedures. The intent of this study was 
to explore 1,4-diene-3-ones and identify if they are capable of inhibiting the export of protons 
from the fungal cell, thus changing the plasma membrane ΔpH and decreasing the 
cytoplasmic pH. These results lead to a decrease in cell growth and cell division (Monk et al., 
1995).  
1.10.1 Objectives 
1) To synthesize a library of dienones comprising bis-benzylidene, bis-pyridylidene and bis-
thienylidene derivatives of N-methylpiperidin-4-one, cyclopentanone and cyclohexanone;  
2) To characterize the synthesized compounds using 1H- and 13C-NMR, mass spectrometry, 
FT-IR spectroscopy, Thin-layer chromatography (TLC) and melting points;  
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3) To determine the potency of the synthesized 1,4-diene-3-ones against S. cerevisiae and  
C. albicans;  
4) To determine the mechanism of action of the synthesized 1,4-diene-3-ones by conducting 
the proton extrusion assays on carbon starved S. cerevisiae cells; 
5) To perform a preliminary structure-activity relationship of the 1,4-diene-3-ones antifungal 
activity with their electronic and lipophilic properties.   
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2 Synthesis and characterization of 1,4-diene-3-ones 
2.1 Introduction 
Several studies have shown that α,β-unsaturated carbonyl compounds are able to undergo a 
Michael addition with cellular or protein thiols (Das et al., 2007). The Michael addition is the 
nucleophilic addition to the electrophilic β-carbon of an α,β-unsaturated carbonyl compound 
(Pati et al., 2009). An α,β-unsaturated carbonyl group is electrophilic in nature, therefore, it 
is easily attacked by a nucleophile at the β-carbon atom. These compounds have noticeable 
reactivities towards thiols but not for hydroxyl or amino groups such as those found in nucleic 
acids (Leonova et al., 2013). Thus they are less likely to have carcinogenic or mutagenic effects 
(Pati et al., 2009). Thus, a possible mechanism of action of the dienones is by the reaction of 
one or more of the sulfhydryl groups found in the various cysteine residues present in the 
fungal plasma membrane PMA1 protein with the dienone (Pati et al., 2009; Tung et al., 2018).  
These α,β-unsaturated carbonyl compounds can be synthesised using the Claisen-Schmidt 
reaction. The Claisen-Schmidt reaction plays an indispensable role in organic chemistry. It is 
a condensation reaction of an (aromatic) aldehyde with a ketone containing a methylene α to 
the carbonyl to generate α,β-unsaturated carbonyl compounds (Rahman, Ali, Jahng, & Kadi, 
2012). This reaction requires a strong base (e.g. sodium hydroxide) in the presence of 
alcoholic or aqueous solvent. Alternatively the reaction can occur using a strong acid like 
hydrochloric acid in glacial acetic acid (Leonova et al., 2010). Ketones containing ‘α’ 
methylene groups have a tendency to undergo tautomerisation due to the formation of 
keto/enol-tautomers (Figure 2.1). Sodium hydroxide solution is not basic enough to 
completely form an enolate ion therefore carbanion attack another molecule of aldehyde and 
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form a bond. This allows coupling of (benz) aldehydes with such ketones to form benzylidene 
structures.  
 
Figure 2. 1. Structures of keto and enol intermediates. 
 
Curcumin a yellow carotenoid, natural product can be isolated from turmeric and which along 
with other α,β-unsaturated enones such as caffeic acid have shown promise as antifungal 
agents (Martins et al., 2009). It has been suggested that this small molecule is an encouraging 
lead compound for structural modification. Therefore, in this study, the 1,3-dicarbonyl 
structure of curcumin (11a) was modified by removing the CH2-CO section (to eliminate 
dicarbonyl metal binding) and various analogs were generated as “dienones” which are the 
mono-carbonyl homologs of curcumin, hereafter referred to as 1,4-diene-3-ones. A library of 
thirty-three symmetrical 1,4-diene-3-ones was synthesized using the Claisen-Schmidt 
reaction.  
In this study, the coupling of ketones, such as N-methylpiperidin-4-one (18c), with ring-
substituted benzaldehydes (19) at carbons 3 and 5 of the ketone was accomplished using the               
Claisen-Schmidt reaction in the presence of a base catalyst, usually aqueous ethanolic sodium 
hydroxide to yield compounds 22a-t (Leonova et al., 2010). Various substituents on aromatic 
rings were introduced to vary the magnitude of their hydrophobic, electronic or (iso)steric 
properties. Common steric effects include steric hindrance and Vander Waals repulsion. The 
library of compounds was further extended by reacting heterocyclic aldehydes such as 
pyridinecarboxaldehydes (which contain a nitrogen atom at either the ortho-, meta- or para-
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positions; 20a, 20b, 20c). Alternatively, the pseudo-aromatic 2-thiophencarboxaldehyde (21) 
was coupled with the appropriate ketone; cyclopentanone (18a), cyclohexanone (18b) or N-
methylpiperidin-4-one (18c). 
 
Figure 2. 2. Structures of various aldehydes and ketones. 
Parent cyclopentanone (18a) and cyclohexanone (18b), N-methylpiperidin-4-one (18c), ring 
substituted benzaldehyde (19), 2-pyridinecarboxaldehyde (20a), 3-pyridinecarboxaldehyde 
(20b), 4-pyridinecarboxaldehyde (20c) and 2-thiophenecarboxaldehyde (21), respectively. 
 
 
2.2 Materials and Methods 
2.2.1 Materials 
Chemical reagents were purchased from either Sigma-Aldrich (UK) or Maybridge Chemicals 
and were used without further purification. Solvents were purchased from Fisher Scientific 
(UK). Silica gel plates for thin-layer chromatography (TLC) were obtained from Macherey-
Nagel, Germany: DC-Fertigfolien POLYGRAM SIL G/UV254. TLC was used to monitor the 
reaction and the purity of the compounds. TLCs were visualized using a UVGL-58 handheld 
ultra-violet (UV) lamp (UVP, Cambridge, UK). Melting points (m.pt) were determined using an 
open capillary tube in the heating block of a Griffin melting point apparatus (EDU-LAB: 
EN61010-1) and are uncorrected.  
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Proton, carbon and DEPT (Distortionless Enhancement by Polarization Transfer) NMR spectra 
were recorded using a JEOL ECA400 spectrometer, CDCl3 (deuterated chloroform) was used 
to dissolve the compounds unless otherwise indicated, in which case dimethyl sulfoxide 
(DMSO) was used. Chemical shifts were measured in ppm (δ) for both proton and 13C-NMR. 
Abbreviations used to identify the splitting or coupling patterns were described as s (singlet), 
d (doublet), dd (doublet of doublets), t (triplet), q (quartet), m (multiplet) and br (broad). The 
coupling constant, J values (Hz) were used to measure the interaction between a pair of 
protons.  
Infrared spectra were obtained using a Perkin-Elmer Fourier Transform Infrared Spectrometer 
(SA-LR 64912C) using a golden gate plate attachment point. The IR peaks were measured in 
wavenumbers (cm-1) over the region 4000–400 cm-1. Liquid chromatography-Mass 
spectrometry (LC-MS) analysis was performed to obtain both molecular mass and molecular 
fragments of synthesized compounds using both positive and negative modes. Unless 
indicated otherwise acetonitrile was used as a solvent to dissolve the compounds. LC-MS data 
were recorded using a VG Micromass V15 spectrometer operating at 70 eV (Varian: 210 LC 
pumps x 2, 1200L Quadrupole MS/MS, 410 autosampler). The LC-MS was equipped with a 
Varian Pursuit C18 column (3000 – 050 x 020 mm, 5μm) and eluted using a gradient method 
containing water with 0.1% formic acid and acetonitrile with 0.1% formic acid (90:10 - 10:90 
- 90:10) at a flow rate of 1 ml/min.  
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2.2.2 Experimental section 
2.2.2.1 General method for the synthesis of ring substituted bis(benzylidene) derivatives of 
methylpiperidin-4-one, cyclopentanone and cyclohexanone 
Method A: The synthetic route to compounds (22a-v) is shown in Figure 2.3. The appropriate 
ketone [cyclopentanone (18a), cyclohexanone (18b) or N-methyl-4-piperidone (18c), 10 
mmol] was dissolved in 25 ml of 95% ethanol in a 100 ml round bottom flask. Subsequently, 
a ring substituted benzaldehyde (19, 20 mmol, Table 2.1) was added and stirred, with cooling, 
to 5 °C. An aqueous solution of sodium hydroxide (10% w/v, 10 ml) was added dropwise with 
vigorous stirring. The reaction mixture was stirred for 120 minutes at room temperature until 
a precipitate was obtained. The reaction mixture was monitored using TLC to check the 
progress of the reaction using ethyl acetate/cyclohexane (1:1) as developing solvents.  
 
Figure 2. 3. Synthesis of bis-benzylidene derivatives of N-methylpiperidin-4-one or 
cyclopentanone or cyclohexanone (22a-v). 
The precipitate was filtered under vacuum, rinsed with cold 95% ethanol (normally 3 ml) and 
dried using a vacuum pistol (50 °C) to a constant weight. The crude product was recrystallized 
from dichloromethane (approximately 5 ml) and 95% hot ethanol (approx. 12 ml). The 
resultant crystalline products ranging from white to yellow/ orange or brown in colour 
depending on the ring substituent(s) were filtered under vacuum, rinsed with ice-cold 95% 
ethanol (usually approx. 3 ml) and finally dried to a constant weight using a vacuum pistol             
(50 °C). The purity of each synthesized compound was initially analysed by TLC on silica using 
ethyl acetate/cyclohexane (1:1) as developing solvents, followed by NMR. Due to the cost and 
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limited amount of starting material available, compounds 22q and 22r were prepared on a 
small-scale utilising one mmol of N-methylpiperidin-4-one and two mmol of the relevant 
iodo-benzaldehyde. 
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Table 2. 1. List of various R-substituted bis-benzylidene derivatives of N-methylpiperidin-4-
one and cycloalkanones (22a-v). 
Compound 
 
Where W= 
 
Where R= 
22a -(N-CH3)-CH2- H 
22b -(N-CH3)-CH2- 2-OCH3 
22c -(N-CH3)-CH2- 3-OCH3 
22d -(N-CH3)-CH2- 4-OCH3 
22e -(N-CH3)-CH2- 2-Cl 
22f -(N-CH3)-CH2- 3-Cl 
22g -(N-CH3)-CH2- 4-Cl 
22h -(N-CH3)-CH2- 2, 4-diCl 
22i -(N-CH3)-CH2- 3, 4-diCl 
22j -(N-CH3)-CH2- 2-COOH 
22k -(N-CH3)-CH2- 4-COOH 
22l -(N-CH3)-CH2- 4-CH3 
22m -(N-CH3)-CH2- 3-CF3 
22n -(N-CH3)-CH2- 4-CF3 
22o -(N-CH3)-CH2- 3-OCF3 
22p -(N-CH3)-CH2- 4-OCF3 
22q -(N-CH3)-CH2- 2-I 
22r -(N-CH3)-CH2- 3-I 
22s -(N-CH3)-CH2- 3-NO2 
22t -(N-CH3)-CH2- 4-NO2 
22u -CH2- H 
22v -(CH2)2- H 
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2.2.2.2 Preparation of bis-pyridylidene derivatives of N-methylpiperidin-4-one and 
cycloalkanones 
Method B: The synthetic route to the bis-pyridylidene derivative of N-methylpiperidin-4-one 
or cyclopentanone or cyclohexanone (22a-h) is shown in Figure 2.4. Briefly, a solution 
containing 10 mmol of ketone (cyclopentanone (18a), cyclohexanone (18b) or N-methyl-4-
piperidone (18c)) was prepared in distilled water (40 ml). Subsequently, isomers of pyridine 
carboxaldehyde (20, 20 mmol, Table 2.2) were added (to different reactions) and stirred, with 
cooling, to 5 °C. An aqueous solution of NaOH 10% w/v (2 ml) was added with vigorous 
stirring. The reaction mixture was stirred for 10 hours at room temperature (Vatsadze et al., 
2006). TLC using ethyl acetate/cyclohexane (1:1) as developing solvents was used to monitor 
the progress of the reaction. The reaction mixture was neutralized using a dilute solution of 
hydrochloric acid (≈1 ml). The resultant yellow precipitate was filtered under vacuum, rinsed 
with cold 95% ethanol (usually 3 ml) and dried using a vacuum pistol (50 °C) to a constant 
weight. The crude product was purified using the recrystallization method detailed in section 
2.2.2.1.  
 
Figure 2. 4. Synthesis of bis-pyridylidene derivatives of N-methylpiperidin-4-one or 
cyclopentanone or cyclohexanone (23a-h). 
 
 
 
Chapter 2: Synthesis and characterization of 1,4-diene-3-ones 
 
60 
 
Table 2. 2. List of bis-pyridylidene derivatives of N-methylpiperidin-4-one, cyclopentanone 
and cyclohexanone (23a-h). 
Compound 
 
Where W=  
23a -(N-CH3)-CH2- X=N, Y=H, Z=H 
23b -(N-CH3)-CH2- X=H, Y=N, Z=H 
23c -(N-CH3)-CH2- X=H, Y=H, Z=N 
23d -CH2- X=N, Y=H, Z=H 
23e -CH2- X=H, Y=N, Z=H 
23f -CH2- X=H, Y=H, Z=N 
23g -(CH2)2- X=H, Y=N, Z=H 
23h -(CH2)2- X=H, Y=H, Z=N 
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2.2.2.3 Preparation of bis-thienylidene derivatives of N-methylpiperidin-4-one and 
cycloalkanones 
Compounds 24a-c were prepared using a modification from the method described in section 
2.2.2.2 Method B and their synthetic route is displayed in Figure 2.5.   
 
Figure 2. 5. Synthesis of thienylidene derivatives of N-methylpiperidin-4-one and 
cycloalkanones (24a-c). 
Ketone (10 mmol; 18a, 18b or 18c, Table 2.3) was dissolved in 95% ethanol (15 ml) followed 
by the addition of 20 mmol of 2-thiophenecarboxaldehyde (21), stirred with cooling, to 5 °C. 
An aqueous sodium hydroxide solution (10% w/v, 0.4 ml) was added dropwise with vigorous 
stirring. The reaction mixture was stirred for 10 hours until a yellow precipitate was obtained. 
The progress of the reaction was monitored using TLC with acetate/cyclohexane (1:1) as 
developing solvents. Crude products were recrystallized by following the method described 
above in section 2.2.2.1 Method A. 
Table 2. 3. List of bis-thienylidene derivatives of N-methylpiperidin-4-one, cyclopentanone, 
and cyclohexanone (24a-c). 
Compound 
 
Where W= 
 
24a -(N-CH3)-CH2- 2-thiophene-carboxaldehyde 
24b -CH2- 2-thiophene-carboxaldehyde 
24c -(CH2)2- 2-thiophene-carboxaldehyde 
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A library of thirty-three symmetric 1,4-diene-3-ones (Figure 2.6) contains three groups of 
molecules, namely; bis-benzylidene, bis-pyridylidene or bis-thienylidene derivatives of N-
methylpiperidin-4-one, cyclopentanone and cyclohexanone. All of these compounds contain 
the dienone pharmacophore with an α,β-unsaturated carbonyl group in the centre. 
 
Figure 2. 6. Structures of synthesized 1,4-diene-3-ones. 
Thirty-three symmetric 1,4-diene-3-ones were synthesized using the Claisen-Schmidt 
reaction. Within the molecular classes, R-substituted bis-benzylidene derivatives of N-
methylpiperidin-4-one and cycloalkanones (22a-v), bis-pyridylidene derivatives of N-
methylpiperidin-4-one and cycloalkanones (23a-h) and bis-thienylidene derivatives of N-
methylpiperidin-4-one and cycloalkanones (24a-c). 
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2.3 Results – Spectral data of synthesized 1,4-diene-3-ones 
2.3.1 Spectral data of bis-(benzylidene)-1-methylpiperidin-4-one 
3,5-Bis[(E)benzylidene]-1-methylpiperidin-4-one (22a)  
Yellow powder, 77% yield; m.pt. 110-111 °C, (literature (Pati et al., 2009) m.pt. 110 °C). 1H 
NMR (400 MHz, CDCl3) δ ppm: 2.49 (s, 3 H), 3.87 (s, 4 H), 7.38 - 7.45 (m, 10 H), 7.88 (s, 2 H). 
13C NMR (400 MHz, CDCl3) δ ppm: 45.90, 57.16, 128.32, 128.65, 129.10, 130.48, 133.21, 
135.36, 136.53, 187.02 (C=O). IR (Vmax): 1671.72 (C=O), 1615.41 (C=C, olefinic), 1585.52 (C=C, 
aromatic) cm-1. LC-MS (ESI): m/z calculated for C20H19NO [M+H]+: 289.37; found: 290.6. 
 
3,5-bis[(E)-2-methoxybenzylidene]- 1-methylpiperidin-4-one (22b)  
Yellow crystals, 72% yield; m.pt. 111-113 °C, (literature (Wu et al., 2013) m.pt. 108.2 – 110.9 
°C). 1H NMR (400 MHz, CDCl3) δ ppm: 2.37 (s, 3 H), 3.66 (d, J=1.74 Hz, 4 H), 3.83 (s, 6 H), 6.90 
– 6.98 (m, 4 H), 7.18 - 7.20 (dd, J=7.60, 1.56 Hz, 2 H), 7.31 - 7.35 (m, J=1.65 Hz, 2 H), 8.06 (s, 2 
H). 13C NMR (400 MHz, CDCl3) δ ppm: 45.62, 55.71, 57.24, 110.72, 110.98, 119.93, 120.23, 
124.59, 130.14, 130.30, 130.62, 132.22, 133.13, 158.56, 187.05 (C=O). IR (Vmax): 1667.9 (C=O), 
1606 (C=C, olefinic), 1575.1 (C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated for C22H23NO3, 
[M+H]+: 349.43; found: 350.5. 
 
3,5-bis[(E)-3-methoxybenzylidene]- 1-methylpiperidin-4-one (22c)  
Yellow crystals, 84% yield; m.pt. 115-117 °C. 1H NMR (400 MHz, CDCl3) δ ppm: 2.44 (s, 3 H), 
3.75 (d, J=1.56 Hz, 4 H), 3.83 (s, 6 H), 6.89 – 6.92 (m, 4 H), 6.96 - 6.99 (d, 4 H), 7.32 - 7.33 (m, 
2 H), 7.77 (s, 2 H). 13C NMR (400 MHz, CDCl3) δ ppm: 45.91, 55.41, 57.15, 114.65, 115.97, 
122.86, 129.64, 133.39, 136.48, 136.62, 159.60, 186.97 (C=O). IR (Vmax): 1670.81 (C=O), 
1603.12 (C=C, olefinic), 1575.81 (C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated for 
C22H23NO3, [M+H]+: 349.43; found: 350.5. 
 
3,5-bis[(E)-4-methoxybenzylidene]-1-methylpiperidin-4-one (22d)  
Yellow crystals, 95% yield; m.pt. 187-188°C, (literature (Pati et al., 2009) m.pt. 186°C). 1H NMR 
(400 MHz, CDCl3) δ ppm: 2.48 (s, 3 H), 3.77 (s, J=1.56 Hz, 4 H), 3.84 (s, 6 H), 6.93 - 6.95 (d, 4 
H), 7.35 - 7.37 (d, 4 H), 7.77 (s, 2 H). 13C-NMR (400 MHz, CDCl3) δ ppm: 45.55, 55.46, 56.97, 
114.20, 127.92, 130.62, 132.46, 136.69, 160.42, 186.51 (C=O). IR (Vmax): 1669.91 (C=O), 
1596.12 (C=C, olefinic), 1515.11 (C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated for 
C22H23NO3, [M+H]+: 349.43; found: 350.4. 
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3,5-bis[(E)-2-chlorobenzylidene]-1-methylpiperidin-4-one (22e)  
Yellow crystals, 75% yield; m.pt. 142-143.5°C, (literature (Wu et al., 2013) m.pt. 143-145.2°C). 
1H NMR (400 MHz, CDCl3) δ ppm: 2.38 (s, 3 H), 3.65 (d, J=1.56 Hz, 4 H), 7.21 – 7.23 (m, 2 H), 
7.27 – 7.33 (m, 4 H), 7.43 - 7.46 (m, 2 H), 8.02 (s, 4 H). 13C-NMR (400 MHz, CDCl3) δ ppm: 45.27, 
56.54, 126.56, 130.06, 130.22, 130.42, 133.56, 133.80, 134.63, 135.25, 185.95 (C=O). IR (Vmax): 
1679.91 (C=O), 1586.12 (C=C, olefinic), 1459.11 (C=C, aromatic) cm-1. LC-MS (ESI): m/z 
calculated for C20H17Cl2NO, [M+H]+: 358.26; found: 359.5. 
 
3,5-bis[(E)-3-chlorobenzylidene]-1-methylpiperidin-4-one (22f)  
Pale yellow powder, yield: 79%, m.pt. 152-154°C. 1H NMR (400 MHz, CDCl3) δ ppm: 2.48 (s, 3 
H), 3.76 (d, J=1.56 Hz, 4 H), 7.24 – 7.27 (m, 2 H), 7.33 - 7.38 (m, 6 H), 7.73 (s, 4 H). 13C-NMR 
(400 MHz, CDCl3) δ ppm: 45.61, 56.68, 128.53, 129.27, 129.99, 130.06, 133.54, 134.66, 
135.61, 136.81, 186.21 (C=O). IR (Vmax): 1679.01 (C=O), 1576.11 (C=C, olefinic), 1489.61 (C=C, 
aromatic) cm-1. LC-MS (ESI): m/z calculated for C20H17Cl2NO, [M+H]+: 358.26; found: 359.5. 
 
3,5-bis[(E)-4-chlorobenzylidene]-1-methylpiperidin-4-one (22g)  
Pale yellow powder, yield: 81%; m.pt. 170-171°C, (literature (Leonard & Locke, 1955) m.pt. 
174-176°C). 1H NMR (400 MHz, CDCl3) δ ppm: 2.47 (s, 3 H), 3.75 (d, J=1.56 Hz, 4 H), 7.29 – 7.32 
(m, 4 H), 7.37 - 7.40 (m, 4 H), 7.76 (s, 4 H). 13C-NMR (400 MHz, CDCl3) δ ppm: 45.60, 56.79, 
129.02, 131.70, 132.82, 133.50, 135.36, 135.83, 186.22 (C=O). IR (Vmax): 1676.31 (C=O), 
1578.31 (C=C, olefinic), 1499.42 (C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated for 
C20H17Cl2NO, [M+H]+: 358.26; found: 359.1. 
 
3,5-bis[(E)-2,4-dichlorobenzylidene]-1-methylpiperidin-4-one (22h)  
Yellow crystals, 71% yield; m.pt. 146-147 °C, (literature (Wu et al., 2013) m.pt. 145.9-147.6 
°C). 1H NMR (400 MHz, CDCl3) δ ppm: 2.37 (s, 3 H), 3.56 (d, J=1.46 Hz, 4 H), 7.16 (d, J=8.33 Hz, 
2 H), 7.27 - 7.29 (m, 2 H), 7.47 (d, J=2.11 Hz, 2 H), 7.90 (s, 2 H). 13C NMR (400 MHz, CDCl3) δ 
ppm: 45.72, 56.71, 126.98, 130.02, 131.09, 132.13, 133.07, 134.62, 135.46, 136.06, 185.86 
(C=O). IR (Vmax): 1676.41 (C=O), 1621.83 (C=C, olefinic), 1580.81 (C=C, aromatic) cm-1. LC-MS 
(ESI): m/z calculated for C20H15Cl4NO, [M+H]+: 427.15; found: 428.3. 
 
3,5-bis[(E)-3,4-dichlorobenzylidene]-1-methylpiperidin-4-one (22i)  
Yellow crystals 74% yield; m.pt. 162-164 °C. 1H NMR (400 MHz, CDCl3) δ ppm: 2.47 (s, 3 H), 
3.70 (d, J=1.83 Hz, 4 H), 7.19 (d, J=2.11 Hz, 1 H), 7.21 (d, J=2.11 Hz, 1 H), 7.45 (d, J=2.11 Hz, 2 
H), 7.47 (s, 1 H), 7.50 (s, 1 H), 7.65 (s, 2 H). 13C NMR (400 MHz, CDCl3) δ ppm: 45.97, 56.82, 
129.49, 130.73, 131.83, 133.00, 133.40, 134.11, 134.29, 135.08, 186.18 (C=O). IR (Vmax): 
1676.41 (C=O), 1617.23 (C=C, olefinic), 1585.42 (C=C, aromatic) cm-1. LC-MS (ESI): m/z 
calculated for C20H15Cl4NO, [M+H]+: 427.15; found: 428.3. 
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2,2’-((1E, 1’E)-(1-methyl-4-oxopiperidine-3,5-diylidene)bis(methaneylylidene))dibenzoic 
acid (22j) 
White powder, 71% yield; m.pt. 227-229 °C. 1H NMR (400 MHz, DMSO-d6) δ ppm 2.65 (s, 3 H), 
3.09 (br s, 2 H), 4.15 (br s, 2 H), 6.26 - 6.27 (d, 2 H), 7.65 – 7.72 (d, J=8.51 Hz, 4 H), 7.89 – 7.91 
(d, J=8.33 Hz, 4 H). 13C NMR (400 MHz, DMSO-d6) δ ppm: 49.00, 51.64, 76.60, 123.63, 125.82, 
130.50, 135.50, 147.70, 169.95 (C=O). IR (Vmax): 1767.42 (C=O), 1731.11 (C=C, olefinic), 
1641.14 (C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated for C22H19NO5, [M+H]+: 377.41; 
found: 378.4. 
 
4,4’-((1E, 1’E)-(1-methyl-4-oxopiperidine-3,5-diylidene)bis(methaneylylidene))dibenzoic 
acid (22k) 
Pale yellow powder, 74% yield; m.pt. 254-256 °C. 1H NMR (400 MHz, DMSO-d6) δ ppm: 2.93 
(s, 3 H), 4.61 (br s, 4 H), 7.66 (d, J=8.51 Hz, 4 H), 7.91 (s, 2 H), 8.05 (d, J=8.33 Hz, 4 H), 10.11 (s, 
2 H). 13C NMR (400 MHz, DMSO-d6) δ ppm: 43.03, 53.90, 130.19, 131.35, 132.19, 138.17, 
138.72, 167.29 (C=O). IR (Vmax): 1703.72 (C=O), 1676.43 (C=C, olefinic), 1617.24 (C=C, 
aromatic) cm-1. LC-MS (ESI): m/z calculated for C22H19NO5, [M+H]+: 377.41; found: 378.4. 
 
3,5-bis[(E)-4-methylbenzylidene]-1-methylpiperidin-4-one (22l)  
Yellow crystals, 91% yield; m.pt. 192-193 °C, (literature (Leonard & Locke, 1955) m.pt. 192-
195 °C). 1H NMR (400 MHz, CDCl3) δ ppm 2.38 (s, 6 H), 2.46 (s, 3 H), 3.75 - 3.76 (m, 4 H), 7.21 
- 7.24 (m, 4 H), 7.29 - 7.31 (m, 4 H), 7.79 (s, 2 H). 13C NMR (400 MHz, CDCl3) δ ppm: 21.55, 
46.00, 57.29, 129.40, 130.61, 132.52, 136.49, 139.41, 187.08 (C=O). IR (Vmax): 1676.41 (C=O), 
1617.22 (C=C, olefinic), 1605.11 (C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated for 
C22H23NO, [M+H]+: 317.43; found 318.5. 
 
3,5-bis[(E)-3-trifluoromethylbenzylidene]-1-methylpiperidin-4-one (22m)  
Yellow crystals, 71% yield; m.pt. 122-123 °C. 1H NMR (400 MHz, CDCl3) δ ppm 2.47 (s, 3 H), 
3.73 (d, J=1.74 Hz, 4 H), 7.25 (s, 2 H), 7.27 (s, 2 H), 7.39 - 7.43 (d, 4 H), 7.76 (s, 2 H). 13C NMR 
(400 MHz, CDCl3) δ ppm: 46.06, 57.02, 120.65, 121.24, 131.67, 133.66, 133.80, 135.21, 
149.52, 186.58 (C=O). IR (Vmax): 1676.41 (C=O), 1617.22 (C=C, olefinic), 1580.84 (C=C, 
aromatic) cm-1. LC-MS (ESI): m/z calculated for C22H17F6NO, [M+H]+: 425.37; found 426.4. 
 
3,5-bis[(E)-4-trifluoromethylbenzylidene]-1-methylpiperidin-4-one (22n)  
Yellow crystals, 78% yield; m.pt. 123-124 °C. 1H NMR (400 MHz, CDCl3) δ ppm 2.46 (s, 3 H), 
3.74 (d, J=1.83 Hz, 4 H), 7.47 – 7.50 (d, 4 H), 7.67 – 7.69 (d, 4 H), 7.80 (s, 2 H). 13C-NMR (400 
MHz, CDCl3) δ ppm: 45.42, 56.12,; 124.22, 125.72, 126.22, 130.29, 131.23, 133.29, 134.77, 
135.28, 138.63, 186.42 (C=O). IR (Vmax): 1676.41 (C=O), 1612.12 (C=C, olefinic), 1590.21 (C=C, 
aromatic) cm-1. LC-MS (ESI): m/z calculated for C22H17F6NO, [M+H]+: 425.37; found 426.4. 
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3,5-bis[(E)-3-trifluoromethoxybenzylidene]-1-methylpiperidin-4-one (22o)  
Yellow crystals, 73% yield; m.pt. 98-99 °C. 1H NMR (400 MHz, CDCl3) δ ppm 2.46 (s, 3 H), 3.73 
(d, J=1.83 Hz, 4 H), 7.22 (d, 4 H), 7.30 – 7.32 (d, 2 H), 7.43 – 7.47 (m, 2 H), 7.75 (s, 2 H). 13C 
NMR (400 MHz, CDCl3) δ ppm: 45.89, 56.89, 121.39, 122.48, 128.66, 130.09, 134.32, 134.89, 
137.15, 149.38, 186.46 (C=O). IR (Vmax): 1675.21 (C=O), 1620.52 (C=C, olefinic), 1588.62 (C=C, 
aromatic) cm-1. LC-MS (ESI): m/z calculated for C22H17F6NO, [M+H]+: 457.30; found 458.4. 
 
3,5-bis[(E)-4-trifluoromethoxybenzylidene]-1-methylpiperidin-4-one (22p)  
Yellow crystals, 71% yield; m.pt. 95-97 °C. 1H NMR (400 MHz, CDCl3) δ ppm 2.46 (s, 3 H), 3.75 
(d, J=1.65 Hz, 4 H), 7.22 (d, 4 H), 7.55 – 7.56 (m, 4 H), 7.62 – 7.64 (d, 4 H), 7.81 (s, 2 H). 13C-
NMR (400 MHz, CDCl3) δ: 45.42, 56.12, 125.62, 127.01, 127.34, 128.11, 129.19, 133.29, 
134.41, 135.28, 135.92, 186.11 (C=O). IR (Vmax): 1676.41 (C=O), 1617.22 (C=C, olefinic), 
1590.21 (C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated for C22H17F6NO, [M+H]+: 457.30; 
found 458.4. 
 
3,5-bis[(E)-2-iodobenzylidene]-1-methylpiperidin-4-one (22q)  
Yellow powder, 68% yield; m.pt. 141-143 °C. 1H NMR (400 MHz, CDCl3) δ ppm: 2.34 (s, 3 H), 
3.54 (d, J=1.74 Hz, 4 H), 7.01 – 7.06 (t, J=1.65 Hz, 2 H), 7.17  - 7.20 (d, J=1.65 Hz, 2 H), 7.36 – 
7.40 (t, J=1.65 Hz, 2 H), 7.81 (s, 2 H), 7.92 (d, J=1.65 Hz, 2 H). 13C NMR (400 MHz, CDCl3) δ ppm: 
45.57, 56.52, 100.60, 127.94, 129.67, 130.11, 133.63, 139.08, 139.67, 140.50, 185.98 (C=O). 
IR (Vmax): 1676.8 (C=O), 1618.6 (C=C, olefinic), 1584.6 (C=C, aromatic) cm-1. LC-MS (ESI): m/z 
calculated for, C20H17I2NO, [M+H]+: 540.84; found 542.3. 
 
3,5-bis[(E)-3-iodobenzylidene]-1-methylpiperidin-4-one (22r)  
Pale yellow crystals, 53% yield; m.pt. 139-140 °C. 1H NMR (400 MHz, CDCl3) δ ppm: 2.46 (s, 3 
H), 3.70 (d, J=1.74 Hz, 4 H), 7.15 (t, 2 H), 7.32 (d, 2 H), 7.68 (d, 2 H), 7.71 (m, 4 H). 13C NMR 
(400 MHz, CDCl3) δ ppm: 45.84, 56.81, 94.46, 129.36, 130.25, 134.06, 134.96, 137.39, 137.93, 
138.94, 186.44 (C=O). IR (Vmax): 1672 (C=O), 1613.7 (C=C, olefinic), 1589.5 (C=C, aromatic) cm-
1. LC-MS (ESI): m/z calculated for, C20H17I2NO, [M+H]+: 540.84; found 542.3. 
 
3,5-bis[(E)-3-nitrobenzylidene]-1-methylpiperidin-4-one (22s) 
Pale yellow powder, 60% yield; m.pt. 158-160 °C. 1H NMR (400 MHz, CDCl3) δ ppm: 2.49 (s, 3 
H), 3.78 (d, J=1.65 Hz, 4 H), 7.60 – 7.65 (t, 2 H), 7.70 – 7.72 (d, 2 H), 7.81 (s, 2 H), 8.22 – 8.24 
(d, J=1.28 Hz, 4 H). 13C NMR (400 MHz, CDCl3) δ ppm: 45.97, 56.71, 123.77, 124.54, 129.85, 
134.06, 135.08, 136.10, 136.64, 148.44, 186.03 (C=O). IR (Vmax): 1672 (C=O), 1595 (C=C, 
olefinic), 1347 (NO2) cm-1. LC-MS (ESI): m/z calculated for C20H17N3O5, [M+H]+: 379.04; found 
380.3. 
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3,5-bis[(E)-4-nitrobenzylidene]-1-methylpiperidin-4-one (22t)  
Brownish orange powder, 48% yield; m.pt. 203-205 °C, (literature (El-Subbagh, Abu-Zaid, 
Mahran, Badria, & Al-Obaid, 2000) m.pt. 204-205 °C). 1H NMR (400 MHz, CDCl3) δ ppm: 2.47 
(s, 3 H), 3.75 (d, J=1.83 Hz, 4 H), 7.52 – 7.54 (d, 4 H), 7.81 (s, 2 H), 8.27 – 8.29 (d, 4 H). 13C NMR 
(400 MHz, CDCl3) δ ppm: 45.97, 56.92, 94.46, 123.93, 130.91, 134.18, 135.74, 141.40, 147.72, 
186.06 (C=O). IR (Vmax): 1652.8 (C=O), 1598.2 (C=C, olefinic), 1346.8 (NO2) cm-1. LC-MS (ESI): 
m/z calculated for C20H17N3O5, [M+H]+: 379.04; found 380.5. 
 
 
2.3.2 Spectral data of bis-(benzylidene)cycloalkanones 
2,5-bis[(E)-(benzylidene]cyclopentanone (22u)  
Yellow crystals, 83% yield; m.pt. 190-192 °C, (literature (Vatsadze et al., 2006) m.pt. 196 °C). 
1H NMR (400 MHz, CDCl3) δ ppm: 3.12 (t, 4 H), 7.36 - 7.40 (m, 2 H), 7.42 – 7.46 (m, 4 H), 7.59 
– 7.60 (m, 4 H), 7.61 (br s, 2 H). 13C NMR (400 MHz, CDCl3) δ ppm: 26.65, 128.87, 129.49, 
130.86, 133.97, 135.89, 137.39, 196.55 (C=O). IR (Vmax): 1689.39 (C=O), 1621.48 (C=C, 
olefinic), 1597.14 (C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated for C19H16O, [M+H]+: 
260.12; found 261.1. 
 
2,6-Bis[(E)-(benzylidene]cyclohexanone (22v)  
Yellow crystals, 79% yield; m.pt. 119-120 °C, (literature (Vatsadze et al., 2006) m.pt. 118 °C). 
1H NMR (400 MHz, CDCl3) δ ppm: 1.75 – 1.82 (p, 2 H), 2.91 – 2.95 (td, 4 H), 7.31 - 7.35 (m, 2 
H), 7.38 – 7.42 (m, 4 H), 7.45 – 7.47 (m, 4 H), 7.80 (s, 2 H). 13C NMR (400 MHz, CDCl3) δ ppm: 
23.11, 28.56, 128.48, 128.69, 130.48, 136.06, 136.27, 137.06, 190.55 (C=O). IR (Vmax): 1682.32 
(C=O), 1617.34 (C=C, olefinic), 1591.41 (C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated for 
C20H18O, [M+H]+: 274.14; found 275.5. 
 
 
2.3.3 Spectral data of bis-pyridylidene derivatives of N-methylpiperidin-4-one and 
cycloalkanones 
(3E,5E)-1-methyl-3,5-bis(pyridine-2-ylmethylene)piperidin-4one (23a) 
Yellow crystals, 87% yield; m.pt. 148-150 °C, (literature (Moore, Zhu, Randolph, Shoji, & 
Snyder, 2014) m.pt. 148-150 °C). 1H NMR (400 MHz, CDCl3) δ ppm: 2.44 (s, 3 H), 3.72 (br d, 
J=1.83 Hz, 4 H), 7.32 – 7.35 (dd, J=7.96, 4.85 Hz, 2 H), 7.65 – 7.67 (dt, J=8.06, 1.92 Hz, 2 H), 
7.73 (s, 2 H), 8.55 - 8.57 (dd, J=4.85, 1.56 Hz, 2 H) 8.63 (d, J=2.20 Hz, 2 H). 13C NMR (400 MHz, 
CDCl3) δ ppm: 45.94, 56.97, 123.55, 131.05, 132.95, 134.76, 137.19, 149.82, 151.08, 186.01 
(C=O). IR (Vmax): 1676.8 (C=O), 1613.7 (C=C, olefinic), 1597.9 (C=C, aromatic) cm-1. LC-MS (ESI): 
m/z calculated for C18H17N3O, [M+H]+: 291.35; found 292.4. 
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(3E,5E)-1-methyl-3,5-bis(pyridine-3-ylmethylene)piperidin-4one (23b)  
Yellow crystals, 76% yield; m.pt. 140-141 °C, (literature (Vatsadze et al., 2006) m.pt. 139 °C). 
1H NMR (400 MHz, CDCl3) δ ppm: 2.40 (s, 3 H), 3.70 (d, J=1.74 Hz, 4 H), 7.29 – 7.32 (ddd, 
J=7.92, 4.81, 0.82 Hz, 2 H), 7.61 – 7.64 (tt, J=7.91 Hz, 2 H), 7.69 (s, 2 H), 8.51 - 8.53 (dd, J=4.85, 
1.65 Hz, 2 H) 8.58 - 8.58 (d, J=2.29 Hz, 2 H). 13C NMR (400 MHz, CDCl3) δ ppm: 45.86, 56.89, 
123.54, 130.99, 132.97, 134.66, 137.16, 149.79, 151.06, 185.91 (C=O). IR (Vmax): 1672 (C=O), 
1615.6 (C=C, olefinic), 1579.7 (C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated for C18H17N3O, 
[M+H]+: 291.35; found 292.4. 
 
(3E,5E)-1-methyl-3,5-bis(pyridine-4-ylmethylene)piperidin-4one (23c) 
Yellow crystals, 46% yield; m.pt. 180-182 °C, (literature (Dimmock et al., 1992) m.pt. 188-190 
°C). 1H NMR (400 MHz, CDCl3) δ ppm: 2.46 (s, 3 H), 3.75 (d, J=1.83 Hz, 4 H), 7.22 – 7.24 (dd, 
J=7.92 Hz, 4 H), 7.68 (s, 2 H), 8.67 - 8.69 (dd, J=7.92 Hz, 4 H). 13C NMR (400 MHz, CDCl3) δ ppm: 
45.72, 56.67, 124.03, 134.00, 135.99, 142.36, 150.29, 185.94 (C=O). IR (Vmax): 1676.8 (C=O), 
1620 (C=C, olefinic), 1587.9 (C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated for C18H17N3O, 
[M+H]+: 291.35; found 292.4. 
 
(2E,5E)-2,5-bis(pyridin-2-ylmethylene)cyclopentan-1-one (23d)  
Pale yellow powder, 94% yield; m.pt. 190-192 °C, (literature (Vatsadze et al., 2006) m.pt. 195 
°C). 1H NMR (400 MHz, CDCl3) δ ppm: 3.35 (t, 4 H), 7.21 - 7.24 (m, 2 H), 7.51 – 7.53 (d, 2 H), 
7.55 (s, 2 H), 7.71 – 7.75 (m, 2 H), 8.73 – 8.75 (d, 2 H). 13C NMR (400 MHz, CDCl3) δ ppm: 27.25, 
122.88, 127.23, 131.61, 136.36, 141.97, 150.09, 155.23, 197.83 (C=O). IR (Vmax): 1699.6 (C=O), 
1636.6 (C=C, olefinic), 1617.2 (C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated for C17H14N2O, 
[M+H]+: 262.31; found 263.4. 
 
(2E,5E)-2,5-bis(pyridin-3-ylmethylene)cyclopentan-1-one (23e)  
Pale yellow powder, 81% yield; m.pt. 216-218 °C, (literature (Vatsadze et al., 2006) m.pt. 216 
°C). 1H NMR (400 MHz, CDCl3) δ ppm: 3.12 (t, 4 H), 7.34 – 7.37 (m, 2 H), 7.53 (s, 2 H), 7.84 – 
7.87 (dt, J=7.99, 1.91 Hz, 2 H), 8.56 – 8.58 (dd, J=4.81, 1.60 Hz, 2 H), 8.81 - 8.82 (d, J=2.20 Hz, 
2 H) . 13C NMR (400 MHz, CDCl3) δ ppm: 26.50, 123.75, 130.71, 131.57, 137.12, 138.89, 149.98, 
151.74, 195.31 (C=O). IR (Vmax): 1685 (C=O), 1622 (C=C, olefinic), 1602.6 (C=C, aromatic) cm-1. 
LC-MS (ESI): m/z calculated for C17H14N2O, [M+H]+: 262.31; found 263.4. 
 
(2E,5E)-2,5-bis(pyridin-4-ylmethylene)cyclopentan-1-one (23f)  
Pale yellow powder, 84% yield; m.pt. 236-238 °C, (literature (Vatsadze et al., 2006) m.pt. 239 
°C). 1H NMR (400 MHz, CDCl3) δ ppm: 3.14 (t, 4 H), 7.38 – 7.40 (dd, 4 H), 7.47 (s, 2 H), 8.67 – 
8.69 (dd, 4 H). 13C NMR (400 MHz, CDCl3) δ ppm: 26.45, 124.18, 131.63, 140.91, 142.58, 
150.48, 195.43 (C=O). IR (Vmax): 1694.8 (C=O), 1636.6 (C=C, olefinic), 1597.9 (C=C, aromatic) 
cm-1. LC-MS (ESI): m/z calculated for C17H14N2O, [M+H]+: 262.31; found 263.4. 
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(2E,6E)-2,6-bis(pyridin-3-ylmethylene)cyclohexan-1-one (23g)  
Yellow crystals, 93% yield; m.pt. 140-142 °C, (literature (Vatsadze et al., 2006) m.pt. 139 °C). 
1H NMR (400 MHz, CDCl3) δ ppm: 1.80 – 1.86 (p, 2 H), 2.91 – 2.94 (td, 4 H), 7.36 - 7.38 (dd, 2 
H), 7.74 (s, 2 H), 7.76 – 7.78 (t, 2 H), 8.55 – 8.57 (dd, 2 H), 8.70 – 8.71 (d, 2 H). 13C NMR (400 
MHz, CDCl3) δ ppm: 22.80, 28.44, 123.51, 131.86, 133.59, 137.45, 137.88, 149.03, 149.18, 
150.82, 150.97, 189.27 (C=O). IR (Vmax): 1665.9 (C=O), 1607.3 (C=C, olefinic), 1578 (C=C, 
aromatic) cm-1. LC-MS (ESI): m/z calculated for C18H16N2O, [M+H]+: 276.33; for 277.4. 
(2E,6E)-2,6-bis(pyridine-4-ylmethylene)cyclohexan-1-one (23h)  
Yellow powder, 86% yield; m.pt. 145-146 °C, (literature (Vatsadze et al., 2006) m.pt. 150 °C). 
1H (400 MHz, CDCl3) δ ppm: 1.82 – 1.88 (p, 2 H), 2.92 – 2.95 (td, 4 H), 7.39 - 7.40 (dd, 4 H), 
7.68 (s, 2 H), 8.67 – 8.69 (dd, 4 H). 13C NMR (400 MHz, CDCl3) δ ppm: 22.80, 28.44, 123.51, 
131.86, 133.59, 137.45, 137.88, 149.03, 149.18, 150.82, 150.97, 189.27 (C=O). IR (Vmax): 
1665.9 (C=O), 1601 (C=C, olefinic), 1592.7 (C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated 
for C18H16N2O, [M+H]+: 276.33; for 277.4. 
 
2.3.4 Spectral data of bis-thienylidene derivatives of N-methylpiperidin-4-one and 
cycloalkanones 
(3E,5E)-1-methyl-3,5-bis(thiophen-2-ylmethylene)piperidin-4-one (24a)  
Yellow crystals, 89% yield; m.pt. 109-110 °C, (literature (El-Subbagh et al., 2000) m.pt. 114-
115 °C). 1H NMR (400 MHz, CDCl3) δ ppm: 2.63 (s, 3 H), 3.92 (br s, 4 H), 7.15 – 7.17 (dd, 2 H), 
7.34 – 7.35 (d, 2 H), 7.57 – 7.58 (d, 2 H), 7.98 (s, 2 H). 13C NMR (400 MHz, CDCl3) δ ppm: 45.88, 
56.60, 128.08, 128.72, 130.02, 130.63, 133.26, 138.72, 185.97 (C=O). IR (Vmax): 1663.6 (C=O), 
1601.3 (C=C, olefinic), 1572.6 (C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated for 
C16H15NOS2, [M+H]+: 301.43; found 302.3. 
 
(2E,5E)-2,5-bis(thiophen-2-ylmethylene)cyclopentan-1-one (24b)  
Yellow crystals, 93% yield; m.pt. 224-225 °C, (literature (Vatsadze et al., 2006) m.pt. 222 °C). 
1H NMR (400 MHz, CDCl3) δ ppm: 3.03 (t, 4 H), 7.15 – 7.17 (dd, 2 H), 7.39 – 7.40 (d, 2 H), 7.56 
– 7.70 (d, 2 H), 7.797 (s, 2 H). 13C NMR (400 MHz, CDCl3) δ ppm: 26.12, 126.38, 128.23, 130.48, 
132.76, 135.89, 140.50, 195.17 (C=O). IR (Vmax): 1682.8 (C=O), 1596.5 (C=C, olefinic), 1508 
(C=C, aromatic) cm-1. LC-MS (ESI): m/z calculated for C15H12OS2, M.Wt: 272.39; found 273.3. 
 
(2E,6E)-2,6-bis(thiophen-2-ylmethylene)cyclohexan-1-one (24c)  
Yellow powder, 90% yield; m.pt. 169-170 °C, (literature (Vatsadze et al., 2006) m.pt. 169 °C). 
1H NMR (400 MHz, CDCl3) δ ppm: 1.91 – 1.97 (p, 2 H), 2.88 - 2.92 (td, 4 H), 7.11 – 7.13 (dd, 
J=5.13, 3.66 Hz, 2 H), 7.35 – 7.36 (d, J=3.66 Hz, 2 H), 7.50 – 7.51 (d, J=5.12 Hz, 2 H), 7.97 (s, 2 
H). 13C NMR (400 MHz, CDCl3) δ ppm: 21.74, 28.21, 127.72, 129.84, 130.06, 132.94, 133.12, 
139.60, 189.08 (C=O). IR (Vmax): 1649.2 (C=O), 1582.2 (C=C, olefinic), 1543.8 (C=C, aromatic) 
cm-1. LC-MS (ESI): m/z calculated for C16H14OS2, [M+H]+: 286.41; found 287.3.
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2.4 Discussion of bis-benzylidene, bis-pyridylidene and bis-thienylidene 
derivatives of N-methylpiperidin-4-one, cyclopentanone and cyclohexanone 
Several methods have been developed to synthesize bis-benzylidene-
piperidone/cyclohexanone (containing 1,4-diene-3-one pharmacophore), which differ in the 
nature of the catalyst or solvent use for the reaction (Dong, Jian, Zhenghao, Kai, & Zuliang, 
2008; Wu et al., 2013; Moore et al., 2014). Some researchers have mentioned the use of dry 
hydrogen chloride and acetic acid as a catalyst to facilitate the reaction e.g. bis-benzylidene-
cyclohexanone (Das et al., 2008; Pati et al., 2009).  
In the present study, a Claisen-Schmidt condensation of cyclopentanone, cyclohexanone or 
N-methyl-piperidin-4-one with aromatic and heteroaromatic aldehydes was performed and a 
series of symmetrical 1,4-diene-3-one compounds were synthesized. The bis-benzylidene and 
bis-thienylidene derivatives of N-methylpiperidin-4-one, cyclopentanone and 
cyclohexanones (22a-v and 24a-c) were synthesized using basic catalyst in aqueous-ethanolic 
media whereas bis-pyridylidene derivatives of N-methylpiperidin-4-one, cyclopentanone or 
cyclohexanone (23a-h) were synthesized using basic catalyst in aqueous media using a 
modification of a previously reported method described by Vatsadze et al., (2006). 
Heterocyclic aromatic compounds were synthesized to increase the solubility of the 
compounds (Moore et al., 2014). As pyridine improves the aqueous solubility due to its weak 
basicity (Hamada, 2018).  
The synthesized compounds were purified by recrystallization method using dichloromethane 
and 95% hot ethanol.  Yields of the synthesized 1,4-diene-3-ones ranged from 48 to 95%. The 
purity of 1,4-diene-3-ones was analysed by melting point, TLC and NMR whereas their 
structures were established using FT-IR, LC-MS, 1H and 13C-NMR analysis and their structural 
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details mentioned in section 2.3. The melting point of compounds 22a, 22b, 22d, 22e, 22g, 
22h, 22l, 22t, 22u, 22v, 23a-h and 24a-c agreed with those quoted in the literature (Leonard 
& Locke, 1955; Dimmock et al., 1992; El-Subbagh et al., 2000; Vatsadze et al., 2006; Pati et 
al., 2009; Wu et al., 2013; Moore et al., 2014). Moreover, compounds 22c, 22f, 22i, 22j, 22k, 
and 22m-s were novel synthesized compounds. The melting point of all synthesized 
compounds was within 1-3 °C range, which is consistent with these compounds being pure.  
The molecular mass of each of the synthesized 1,4-diene-3-one was calculated using the 
ChemDraw Professional 16.0 software (Perkin Elmer). The mass spectra of all the synthesized 
compounds showed their molecular ion peak at the expected value, corresponding to the 
molecular mass ion measured under positive ion mode. Therefore, the mass to charge ratio 
(m/z) of each compound was M+1 which is expressed as M+H. FT-IR spectroscopic analysis of 
all 1,4-diene-3-ones gave a peak corresponding to an unsaturated carbonyl (C=O) group in the 
region of 1600 cm-1 signifying the presence of a carbonyl group. In addition, an IR peak 
between the region of 1390-1595 cm-1, represents the presence of an olefinic (C=C) double 
bonds in all compounds.  
The presence of carbonyl (C=O) is further confirmed by 13C-NMR resonances between 180 
and 198 ppm for compounds 22a-I, 22l-v, 23a-h and 24a-c whereas compounds 22j and 22k 
gave resonances at 170 and 167 ppm respectively. This shift in the resonance is possibly due 
to the use of different solvent for NMR analysis as both compounds 22j and 22k were not 
soluble in CDCl3 and therefore DMSO-d6 was used. Alternatively this could be due to the 
presence of carboxylic acid group attached to the aromatic rings. Compound 22j has a 
carboxylic acid group at the ortho-position whereas 22k has a carboxyl group at the para-
position of the aromatic rings. 
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The 1H-NMR spectra of 1,4-diene-3-ones containing a central piperidyl ring with nitrogen 
atom (22a-t, 23a-c and 24a) displayed the presence of aliphatic protons (-CH3) with a singlet 
peak between δ 2.38 to 2.48 ppm for the methyl protons. Other aliphatic methylene protons 
-CH2, one each attached to the nitrogen atom of the various piperidine dienone derivatives 
exhibit a singlet peak ranging between δ 3.56 to 3.84 ppm depending on the derivative. In 
contrast the derivatives of cyclopentanone and cyclohexanone have multiple CH2 groups 
these being two in the case of cyclopentanone and three in the case of cyclohexanone. The 
1H-NMR spectra of bis-benzylidene derivatives of cyclopentanone (22u), bis-pyridylidene 
derivatives of cyclopentanone (23d-f) and bis-thienylidene derivative of cyclopentanone 
(24b) showed an aliphatic protons (-CH2) with a triplet peak between δ 3.03 and 3.35 ppm. 
Likewise, the 1H-NMR spectra of bis-benzylidene derivatives of cyclohexanone (22v), bis-
pyridylidene derivatives of cyclohexanone (23g-h) and bis-thienylidene derivative of 
cyclohexanone (24c) displayed the presence of an three sets of aliphatic protons; first (-CH2) 
showed a pentet peak between δ 1.80 and 1.97 ppm and second (-CH2)2 showed three 
doublet peaks between δ 2.88 and 2.95 ppm. 
The 1H-NMR spectra of 1,4-diene-3-one compounds (bis-benzylidene, bis-pyridylidene and                                  
bis-thienylidene derivatives of N-methylpiperidin-4-one and cycloalkanones) revealed the 
presence of (two) olefinic protons (attached at the β-carbon) between δ 7.47 – 7.89 ppm, 
which is characteristic of E isomers (Das et al., 2008). The synthesized 1,4-diene-3-ones can 
exist in either E,E, E,Z or Z,Z tautomers. It has been shown that olefinic protons in the E-
isomers exhibit NMR peaks at δ 7.5 ppm whereas Z-isomers exhibit peaks in the region of 6.80 
ppm (Vatsadze et al., 2006). No peaks were observed in the 6.80 ppm region thus all 
synthesized compounds were deemed to be the E,E-isomers. The 1H-NMR and 13C-NMR 
spectra of all compounds are presented in Appendix 1, Page 241-273. 
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2.5 Conclusions 
In conclusion, a series of previously synthesized and novel bis-benzylidene, bis-pyridylidene 
and bis-thienylidene derivatives of N-methyl-piperidin-4-one, cyclopentanone and 
cyclohexanone with various substituents on rings were synthesized using the Claisen-Schmidt 
condensation method. The value of this methodology is that it is simple and efficient. The 
spectral data of the synthesized compounds reveal that all synthesized 1,4-diene-3-ones were 
isomerically pure at the time of synthesis and after first recrystallization.  
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3 Evaluation of antifungal activity 
3.1 Introduction 
The increasing occurrence of fungal infections and regular use of available antifungal agents 
have strengthened the need for useful and reliable antifungal susceptibility test methods. 
Various standardised methods have been developed to investigate the antifungal activity of 
drugs including protocols developed by the European Committee of Antifungal Susceptibility 
Testing (EUCAST), the Clinical Laboratory and Standards Institute (CLSI) and the British Society 
for Antimicrobial Chemotherapy. The CLSI has developed and approved several methods for 
determining the drug susceptibility of yeasts in both biofilm and planktonic form (Fothergill, 
2012). However, these methods are time-consuming and less suitable for high throughput 
screening of compound libraries for antifungal susceptibility testing. Conversely Galgiani & 
Stevens, (1976) have developed both macro- and micro-dilution broth susceptibility testing 
methods, which are reproducible and independent of inoculum size.   
Antifungal susceptibility screening of the compound library synthesized as described in 
Chapter-2 was performed using the method described by Galgiani & Stevens, (1976). The 
parameters described by Galgiani and co-workers were: an inoculum size of 2.0 to 2.5x 104 
cells/ml and malt extract broth (MEB) as a medium. An incubation time of 24 hours was used, 
as optimized by Hussain, (2014) and which depends on the fungal species being  screened.  
The antifungal activity of a drug can be described as either fungistatic or fungicidal at a known 
concentration. The ability of the drug to inhibit the growth of yeast cells can be obtained by 
measuring the absorbance at 600 nm of the cell growths with and without the test 
compounds. The inhibitory activity of the antifungal agents can be determined using various 
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analyses of the dose-response curve (percentage inhibition of the cell growth compared to 
control) against a range of drug concentrations, although primary high throughput screening 
has often used a single inhibitor concentration value, such as a concentration in the low (10 - 
60) micromolar region (Giacometti et al., 2000). The inhibitory activity of the drug can be 
evaluated using various parameters such as IC10, IC25, IC50, IC90, area under the curve (AUC) 
and the Hill slope sometime termed the Hill coefficient or slope factor. 
3.1.1 Theory of dose-response curves 
A dose-response curve reveals the potency of a compound. By observing what happens to a 
dose-response curve over time, it is possible to differentiate between fungicidal and 
fungistatic activity (Rautenbach, Gerstner, Vlok, Kulenkampff, & Westerhoff, 2006). Dose-
response curves from bioassays, radioimmunoassays or radioreceptor assays may be either 
symmetrical in shape (reflection around the point of inflection), smooth or sigmoidal when 
the drug concentration is expressed on a logarithmic scale. These curves are well defined by 
Gaussian cumulative distribution or logistic models (DeLean, Munson, & Rodbard, 1978). 
Gaussian cumulative distribution is also called a normal distribution or bell curve. It is used to 
characterize real values of inhibitory concentration random variables whose distributions are 
not known. The logistic model is a predictive analysis, which is commonly used to describe 
the relationship between dependent binary variables with one or more nominal independent 
variables (DeLean et al., 1978). 
Until recently the dose-response curve as used in drug development studies utilised a four-
parameter logistic model (Figure 3.1a) which fits the minimum and maximum plateaus of the 
curve. From this curve, the Hill slope and point of inflection (IC50) could be determined. 
However, unless 100% inhibition of growth is observed the point of inflection will be different 
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from the 50% reduction in antimicrobial growth assays. In addition, a four-parameter logistic 
model cannot effectively model asymmetric data (Rautenbach et al., 2006). The maximum 
information can be obtained from the dose-response curve at a point where there is the 
maximum change in the shape of the curve. The main purpose of fitting the dose-response 
curve is to determine the best fit value of a drug at known concentration (DeLean et al., 1978).
(DeLean et al., 1978)(DeLean et al., 1978)(DeLean et al., 1978) 
Figure 3. 1. Schematic representation of dose-response curves. 
The dose-response curve of response against drug concentration fitted using a four-
parameter [a] and five-parameter [b] logistic model. The curve is symmetrical around its 
midpoint in four-parameter whereas a five-parameter logistic equation curves are 
asymmetrical. A five-parameter equation also includes an additional parameter ‘S’ which 
measures the asymmetry of the curve.  
 
The Hill slope (h) commonly referred to as the slope factor (As) or Hill coefficient may be 
suggestive of an underlying mechanism and is valuable in comparison of drug potencies 
(Rautenbach et al., 2006). However this term has limited utility in cell growth assays due to 
the complexity of such systems. Hill coefficients provides information about the number of 
interacting sites in a receptor or enzyme but cannot differentiate between competitive or 
non-competitive mechanisms (Prinz, 2010). Hill coefficient is best understood as an 
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interaction coefficient, reflecting the level of cooperativity among multiple ligand binding 
sites when studying isolated receptors or enzymes. 
Prism software calculates the Hill slope using the Levenberg-Marquardt algorithm for non-
linear least square minimization. In Figure 3.1[a], Hill slope defines the steepness of the curve; 
if the Hill slope is 1.0 then the curve is a standard slope. The dose-response curve is steep 
when a Hill slope is >1.0 which suggests a greater chance of correspondence between desired 
and undesired effects of a drug. Hill slope is >1.0 also indicate high order of concentration 
dependence, this can sometimes be explained by high levels of aggregating molecules. In 
contrast, if the curve is shallow then a Hill slope is <1.0 which suggests no problem of 
aggregation of the molecule. In recent years a further term has been introduced to reflect the 
symmetry of the sigmoidal curve (Gottschalk & Dunn, 2005). In a five-parameter logistic 
model ‘S’ is an extra, unitless, parameter reflecting the symmetry of the curve around its point 
of inflection (Figure 3.1b). If S=1, the curve is symmetrical and identical to the standard four 
parameter dose-response equation. If S is not equal to 1.0, then the curve is asymmetric. The 
advantage of a five-parameter logistic model is that it eliminates the ‘lack-of-fit’ error, which 
usually occurs in a four-parameter logistic model. 
Other studies have used the concept of area under the curve as a measure of the inhibitory 
potency of antimalarial or antifungal agents since using MICs or IC50s can often give 
ambiguous results (Odds & Abbott, 1984). Consequently Odds & Abbott, (1984) developed a 
new parameter which measures the area under the dose-response curve (AUC) using an 
indefinite, or unbounded, integral between two different concentrations common to all of 
the inhibitors being tested. Better reproducibility of the inhibitory activity of the compounds 
between two log dose concentrations can be obtained from the AUC (Figure 3.2). Odds & 
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Abbott, (1984) also stated that accurate assessment of the activity of various drugs can be 
achieved by comparing the AUC with the other inhibitory parameters such as IC50 or IC90. 
The AUC between C1 and C2 can be presented as a percentage of the theoretical maximum 
area to provide a relative inhibition factor (RIF). A RIF close to 0% means the yeast is 
susceptible to a particular drug whereas RIF close to 100% means the yeast is resistant to that 
drug. The areas are measured and presented as a percentage of the area of the rectangle 
between C1 and C2, and 0% and 100%.  
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Figure 3. 2. Example of the dose-response curves of three drugs. 
An example of the dose-response curve of three drugs, growth stated as a percentage of 
negative control cultures against log concentration. The drugs X and Z shows a clear minimum 
inhibitory concentration (MIC) end-points but drug Y shows partial inhibitory activity. The AUC 
was obtained by selecting two concentrations, C1 and C2, which specifies the upper and lower 
limits of the test range. The AUC of Z is high and therefore it is considered to be least inhibitory 
antifungal agent whereas, low AUC of X denotes most inhibitory activity and drug Y indicates 
the intermediate value of AUC indicates partial inhibitory activity (Odds & Abbott, 1984).  
 
The aim of the work described in this chapter was to identify and analyse the (potential) and 
relative anti-fungal activities of the thirty-three synthesized 1,4-diene-3-one compounds. This 
was accomplished by performing the in vitro macro-broth susceptibility assays against both 
S. cerevisiae and C. albicans.  
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3.2 Materials and Methods 
3.2.1 Macro-broth susceptibility assay 
3.2.1.1 Cell cultures 
Yeasts S. cerevisiae ATCC 46182 (UH fungal culture collection strain code Y13a) and C. albicans 
NCYC 854 (UH fungal culture collection strain code Y100) were obtained from the University 
of Hertfordshire fungal culture collection.  
3.2.1.2 Growth medium and materials 
Malt Extract Agar (Malt extract 30 g/l, Mycological peptone 5 g/l and agar 15 g/l) was 
purchased from Oxoid microbiological products, CM0059, Lot-1671689. Malt extract agar 
(MEA) was used to culture the yeasts in Petri dishes to obtain individual colonies derived from 
single cells. MEA powder (20 g) was dissolved in distilled water to a final volume of 400 ml. 
The pH of MEA was adjusted to 5.4 using either 1M hydrochloric acid or 1M NaOH solution, 
followed by autoclaving at 121 °C/15 psi for 15 minutes. Petri dishes containing approximately 
20 ml of MEA were prepared from freshly autoclaved medium. Yeast cultures were sub-
cultured every two weeks. Cultured plates were incubated at 30 °C for 48 hours and then 
stored at 4 °C until needed. 
Malt extract broth (Malt extract 17 g/l, Mycological peptone 3 g/l) was purchased from Oxoid 
microbiology products, CM057, Lot-1350078. Malt extract broth (MEB) was used to grow the 
yeast in liquid medium. MEB powder (20 g) was dissolved in distilled water just under final 
volume then adjusted the pH to 5.4 using 1M HCl or 1M NaOH, then to the final volume of     
1 Litre. All glassware used for antifungal studies was acid washed overnight followed by 
rinsing with distilled water, drained and allowed to dry to eliminate any traces of organic or 
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interfering materials. Aliquots of MEB (2.0 ml and 80 ml) were prepared in 5 ml bijous or       
250 ml conical flasks respectively, followed by autoclaving as described above and stored at 
4 °C until used.  
3.2.1.3 Stock solution of the antifungal agent 
Miconazole nitrate powder (4) (Sigma-Life Science, M3512, Lot: BCBD5966V) was used as a 
positive reference control. Miconazole nitrate (4.8 mg) was dissolved in dimethyl sulfoxide 
(Hybri-Max; D2650, Sigma-Life Science) to obtain a final concentration of 1.92 mM. A stock 
solution of miconazole in DMSO was prepared freshly daily. Stock solution was diluted with 
DMSO to obtain range of standard concentrations between 0.91 nM and 27.4 µM.  
3.2.1.4 Stock solutions of the synthesized compounds 
Stock solutions of synthesized compounds were prepared at 0.1 M concentration in DMSO. 
The stock solution was sonicated for 10 minutes to dissolve the compound completely. The 
stock solutions were diluted appropriately in DMSO (Hybri-Max; D2650) to obtain 
concentrations ranging from 2 x 10-2 to 2 x 10-5 M. Solutions were prepared fresh daily. DMSO 
was used as a negative control (0.5% and 1.5%) when treating yeast cells with a solution of 
the test compound. A ‘blank’ control was also used for macro-broth susceptibility assay to 
determine the effect of MEB medium on the test compounds (composition: 2.1 ml MEB, 10 
µl or 30 µl of test compound). 
3.2.1.5 Growth of yeast cells for macro-broth susceptibility assay 
A few colonies of yeast (S. cerevisiae or C. albicans) were aseptically inoculated into MEB (80 ml). This 
cell suspension was incubated in an orbital shaker overnight at 32 °C, 100 rpm. The absorbances of 
the fungal cultures were measured at 600 nm using a Cecil (CE1011) UV-Visible spectrophotometer. 
Subsequently, cell counts were performed using a Naubauer haemocytometer to identify the number 
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of cells present in the cell suspension. A cell suspension (1.0 ml) containing approximately 1 x 108 
cells/ml from an overnight culture was re-suspended in a 250 ml sterile conical flask containing MEB 
(80 ml) and incubated at 32 °C, 100 rpm until the cells reached the mid-log phase (approximately 5-7 
hours). Absorbance measurements at 600 nm and cell counts were performed each hour between 1 
to 8 hours and finally after 24 hours (Galgiani & Stevens, 1976; Fothergill, 2012).  
3.2.1.6 Macro-broth susceptibility testing of 1,4-diene-3-ones 
The library of 1,4-diene-3-ones was investigated for their in-vitro antifungal activity against       
C. albicans and S. cerevisiae using a macro-broth dilution method (Galgiani & Stevens, 1976). 
The reason for choosing this method is due to its reproducibility and that results are 
independent of cell inoculum size e.g. 2.0 x 104 or 2.0 x 105 cells/ml. The fungal strains of both 
C. albicans and S. cerevisiae were grown to mid-log phase (5 hours) as described in section 
3.2.1.5. The cell counts and absorbance at 600 nm measurements were performed to 
determine the number of cells present. Cell viability was determined by adding Methylene 
blue (MB) dye to the cell suspension. Cell suspensions containing mid-log phase cells were 
diluted first with MEB medium (1/10; 100 µl of cell suspension added to 900 µl of MEB) then 
with MB (1:1; 100 µl of diluted cell suspension added to 100 µl MB) to obtain the overall 
dilution of 1/20. Cell suspensions were diluted with MEB to obtain stock cell concentrations 
of 4.2-5.2 x 105 cells/ml for C. albicans cells, and 4.2-5.2 x 106 cells/ml for S. cerevisiae cells.  
For the macro-broth susceptibility assay, 10 or 30 µl volumes from stock or standard dilutions 
of either the synthesized 1,4-diene-3-one, miconazole nitrate or DMSO were added to each 
bijou containing MEB (2.0 ml). The final concentrations of 1,4-diene-3-ones ranged between 
0.10 and 3000 µM. The final concentration of miconazole ranged between 9 nM and 27.4 µM. 
For C. albicans susceptibility assays, a cell suspension (100 µl) containing 4.2 – 5.2 x 105 
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cells/ml was inoculated into each bijou. Similarly for S. cerevisiae susceptibility assays, a cell 
suspension (100 µl) containing 4.2 – 5.2 x 106 cells/ml was inoculated into each bijou. 
The final concentration of the C. albicans or S. cerevisiae cells in each bijou was 2.0 – 2.5 x 104 
cells/ml and 2.0 – 2.5 x 105 cells/ml respectively. All bijous were prepared in duplicate and 
incubated for 24 hours at 32 °C, 100 rpm. Each experiment was performed with three 
different growths of cells for S. cerevisiae susceptibility assays and twice for C. albicans 
susceptibility assays. The inhibitory activities of the various 1,4-diene-3-ones against                    
C. albicans and S. cerevisiae were obtained by measuring the optical density (600 nm) of each 
sample after incubating for 24 hours.   
3.2.1.7 Data processing for macro-broth susceptibility assay 
Absorbance values of the yeast cell suspensions (S. cerevisiae and C. albicans), test 
compounds and controls were recorded using a Cecil (CE1011) UV-Vis spectrophotometer at 
600 nm. The absorbance of the cell suspension containing the test compound was converted 
to the percentage growth of treated S. cerevisiae or C. albicans cells as compared to the 
control (DMSO 1.5%) using Equation 1. 
 𝑪𝒆𝒍𝒍 𝒈𝒓𝒐𝒘𝒕𝒉 (% 𝒐𝒇 𝒄𝒐𝒏𝒕𝒓𝒐𝒍) =
                  
𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆 𝒐𝒇 𝒄𝒆𝒍𝒍 𝒔𝒖𝒔𝒑𝒆𝒏𝒔𝒊𝒐𝒏 𝒘𝒊𝒕𝒉 𝑫𝒓𝒖𝒈 ×𝟏𝟎𝟎
𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆 𝒐𝒇 𝒄𝒆𝒍𝒍 𝒔𝒖𝒔𝒑𝒆𝒏𝒔𝒊𝒐𝒏 𝒘𝒊𝒕𝒉𝒐𝒖𝒕 𝒅𝒓𝒖𝒈 (𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆 𝒄𝒐𝒏𝒕𝒓𝒐𝒍 𝒘𝒊𝒕𝒉 𝑫𝑴𝑺𝑶 𝟏.𝟓%)
     (𝑬𝒒. 𝟏) 
The inhibitory activities of the 1,4-diene-3-ones were analyzed using the software GraphPad 
Prism 5. Non-linear regression model fitted to response (variable on Y axis) vs log (inhibitor 
concentration) was performed on the dose-response data acquired from the macro-broth 
susceptibility assays (Rautenbach et al., 2006). A sigmoidal curve with variable slope (Figure 
3.1a) and continuous variation of 100 between the top (inhibition at high drug 
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concentrations) and bottom (response with no inhibition) were fixed to each datasets using 
the four-parameter model, Equation 2.  
𝑮𝒓𝒐𝒘𝒕𝒉 𝒊𝒏𝒉𝒊𝒃𝒊𝒕𝒊𝒐𝒏 = 𝑩𝒐𝒕𝒕𝒐𝒎 +
𝑻𝒐𝒑 − 𝑩𝒐𝒕𝒕𝒐𝒎
𝟏 + 𝟏𝟎(𝐥𝐨𝐠(𝒄𝒐𝒏𝒄.)−𝑿)×𝑯𝒊𝒍𝒍 𝒔𝒍𝒐𝒑𝒆)
                (𝑬𝒒. 𝟐) 
Where X represents the log (base 10) of 1,4-diene-3-one concentrations in terms of molarity. 
The concentration of drug at the point of inflection 50% inhibitory concentration (IC50) was 
obtained from the x value equivalent to a response halfway between the top and bottom 
plateaus. The 10% and 25% inhibitory concentration (IC10 and IC25) of each 1,4-diene-3-one 
was the calculated x value at the intercept between the bottom plateau and maximum slope 
(Figure 3.1b). The 90% inhibitory concentration (IC90) was the calculated x value at the 
intercept between the top plateau and maximum slope. The Hill slope or slope factor was 
calculated from the dose-response curve using Equation 2. 
The dose-response curves were also analyzed using a five-parameter logistic (Eq. 3). This 
equation contains an additional parameter ‘S’ that quantifies the asymmetry of the curve 
(Figure 3.1b): 
𝑮𝒓𝒐𝒘𝒕𝒉 𝒊𝒏𝒉𝒊𝒃𝒊𝒕𝒊𝒐𝒏 = 𝑩𝒐𝒕𝒕𝒐𝒎 +
𝑻𝒐𝒑 − 𝑩𝒐𝒕𝒕𝒐𝒎
𝟏 + 𝟏𝟎(𝐥𝐨𝐠(𝒄𝒐𝒏𝒄.)−𝑿)×𝑯𝒊𝒍𝒍 𝒔𝒍𝒐𝒑𝒆)^𝑺
             (𝑬𝒒. 𝟑) 
Data was also analysed by plotting the dose-response curve of growth of cells as peracentage 
of control. Areas under the dose-response curve (AUC, Figure 3.2) was obtained by selecting 
two concentrations and applying the following formula: 
𝑨𝑼𝑪 = ∫ 𝒇(𝒙)𝒅𝒙
𝑪𝟐
𝑪𝟏
                                    (𝑬𝒒. 𝟒) 
Where, C1 = concentration (1400 μM; S. cerevisiae and C. albicans)  
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              C2 = concentration (0.1 μM; S. cerevisiae and C. albicans) 
            ∫  𝑓(𝑥)𝑑𝑥
𝐶2
𝐶1
  = area under the curve from concentration C1 to C2. 
All synthesized 1,4-diene-3-one compounds showed turbidity in the cell suspension at 
concentrations >1400 μM, this may be due to the problem of solubility at high concentration. 
Therefore, the AUCs were obtained by selecting 1400 μM as C1 and 0.1 μM as C2 for both                
S. cerevisiae and C. albicans susceptibility assays. Concentrations C1 to C2 represents the lower 
and upper limits of a test range to identify the area under the dose-response curves (Odds & 
Abbott, 1984).  
The antifungal activity of each compound was stated in terms of specific percentage Inhibitory 
concentrations (IC). The relevant IC10, IC25, IC50 and IC90 values for compounds giving 10, 25, 
50 or 90 % levels of inhibition were obtained manually at the point of intersection between 
the intercept value and the corresponding log concentration value. The ‘point of inflection’ 
IC50 values obtained from GraphPad was described as the asymptotic I50 values. The values of 
asymptotic I50 (i.e. 50% of the curve according to the shape of the curve generated with Prism 
5) and manually calculated IC50 (by plotting a line across 50% inhibition of growth) were 
compared to identify the difference in the inhibitory activity of these 1,4-diene-3-ones (Tables 
3.1 and 3,2, pages 105 and 119). 
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3.3 Results – Investigation of Antifungal activity 
3.3.1 Growth curves of S. cerevisiae and C. albicans  
The growth of S. cerevisiae and C. albicans was determined by plotting absorbance at 600 nm 
against time (Figure 3.3). The point at which the cells proliferate at their maximal rate is 
termed the mid-exponential or mid-log phase.  
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Figure 3. 3. Growth curves of the two fungal strains over 24 hours. 
The growth curves of the absorbance (600 nm) against time of C. albicans and S. cerevisiae. 
Each data point represents the mean ± SD of the two individual experiment each conducted 
in duplicate, n=4. Error bars were difficult to observe on the plots due to very low standard 
deviation value. 
 
The exponential phase was observed to be between 5-7 hours for both C. albicans and                   
S. cerevisiae. The yeast cells enter the deceleration or late log phase after 7 hours of 
incubation followed by entry to the stationary phase by 24 hours. Although the absorbance 
of S. cerevisiae and C. albicans were relatively similar to each other, there was a difference in 
the absolute cell numbers. Therefore, individual calibration between absorbance and cell 
numbers is necessary. Hence, correlation plots of absorbance of the cell suspension with the 
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number of cells present in the suspension of S. cerevisiae and C. albicans were implemented 
to identify the relationship between them (Figure 3.4). 
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Figure 3. 4. Correlation plots of absorbance and cell counts of fungal species. 
Absorbance against cell.ml-1 [a] and its derivative logarithmic absorbance values against  
cells.ml-1 of both S. cerevisiae and C. albicans [b]. Each data point represents the mean of the 
two individual experiments each conducted in duplicate, n=4. Error bars were difficult to 
observe on the plots due to very low standard deviation value. 
 
S. cerevisiae depicted a linear relationship between the absorbance values of 0 to 0.9 with 
the cell counts whereas C. albicans displayed limited correlation between the absorbance and 
the cell counts especially at high cell concentrations (Figure 3.4a). This could be possibly due 
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to environmental stress such as changes in the pH during the cell growth (Francois et al., 
2005). In addition, both S. cerevisiae and C. albicans shows deviation in their values after 
reaching an absorbance of 0.9. This may be because absorbance is a log function for the 
general transmission of light. Therefore, log transformation of absorbance and cells.ml-1 for 
both fungal species have been performed to stabilise the variances of the data points. 
Correlation plots of log (absorbance) and log (cells.ml-1) for both S. cerevisiae and C. albicans 
were fitted using linear equation (Fig 3.4b). The plots of logarithmic transformed values 
displayed good correlation coefficient values for both S. cerevisiae and C. albicans, these 
being R2 = 0.948 and 0.927 respectively. 
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3.3.2 Investigation of the inhibitory activity of 1,4-diene-3-ones using a macro-
broth susceptibility assay  
3.3.2.1 Susceptibility of S. cerevisiae to 1,4-diene-3-ones 
 The potency of each synthesized 1,4-diene-3-one compound was determined by comparing 
the IC10, IC25, IC50, IC90, asymptotic I50 values, slope factors (Hill slopes) and the area under the 
curve (AUC) values. The latter values were obtained from the dose-response curves using the 
five-parameter logistic model (GraphPad, Prism 5) and an indefinite integral between two 
common concentrations, C1 and C2. Standard deviation (SD) of the latter values was calculated 
from the dose-response curves of three individual experiments each assayed in duplicate.  
The asymptotic I50 value depends on the shape of the curve and the overall degree of 
inhibition exhibited. In this study, the dose-response curve of 1,4-diene-3-one compounds 
vary in shape. For example, some compounds show a maximum response of 90% inhibition 
whereas some only show 20% inhibition of the growth. An asymptotic I50 value usually takes 
an account of the shape and nature of the curve and determines the I50 value based on 50% 
inhibition of that curve.  
Therefore an asymptotic I50 value could lead to a false interpretation of the results. It is thus 
important to compare the manually obtained IC10, IC25, IC50 and IC90 values from the dose-
response curve along with the I50 and AUC values. The dose-dependent curve of bis-
benzylidene, bis-pyridylidene and bis-thienylidene derivatives of N-methylpiperidin-4-one 
and cycloalkanones against S. cerevisiae were shown in figures 3.5 to 3.9. 
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Figure 3. 5. Dose-dependent inhibition of S. cerevisiae growth by various para-substituted 
bis-benzylidene derivatives of N-methylpiperidin-4-one after 24 hours.  
Dose-dependent inhibition of S. cerevisiae growth by the bis-benzylidene derivatives of N-
methylpiperidin-4-one with various substituents attached to the para-position of the 
aromatic ring. The para-substituent groups include hydrogen, trifluoromethyl, 
trifluoromethoxy, methoxy and methyl [a]; hydrogen, chloro, nitro and carboxylic acid [b]. 
The inhibitory activity was expressed as the growth of S. cerevisiae in the presence of a 
compound as a percentage of the negative drug-free control after 24 hours. All assays 
contained 1.5% DMSO. The dose-response curve was fitted using the five-parameter logistic 
model on GraphPad, Prism 5. Data were presented as the mean of three individual growth 
experiments. Each assay was performed in duplicate. SD values were omitted for clarity of 
graphs. 
 
The various dose-dependent curves in figure 3.5 show that increasing the concentrations of 
compounds results in increased inhibition as measured after treatment for 24 hours. The 
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para-trifluoromethyl substituted bis-benzylidene derivative of N-methylpiperidin-4-one (22n) 
was found to be the most potent inhibitor of S. cerevisiae growth (IC50 = 0.62 µM) amongst 
the group of para-substituted compounds (Figure 3.5a). Compound 22n shows a shallow 
dose-response curve with low Hill slope (0.63) which suggests this compound does not have 
a problem regarding molecular aggregation (Seidler, McGovern, Doman, & Shoichet, 2003).  
Compounds 22d and 22p also showed shallow dose-response curve with low Hill slopes values 
(0.56 and 0.71 respectively) suggests no formation of aggregates (Seidler et al., 2003). In 
addition, compounds 22d and 22p both exhibited good activity by inhibiting the growth of S. 
cerevisiae with IC50 values of 27.9 and 12.9 µM. The difference in the activity of compounds 
22d and 22p was only 2.16-fold this being due to the difference in their R-group on the rings, 
22d has methoxy group as electron donating group (EDG) whereas 22p has an electron 
withdrawing (EWG) trifluoromethoxy group. Due to the presence of the EWG 22p exhibited 
slightly better activity than 22d. The para-methyl substituted bis-benzylidene-N-
methylpiperidin-4-one (22l) in Figure 3.5[a] was identified as the least active compound in the 
1,4-diene-3-ones library. 
Compounds 22a and 22k both showed more than 90% inhibition at concentrations above               
100 µM (Fig. 3.5b). The dose-response curve of 22a was slightly steeper than 22k and their 
Hill slopes were identified as 2.80 and 0.97, respectively suggesting aggregation of the former 
molecule. However in terms of the IC50 values, 22a (40.7 µM) showed better potency than 
22k (218 µM). The higher inhibitory activity of 22a could possibly be due to promiscuous 
aggregation (Seidler et al., 2003). On the other hand, compounds 22g and 22t exhibited good 
potency with low IC50 values (5.56 and 3.37 µM respectively). Both 22g and 22t showed 
shallow curve with low Hill slope values (0.25 and 0.56). This may be due to factors associated 
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with compound solubility (Seidler et al., 2003). The inhibitory potency of 22g and 22t was 46 
and 28-fold lower than miconazole nitrate. Based on the above information the group 
potency order in the para-substituted compounds, in terms of their IC50 values was identified 
as CF3 >NO2 >Cl >OCF3 >OCH3 >H> COOH >CH3.  
Furthermore, the dose-response curves of bis-benzylidene derivatives of N-methylpiperidin-
4-one and its meta- substituents on the benzene ring is shown in Figure 3.6. 
 
 
 
 
Chapter 3: Evaluation of antifungal activity 
 
93 
 
[a]
-9
.0
-8
.5
-8
.0
-7
.5
-7
.0
-6
.5
-6
.0
-5
.5
-5
.0
-4
.5
-4
.0
-3
.5
-3
.0
-2
.5
0
10
20
30
40
50
60
70
80
90
100
110
22a (H.pip)
22m (3-CF3.pip)
22o (3-OCF3.pip)
22c (3-OCH3.pip)
4 (miconazole)
Log concentration (M)
G
ro
w
th
 o
f
S.
 c
er
ev
is
ia
e
(a
s 
%
 o
f 
n
eg
at
iv
e 
co
n
tr
o
l)
 
[b]
-9
.0
-8
.5
-8
.0
-7
.5
-7
.0
-6
.5
-6
.0
-5
.5
-5
.0
-4
.5
-4
.0
-3
.5
-3
.0
-2
.5
0
10
20
30
40
50
60
70
80
90
100
110
22a (H.pip)
22f (3-Cl.pip)
22r (3-I.pip)
22s (3-NO2.pip)
4 (miconazole)
Log concentration (M)
G
ro
w
th
 o
f
S.
 c
er
ev
is
ia
e
(a
s 
%
 o
f 
n
eg
at
iv
e 
co
n
tr
o
l)
 
Figure 3. 6. Dose-response curves of the meta- substituted bis-benzylidene derivatives of    
N-methylpiperidin-4-one against S. cerevisiae after 24 hours.  
Dose-dependent inhibition of S. cerevisiae growth by the bis-benzylidene derivatives of            
N-methylpiperidin-4-one with various substituents attached to the meta- position of the 
aromatic ring. The meta- substituent groups include hydrogen, trifluoromethyl, 
trifluoromethoxy, methoxy [a]; hydrogen, chloro, iodo and nitro [b]. The inhibitory activity 
was expressed as the growth of S. cerevisiae in the presence of a compound as a percentage 
of the negative drug-free control (DMSO 1.5%) after 24 hours. The dose-response curve was 
fitted using the five-parameter logistic model on GraphPad, Prism 5. Data was recorded as 
the mean of three individual growth experiments. Each assay was performed in duplicate. SD 
values were omitted for clarity of graphs. 
 
Compounds 22c, 22m and 22o exhibited good inhibitory activity by inhibiting the growth of 
S. cerevisiae with low IC50 values 3.24, 2.22 and 2.83 μM, respectively (Figure 3.6a). 
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Compounds 22m and 22o both showed shallow curves with low Hill slope values (0.43 and 
0.85 respectively) whereas 22c gave a steep curve with Hill slope of 1.65. High hill slope of 
22c suggesting aggregation of the molecule and consequently increase in the activity of this 
compound due to promiscuous aggregation. While 22m and 22o have low Hill slope (<1) 
indicating their potency is not linked to aggregation. In contrast, compound 22a displays a 
very steep dose-response curve between concentrations of 30 and 100 μM with a high Hill 
slope (2.80), which indicates that the inhibitory action could possibly be due to drug 
aggregation at higher concentrations (Seidler et al., 2003).  
Compounds 22f, 22r and 22s all exhibited good inhibitory activities against S. cerevisiae with 
IC50 values of 1.21, 7.64 and 1.87 respectively. In addition, compounds 22f and 22s displayed 
fairly steep curves with high Hill slopes (1.73 and 2.90), whereas 22r gave a shallow curve with 
Hill slope of 0.65. Although 22f and 22s gave better potency than 22r, the high Hill slope values 
of 22f and 22s again suggesting promiscuous inhibition due to aggregation. In conclusion the 
iodo-substituent was identified as the least active inhibitor compared to other meta-
substituent groups. This may be due to the size of the iodine atom compared to the other 
substituents. Based on the results the order of potency for groups in the meta-substituted 
compounds, in terms of their IC50 values was identified as Cl >NO2 >CF3 > OCF3 >OCH3 >I >H. 
The dose-response curve of ortho-substituted and di-chloro substituted bis-benzylidene 
derivative of N-methylpiperidin-4-one is shown in Figure 3.7.   
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Figure 3. 7. Dose-response curves of the ortho-substituted [a] and dichloro substituted [b] 
bis-benzylidene derivatives of N-methylpiperidin-4-one against S. cerevisiae after 24 hours.  
Dose-response curves of the ortho-substituted and dichloro substituted bis-benzylidene 
derivatives of N-methylpiperidin-4-one against S. cerevisiae. The ortho-substituents were 
hydrogen, methoxy, chloro, carboxylic acid and iodo [a]; hydrogen, 2,4-dichloro and 3,4-
dichloro [b]. The inhibitory activity was determined by comparing the growth of S. cerevisiae 
with and without compound as the percentage of negative control (DMSO 1.5%) after 24 
hours. The dose-response curve was fitted using the five-parameter logistic model. Data was 
recorded as the mean of three individual growth experiments, each assay conducted in 
duplicate. SD values were omitted for clarity of graphs 
 
Compound 22e ortho-chloro substituted bis-benzylidene derivative of N-methylpiperidin-4-
one in Figure 3.7[a] was the most potent inhibitor of S. cerevisiae growth compared to other 
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ortho-substituents with an IC50 of 3.90 μM. However miconazole was 32.5-fold more potent 
than 22e. Both compounds 22b and 22q (ortho-methoxy and ortho-iodo substituted bis-
benzylidene N-methylpiperidin-4-one) showed moderate inhibitory activity against                              
S. cerevisiae, their IC50 values being 53.7 and 21.4 μM respectively. However, the IC50 value of 
compound 22c (meta-methoxy) was 3.24 μM (Fig 3.6a) whereas the IC50 value of compound 
22s (para-methoxy) was 27.9 μM (Fig 3.5a). On the other hand, compound 22r (meta-iodo 
substituent) showed good potency with its IC50 value of 7.64 μM (Fig 3.6b). This shows a 
significant difference suggests positional bumping (overlapping of atoms) may be important 
and not lipophilicity which is similar for ortho, meta or para- substituted compounds. Also this 
could suggest a large volume group (e.g. iodine or methyl is required at the meta position) of 
the compound for maximum potency. Compound 22j contains an ortho-carboxylic acid group 
which has been identified as the least active amongst all of the ortho-groups tested with IC50 
value of 124 μM.  
The dose-response curves of 2,4-dichloro and 3,4-dichloro substituted bis-benzylidene             
N-methylpiperidin-4-one (22h and 22i) were almost identical to each other showing a shallow 
curve over the range of concentrations (Figure 3.7b). Compounds 22h and 22i both displayed 
poor inhibitory activity showing a maximal response at 3000 µM concentration with 80% 
inhibition of S. cerevisiae growth. The IC50 values of 22h and 22i were 153.6 and 153.9 μM 
respectively, whereas their Hill slopes were 0.22 and 0.64 which indicates these two 
compounds are not aggregators. In contrast, compounds (22e, 22f and 22g) with a single 
chloro group each of the aromatic rings at either ortho, meta or para position gave good 
potency with IC50 values of 3.90, 1.21 and 5.56 μM (Fig. 3.7a, 3.6b and 3.5b). This suggests 
that presence of di-chloro groups on the aromatic ring gives about 30-fold decrease. It is more 
likely that the presence of two chlorine atoms increases the volume of the molecule 
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sufficiently that although it is able to react, the molecule has less accessibility to the binding 
site (chlorine being quite large and there being four of them). The potency order of groups in 
the ortho-substituted and di-chloro substituted bis-benzylidene derivatives of N-
methylpiperidin-4-one, in terms of their IC50 values, was identified as Cl >I >H >OCH3 >COOH 
>2,4-diCl.  
The dose-response curves of bis-pyridylidene derivatives of N-methylpiperidin-4-one is 
displayed in Figure 3.8. 
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Figure 3. 8. Dose-response curves of the bis-benzylidene and bis-pyridylidene derivatives of 
N-methylpiperidin-4-one against S. cerevisiae after 24 hours. 
Dose-response curves of the bis-pyridylidene derivatives of N-methylpiperidin-4-one against 
S. cerevisiae with miconazole as a positive control. The inhibitory activity was determined by 
comparing the growth of S. cerevisiae with and without compound as the percentage of 
negative control (DMSO 1.5%) after 24 hours. The dose-response curve was fitted using the 
five-parameter logistic model. Data was determined as the mean of three individual growth 
experiments each of which conducted in duplicate. SD values were omitted for clarity of 
graphs. 
 
The position of the nitrogen-atom at either the ortho-, meta- or para- position in the aromatic 
ring differentiates compounds 23a, 23b and 23c from each other. The dose-response curves 
of compounds 23a, 23b and 23c showed steep curves between concentrations of 30 and 300 
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μM with their Hill slope values all being well above 1.5 (see Table 3.1, page 105). Similarly, 
compound 22a also shows a steep curve between concentrations of 30 and 100 μM. 
Compounds 23a, 23b and 23c exhibited good inhibitory activity against S. cerevisiae with their 
IC50 values being 12.6, 8.84 and 9.45 μM, respectively. The potency order of pyridyl 
derivatives of N-methylpiperidin-4-one in terms of their IC50 values was identified as meta 
>para >ortho. However the difference in the activity between different isomeric pyridyl rings 
of compounds is minimal. The major difference is between the pyridine ring and the benzene 
ring thus suggesting the difference in potency relates to the change in solubility and/or 
hydrophobicity.  
The dose-response curve of bis-pyridylidene derivatives of cyclopentanone is presented in 
Figure 3.9. 
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Figure 3. 9. Dose-response curves of the bis-pyridylidene derivatives of cycloalkanones 
against S. cerevisiae after 24 hours. 
Dose-response curves of the bis-pyridylidene derivatives of cyclopentanone [a] and 
cyclohexanone [b] against S. cerevisiae with miconazole as a positive control. The inhibitory 
activity was determined by comparing the growth of S. cerevisiae with and without compound 
as the percentage of negative drug-free control (DMSO 1.5%) after 24 hours. The dose-
response curve was fitted using the five-parameter logistic model. Data was displayed as the 
mean of three individual growth experiment each conducted in duplicate. SD values were 
omitted for clarity of graphs. 
 
Compound 22u, the bis-phenylidene derivative of cyclopentanone in Figure 3.9[a] does not 
contain any nitrogen in the aromatic ring system, whereas compounds 23d, 23e and 23f each 
contain a single nitrogen atom in the aromatic ring at either ortho-, meta- or para- positions. 
The inhibition curves of compounds 23e and 23f (meta and para) were very steep and almost 
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identical to each other whereas compound 23d (ortho) exhibits a shallow curve. Compounds 
23e and 23f displayed high Hill slopes (1.80 and 1.76 respectively), greater than 23d (0.94). In 
addition the IC50 values of compounds 22u, 23d, 23e and 23f were 1290, 20.33, 9.29 and 8.46 
μM respectively. This may be suggestive of compound 23d having lower levels of aggregation 
and thus its IC50 being a true representation of the potency compared to compounds 23e and 
23f which may be aggregating to a greater extent which is suggestive by the high Hill slopes. 
The above dose-response curves clearly shows that the pyridine containing compounds were 
more potent than phenyl rings compound suggesting a higher ability to cross the membrane. 
This information confirms that the introduction of the nitrogen atom in the ring system 
increases the solubility and it enhances the inhibitory activity of these compounds. 
In addition, the clogP values of 22u, 23d, 23e and 23f were determined to be 4.77, 1.60, 1.91 
and 1.90 respectively. This suggests the hydrophobicity of the ring may be related to the 
potency in the sense that the highly hydrophobic benzene ring would impart a lower aqueous 
solubility to the potential drug molecule than the equivalent drug with a pyridine ring. Thus 
the presence of benzene and pyridyl substituted molecules 22u, 23d, 23e and 23f are 
consistent with a role for aqueous solubility in defining drug potency.  
In Figure 3.9[b] compound 22v, the bis-phenylidene derivative of cyclohexanone, gave a 10% 
inhibition of growth at a concentration of 57 μM whereas the bis-pyridylidene derivatives of 
cyclohexanone, 23g and 23h, have shown 10% inhibitory activity at only 0.99 and 2.22 μM. 
The IC50 value of compound 22v has been determined to be 309 μM. Compound 23g 
represents the pyridyl derivative of cyclohexanone where the nitrogen atom is present at the 
meta-position on the pyridyl ring, whereas compound 23h represents the para-position of N-
atom on the pyridyl ring. Compounds 23g and 23h both exhibited steep curves between 3.0 
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and 30 μM with their IC50 values being 5.52 and 6.25 µM respectively, thus indicating their 
good inhibitory activity against S. cerevisiae growth. 
When comparing the Hill slopes of these compounds it has been identified that 22v, 23g and 
23h have a higher Hill slopes (2.50, 2.83 and 2.97) than compounds 22u, 23e and 23f (0.63, 
1.80 and 1.76). A high Hill slope is associated with the aggregation status of the drug 
molecules and a consequent artifactual lowering of the IC50 values. When comparing the 
inhibitory activity in terms of the IC50 values of phenylidene or pyridylidene derivatives of 
cyclopentanone (22u, 23d, 23e and 23f) with cyclohexanone (22v, 23g and 23h), it was 
determined that compounds containing a cyclohexanone moiety were more potent than their 
cyclopentanone analogue. This is most likely due to the structural consequence of five 
carbons in the ring compared to a six-carbon ring. The central ring with five carbon atoms is 
flatter whereas six carbon ring adopts more a chair like conformation which may increase the 
effect on the reactivity of the 1,4-diene-3-one with the target enzyme. Therefore, the potency 
order of bis-pyridylidene derivatives of cyclopentanone and cyclohexanone based on their 
IC50 values can be described as para >meta >ortho-position of nitrogen atom in the ring.  
The dose-response curve of bis-thienylidene derivatives of N-methyl-piperidin-4-one, 
cyclopentanone and cyclohexanone is displayed in Figure 3.10. 
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Figure 3. 10. Dose-response curves of the bis-thienylidene derivatives of N-methylpiperidin-
4-one and cycloalkanones against S. cerevisiae after 24 hours. 
Dose-response curves of the bis–thienylidene derivatives of N-methylpiperidin-4-one, 
cyclopentanone and cyclohexanone against S. cerevisiae. Positive control: miconazole. The 
inhibitory activity was determined by comparing the growth of S. cerevisiae with and without 
compound as the percentage of negative drug-free control (DMSO 1.5%) after 24 hours. The 
dose-response curve was fitted using a five-parameter logistic model. Data was determined 
as the mean of three individual growth experiment each of which was conducted in duplicate. 
SD values were omitted for clarity of graphs. 
 
Compounds 24a and 24b both exhibited some activity and capable of inhibiting the growth of 
S. cerevisiae with the IC50 values of 2233and 619 μM, respectively. However, 24c does not 
reach even 50% inhibition. In contrast, 22a (3,5-bis-[(E)-benzylidene]-1-methylpiperidin-4-
one) gave an IC50 value of 41 μM. The curve of 24b was very steep between the concentration 
range 300 to 1000 μM, yielding a high Hill slope of 2.29 suggestive of possible compound 
aggregation whereas 24a showed a Hill slope of 0.46. In comparison with miconazole, 
compounds 22a, 24a, 24b and 24c were far less potent. 
The thienyl group is near isosteric with benzene or pyridine due to the size of the sulphur 
atom being considered isosteric against CH=CH and sulphur also containing lone pairs of 
electrons and being a potential isostere of the N-atom in pyridine. Thienyl derivatives were 
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identified as the least active amongst the whole 1,4-diene-3-one library against S. cerevisiae 
and they were classified as poor anti-fungal compounds.  
When considering the different potencies of 24a with 24c it is interesting to note that 
although these compounds contain the thiophene ring the difference is associated with the 
central ring structure; 24c has a cyclohexyl ring whilst 24a has a piperidine ring. Thus, 24a may 
be able to form a hydrogen bond between the lone pair of >N-Me of piperidine ring and a 
hydrogen atom associated with the target. The cyclohexyl group of 24c would be unable to 
form such an interaction. 
When comparing compound 24b (with 24a and 24c) which had the highest potency in this 
group of compounds it is worth considering the fact that a cyclopentyl (five membered) ring 
is somewhat flatter than the six membered cyclohexyl or piperidine rings (both of which 
would adopt a near chair conformation). In addition a cyclopentyl ring has smaller bond angle 
than cyclohexyl or piperidine rings (Schaad & Hess, 1974). Therefore, one potential 
consequence of this ring flattening could be an increase in the electrophilicity of the β-carbon 
atom of the dienone structure thus making the compound 24b more reactive. The five 
membered ring will be flatter and thus four different sp2 orbitals of C/C/C/O are more likely 
to be able to facilitate the keto-enol tautomerism and thus increases the electrophilicity of 
the β-carbon attached to the five membered ring. 
It is a challenge to characterise the inhibitory potency of a compound in terms of a single 
parameter. The end point of any test to identify the inhibitory potency of 1,4-diene-3-ones is 
somewhat arbitrary due to the partial inhibition of fungal growth sometimes shown at high 
inhibitor concentrations. It is, therefore necessary to include other parameters and compare 
them. Commonly these include the Hill slope, the area under the curve (AUC), IC10, IC25, IC50, 
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IC90 and MIC as mentioned in the section 3.2.1.7, their values were obtained from application 
of five-parameter logistic equation and values were shown in Table 3.1, page 105.  
The most potent compound identified from the library of 1,4-diene-3-ones was                                                    
3,5-bis(4-trifluoromethylbenzylidene)-1-methylpiperidin-4-one (22n), having the lowest IC10, 
IC25, IC50 and AUC values. In contrast, 2,6-bis(thiophen-2ylmethylene)cyclohexan-1-one (24c) 
was identified as the least active compound because this compound was unable to inhibit 
even 10% growth of S. cerevisiae. Most of the 1,4-diene-3-ones exhibited good inhibitory 
activity against S. cerevisiae with their IC50 values usually being less than 100 μM these being 
22a-g, 22m-t and 23a-h, respectively. Out of which compounds 22a, 22c-g, 22m-t and 23a-h 
exhibited IC50 values <50 μM, whilst compounds 22c-g, 22m-t and 23a-h gave IC50 values <30 
μM and compounds 22c, 22e-g, 22m-o, 22r-t, 23b-c and 23e-g gave IC50 values <10 μM. 
However all continue to be higher than the IC50 of the clinically relevant reference control 
compound miconazole which was determined to be 0.12 μM.  
Moreover only 23 compounds from the library have shown inhibitory activity >90%, these 
being 22a-g, 22j-k, 22m-p, 22s-t and 23a-h, respectively. Comparatively, the IC90 value of 
miconazole was 1.29 μM. In terms of the Hill slope values of compounds; 22b, 22d, 22e, 22g-
r, 22t, 22u and 23d gave Hill slopes <1 whereas compounds 22c, 22f, 23a, 23e and 23f, as well 
as miconazole, exhibited Hill slopes between 1 and 2. Some compounds gave Hill slope values 
>2 these being 22a, 22s, 23b, 23c, 23g, 23h, 24b and 24c, respectively. The AUCs of all 
compounds were between 97 and 328 whereas miconazole showed much lower AUC value 
and this being 43.    
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Table 3. 1. The antifungal activity of various 1,4-diene-3-ones against S. cerevisiae.  
Compound IC10 ± SD (µM) IC25 ± SD (µM) IC50 ± SD (µM) Asymptotic I50 ± SD (µM) IC90 ± SD (µM) Hill slope  ± SD AUC ± SD 
22a 16.17 ± 3.17 25.2 ± 2.90 40.7 ± 0.94 40.4 ± 1.36 101.4 ± 28.04 2.80 ± 1.10 248 ± 1.67 
22b 0.76 ± 0.44 6.04 ± 2.99 53.7 ± 11.5  54.1 ± 14.8 2463.4 ± 264 0.49 ± 0.06 249 ± 10.9 
22c 0.60 ± 0.37 1.20 ± 0.44 3.24 ± 0.47 3.89 ± 1.43 11.8 ± 4.30 1.65 ± 0.30 144 ± 12.4 
22d 0.50 ± 0.30 3.87 ± 2.39 27.9 ± 18.4 29.2 ± 18.9 1024 ± 232.3 0.56 ± 0.01 230 ± 16.1 
22e 0.62 ± 0.35 1.50 ± 0.80 3.90 ± 2.81 2.71 ± 1.62 1209  ± 1233 0.62 ± 0.41 188 ± 37.9 
22f 0.11 ± 0.06 0.34  ± 0.79 1.21 ± 1.29 1.15 ± 1.16 4.16  ± 3.97 1.73 ± 0.34 97.3 ± 52.5 
22g 1.05 ± 0.27 2.90 ± 0.39 5.56 ± 8.01 2.20 ± 1.63 458 ± 406.4 0.25 ± 0.03 160 ± 49.14 
22h 1.30 ± 1.26 15.0 ± 13.3 154 ± 33.6 1178 ± 1358 N/R 0.22 ± 0.14 269 ± 15.9 
22i 5.11 ± 1.73 27.6 ± 2.54 153 ± 10.9 149 ± 6.58 N/R 0.64 ± 0.01 289 ± 3.42 
22j 0.68 ± 0.19 7.35 ± 1.04 124 ± 20.3 383 ± 40.3 2533 ± 389.5 0.13 ± 0.00 258 ± 3.15 
22k 21.8 ± 18.9 73.8 ± 37.9 218 ± 26.4 359 ± 123 1077 ±133  0.97 ± 0.35 299 ± 14.4 
22l 17.7 ± 16.9 398 ± 311.6 N/R 4027 ± 551 N/R 0.19 ± 0.12 314 ± 10.5 
22m 0.43 ± 0.42 0.65 ± 0.72 2.22 ± 1.71 7.78 ± 11.4 346 ± 155.8 0.43 ± 0.37 138 ± 29.5 
22n 0.10 ± 0.04 0.22 ± 0.10 0.62 ± 0.26 0.48 ± 0.28 27.3 ± 17.9 0.63 ± 0.44 104 ± 6.73 
22o 0.25 ± 0.27 0.79 ± 0.70 2.83 ± 0.96 3.50 ± 2.71 262 ± 47.6 0.85  ± 0.45 176 ± 31.7 
22p 0.25 ± 0.29 1.35 ± 1.58 12.9 ± 0.91 12.5 ± 10.1 142 ± 53.6 0.71 ± 0.09 180 ± 44.8 
22q 0.57 ± 0.30 3.34 ± 0.54 21.4 ± 0.99 19.3 ± 7.37 N/R 0.61 ± 0.12 221 ± 17.6 
22r 0.29 ± 0.22 1.56 ± 0.33 7.64 ± 0.27 6.69 ± 2.49 N/R 0.65 ± 0.20 196 ± 10.6 
22s 0.39 ± 0.49 0.67 ± 0.71 1.87 ± 0.60 1.95 ± 0.56 4.79  ± 1.79 2.90 ± 1.38 125 ± 16.9 
22t 0.61 ± 0.52 1.35 ± 1.15 3.37 ± 2.01 3.43 ± 1.92 19.9  ± 15.1 0.56 ± 1.29 146 ± 48.5 
22u 69.4 ± 10.7 249 ± 39.8  1290 ± 89.0 1358 ± 125.8 N/R 0.63 ± 0.16 321 ± 12.3 
22v 56.9 ± 11.9 167 ± 83.6 309 ± 48.5 306 ± 47.5 N/R 2.50 ± 2.03 314 ± 5.51 
23a 2.77 ± 0.56 5.64 ± 0.52 12.60 ± 1.87 12.5 ± 1.33 53.9 ± 25.3 1.62 ± 0.47 208 ± 7.62 
23b 2.27 ± 1.18 4.00 ± 0.52 8.84 ± 2.11 8.58 ± 1.93 45.6 ± 30.8 2.22 ± 1.90 194 ± 12.7 
23c 3.15 ± 0.72 5.51 ± 0.45 9.45 ± 1.94 9.66 ± 2.15 26.2 ± 11.8 2.52 ± 1.09 194 ± 11.4 
23d 2.57 ± 0.63 6.34 ± 0.82 20.3 ± 1.80 18.6 ± 2.18 309 ± 245 0.94 ± 0.26 231 ± 8.80 
23e 2.50 ± 1.06 4.50 ± 0.65 9.29 ± 1.75 8.35 ± 0.91 31.7 ± 6.91 1.80 ± 0.68 207 ± 17.0 
23f 2.20 ± 0.91 4.29 ± 1.04 8.46 ± 0.68 8.42 ± 0.80 38.4 ± 24.5 1.76 ± 0.65 194 ± 6.52 
23g 0.99 ± 0.78 2.80 ± 1.31 5.52 ± 2.47 5.76 ± 2.31 13.9 ± 5.26 2.83 ± 1.83 164 ± 22.7  
23h 2.22 ± 0.76 3.65 ± 0.74 6.25 ± 1.49 6.25 ± 1.33 20.5 ± 17.8 2.97 ± 1.71 178 ± 10.3 
24a 77.9 ± 126 467 ± 460 2233 ± 292 3934 ± 2602 N/R 0.46 ± 0.27 315  ± 15.4 
24b 132 ± 215 281 ± 201 619 ± 158 539 ± 110.7 N/R 2.29 ± 2.16 319 ± 19.0 
24c N/R N/R N/R N/R N/R 2.40 ± 3.34 328 ± 14.1 
4 0.03 ± 0.01 0.05 ± 0.02 0.12 ± 0.01 0.10 ± 0.01 1.29 ± 0.41 1.40 ± 0.19 43.0 ± 5.73 
Note: N/R = Compounds not reached specified level of inhibition (e.g. 10%, 25%, 50% or 90%). Data was expressed in terms of the mean ± SD of the three individual experiment 
conducted in duplicates, therefore n=6. 
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3.2.2.2 Susceptibility of C. albicans to 1,4-diene-3-ones 
The area under the curve (AUC) of each compound was measured by selecting two 
concentrations, C1 and C2 these being 0.1 and 1400 μM respectively i.e. log values of -7.02 
and -2.85 (Odds & Abbott, 1984). These latter values specify the lower and upper limits of the 
test range and are based on the individual ranges associated with the compound library. The 
reason for selecting C2 at 1400 μM concentration was that most of the compounds showed 
low inhibitory activity against C. albicans. In addition, all compounds displayed turbidity in the 
cell suspension at concentrations >1400 μM. The AUC for each test compound was 
determined from the dose-response curves of two individual experiments each assayed in 
duplicate. The standard deviation was calculated from the AUC obtained from the dose-
response curves of these two individual experiments. The relevant IC10, IC25, IC50 and IC90 
values were obtained manually from the percentage inhibition against compound 
concentration dose-response graphs (Figure 3.11 to 3.16).  
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Figure 3. 11. Dose-response curves of the para-substituted bis-benzylidene derivatives of     
N-methylpiperidin-4-one against C. albicans.  
The inhibitory activity was determined by comparing the growth of C. albicans with or without 
the test compound as the percentage of negative drug-free control (DMSO 1.5%) after               
24 hours. Internal control: miconazole. The para-substituent groups were hydrogen, 
trifluoromethyl, trifluoromethoxy, methoxy, methyl [a]; hydrogen, chloro, nitro and 
carboxylic acid [b]. The dose-response curve was fitted using the five-parameter logistic 
model on GraphPad, Prism 5. Data were presented as the mean of two individual growth 
experiment each conducted in duplicate. SD values were omitted for clarity of graphs. 
 
Compound 22a in Figure 3.11[a] exhibited >95% inhibition at concentrations above 300 µM, 
but the curve was very steep between 100 to 300 µM with a Hill slope of 2.13. Compound 22a 
gave an IC50 of 128 µM and AUC of 294. Compound 22a also displayed a high Hill slope (2.80) 
for the S. cerevisiae dose-response curve. This suggests that compound 22a aggregates in 
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both experiments. Compounds 22n and 22p demonstrated their inhibitory activity in a 
concentration-dependent manner against C. albicans (Figure 3.11a). Both of these 
compounds exhibited moderate IC50 values, these being 409.5 and 473.5 µM respectively. In 
addition compounds 22n and 22p gave shallow curves with Hill slopes of 0.46 and 0.63 
suggestive of no aggregation. Moreover compound 22d in Fig 3.11[a] displayed little 
inhibitory activity with high AUC (356) and IC50 (1112 µM) values, but the shallow curve 
representing low Hill slope (0.60), which suggests 22d does not show aggregating issue.  
In Figure 3.11[b], compounds 22g and 22t displayed reasonable although not high inhibitory 
activity against C. albicans with IC50 values of 309 and 353 µM and their AUCs were 316 and 
319, respectively. In addition, 22g and 22t displayed low Hill slope these being 0.57 and 0.50, 
respectively and thus suggesting no inhibitor aggregation occurs. On the other hand, 
compounds 22k and 22l revealed poor activity against C. albicans, capable of inhibiting only 
16 and 19% of C. albicans growth at the highest concentrations tested. Compounds 22k and 
22l depicted very high AUC, being 387 and 389 respectively. However 22k and 22l exhibited 
low slope factor, being 0.29 and 0.62 respectively. 
The order of potency in terms of IC50 values of groups in the para-substituted compounds was 
H>Cl>NO2>OCF3>CF3>OCH3>CH3>COOH. The presence of electron-withdrawing groups (e.g. 
CF3, OCF3, NO2 and Cl) at the para-position of the aromatic ring showed an increase in the 
activity of the bis-benzylidene derivatives of N-methylpiperidin-4-one but the most potent of 
this set appears to be unsubstituted.  
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Figure 3. 12. Dose-response curves of the meta-substituted bis-benzylidene derivatives of N-
methylpiperidin-4-one against C. albicans.  
Inhibition was determined by comparing the growth of C. albicans with and without the test 
compound as the percentage of negative drug-free control (DMSO 1.5%) after 24 hours. 
Positive control: miconazole. The meta- substituent groups were hydrogen, trifluoromethyl, 
trifluoromethoxy, methoxy [a]; hydrogen, chloro, iodo and nitro [b]. The dose-response curve 
was fitted using the five-parameter logistic model (GraphPad, Prism 5). Data were presented 
as the mean of two individual growth experiments each conducted in duplicate. SD values 
were omitted for clarity of graphs. 
 
The dose-response curves in Figure 3.12 represent the meta-substituted bis-benzylidene 
derivatives of N-methylpiperidin-4-one against C. albicans after 24 hours growth. Compounds 
22c, 22m and 22o demonstrated their inhibitory activity in a concentration-dependent 
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manner over the range of concentrations studied (Figure 3.12a). The IC50 values of 
compounds 22c, 22m and 22o were 313, 525 and 549 μM whereas their AUC being identified 
as 329, 335 and 329, respectively. Thus IC50 values suggest 22m and 22o were less potent 
than compound 22c whilst AUC does not support this all because AUV values were very close. 
Compounds 22m and 22o displayed shallow curves with Hill slope of 0.39 and 0.60 whereas 
22c gave a steep curve between the concentrations 100 and 300 μM and high Hill slope (1.27). 
Thus suggesting higher potency of 22c in terms of IC50 is a reflection of aggregation status. 
Among all meta-substituents (22c, 22m, 22o, 22r and 22s), compound 22f exhibited higher 
degree of inhibition of C. albicans growth with the IC50 and IC90 values of 114 and 677 μM, 
respectively. The AUC of compound 22f was 288 however the Hill slope of 1.21 demonstrating 
a steep curve. In contrast, compound 22r displayed moderate inhibitory activity with 
moderate IC50 (243 μM) and low Hill slope (0.26) values. Thus a significant component of the 
inhibition in compound 22f was due to non-aggregation. Similarly, compound 22s showed low 
to moderate inhibitory activity with the IC50 value of 666 μM and AUC of 316 but low Hill 
slope, this being 0.33. The order of potency of groups in the meta-substituted compounds in 
terms of the IC50 values was Cl >H >I >OCH3 >CF3 > OCF3 >NO2. Iodine containing 1,4-diene-3-
one compound has a lower electronegativity, lower electron affinity, lower ionisation energy 
and lower reactivity than chlorine. Hence the lower AUC and IC50 values of compound 22f 
than 22r proves that compound containing chlorine group at meta-position of the aromatic 
ring is more potent that iodine group.  
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Figure 3. 13. Dose-response curves of the ortho-substituted [a] and dichloro substituted [b] 
bis-benzylidene derivatives of N-methylpiperidin-4-one against C. albicans.  
The inhibitory activity was determined by comparing the growth of C. albicans with and 
without compound as the percentage of negative control (DMSO 1.5%) after 24 hours. 
Positive control: miconazole. The ortho-substituents were hydrogen, methoxy, chloro, 
carboxylic acid and iodo [a]; hydrogen, 2,4-dichloro and 3,4-dichloro [b]. The dose-response 
curve was fitted using the five-parameter logistic model (GraphPad, Prism 5). Data were 
presented as the mean of two individual growth experiment each conducted in duplicate. SD 
values were omitted for clarity of graphs. 
 
C. albicans was, to some extent, susceptible to compounds 22b, 22e and 22q (Figure 3.13). 
Compounds 22b, 22e and 22q all exhibited shallow dose-response curves with low Hill slopes 
of 0.49, 0.62 and 0.61 respectively. Compounds, 22b and 22q exhibited higher degree of 
potency with IC50 values being 531.5 and 454.3 μM respectively. In contrast 22e gave an IC50 
Chapter 3: Evaluation of antifungal activity 
 
112 
 
of 1101 μM and 22j capable of inhibiting only 16% of C. albicans growth at highest 
concentration.  
On the other hand in Figure 3.13[b], both compounds 22h and 22i (2,4-dichloro and                  
3,4-dichloro-substituted bis-benzylidene derivatives of N-methylpiperidin-4-one) showed 
identical dose-response curves which may be because the clogP values for both 22h and 22i 
are the same (6.51). Low activity of 22h and 22i is possibly related to their high clogP values, 
which makes these compounds more lipophilic therefore making it difficult to exit the 
membrane. Compounds 22h and 22i both gave their maximum response inhibiting only 30% 
growth of C. albicans. Based on the IC50 values of ortho-substituted compounds, the potency 
order of this group of compounds can be described as H >I >OCH3 >Cl >COOH. 
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Figure 3. 14. Dose-response curves of the bis-pyridylidene derivatives of N-methylpiperidin-
4-one against C. albicans after 24 hours. 
The inhibitory activity was determined by comparing the growth of C. albicans with and 
without the test compound as the percentage of negative drug-free control (DMSO 1.5%). 
Positive control: miconazole. A dose-response curve was fitted using the five-parameter 
logistic model (GraphPad, Prism 5). Data were presented as the mean of two individual 
growth experiment each conducted in duplicate. SD values were omitted for clarity of graphs. 
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Compounds 23a, 23b and 23c differ from each other by the ortho-, meta- or para- position of 
the nitrogen atom in the aromatic ring (Figure 3.14). A heteroatom, such as a nitrogen atom, 
in the aromatic system is likely to facilitate an increase in the aqueous solubility of the 
compound compared to the phenyl equivalent. It was anticipated that the clogP values of N-
containing ring compounds would be lower than the non-N-containing ring compound. The 
clogP of compounds 22a, 23a, 23b and 23c were calculated to be as 4.07, 1.53, 1.83 and 1.61 
respectively thus confirming our hypothesis. 
The IC50 values of compounds 22a, 23a, 23b and 23c were good being 128, 367, 238 and                  
248.5 μM compared to their AUC values which were 294, 329, 320 and 314 respectively. 
Compound 22a gave the highest potency whereas 23a exhibited lowest potency based on 
their ability to inhibit the growth of C. albicans. However, 23b and 23c were similar in their 
activities in terms of both the AUC and IC50 values. The dose-response curves of all of these 
compounds displayed steep curve between 100 and 470 μM. Consequently their Hill slopes 
were high, these being 2.13, 3.27, 1.36 and 2.57 respectively. Compounds 22a, 23a, 23b and 
23c were all significantly less potent than miconazole. The order of potency of the bis-
pyridylidene derivatives of N-methylpiperidin-4-one in terms of their IC50 values can be 
described as meta >para >ortho-position of N-atom on the ring. However, when comparing 
the AUC values, their order of potency has changed to para >meta >ortho-position of N-atom 
on the ring.  
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Figure 3. 15. Dose-response curves of bis-benzylidene and bis-pyridylidene derivatives of 
cycloalkanones against C. albicans after 24 hours. 
Dose-response curves of the bis-pyridylidene derivatives of cyclopentanone [a] and 
cyclohexanone [b] against C. albicans. The inhibitory activity was determined by comparing 
the growth of C. albicans with and without compound as the percentage of negative control 
(DMSO 1.5%) after 24 hours. Positive control: miconazole. A dose-response curve was fitted 
using the five-parameter logistic model (GraphPad, Prism 5). Data was determined as the 
mean of two individual growth experiment each conducted in duplicate. SD values were 
omitted for clarity of graphs. 
 
Compound 22u in Figure 3.15[a] represents the bis-benylidene derivative of cyclopentanone, 
while compounds 23d, 23e and 23f are analogues containing a nitrogen atom in the aromatic 
ring at either the ortho-, meta- or para-positions. Compounds 22u, 23d and 23e all exhibited 
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very low potencies, with IC50 values of 1604, 2196 and 1493 μM respectively. The dose-
response curves of 22u, 23d and 23e were shallow and had Hill slope values were 0.55, 0.99 
and 0.90 respectively. Compound 23f exhibited good potency against C. albicans growth with 
an IC50 value of 68.5 μM but a high Hill slope (2.33).     
In Figure 3.15[b], bis-benzylidene derivative of cyclohexanone (22v) exhibited modest 
inhibitory activity with an IC50 value of 263 μM and a maximum of 70% inhibition of C. albicans 
growth at the highest concentration tested. Compound 22v gave a shallow dose-response 
curve with a Hill slope of 0.67. Compounds 23g and 23h both exhibited the highest potency 
against C. albicans with IC50 values of 57.6 and 50.7 μM and AUCs of 273 and 261 respectively. 
However 23g and 23h displayed steep dose-response curves between the concentration 
ranges of 100 and 300 μM and high Hill slope values (1.45 and 2.21 respectively).  
Considering the IC50 values, the order of potency of pyridyl derivatives of cyclopentanone was 
identified as para >meta >ortho >non-nitrogen whilst the pyridyl derivatives of cyclohexanone 
can be classified as para >meta >non-nitrogen.  
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Figure 3. 16. Dose-response curves of the bis-benzylidene and bis-thienylidene derivatives 
of N-methylpiperidin-4-one and cycloalkanones against C. albicans after 24 hours. 
The inhibitory activity was determined by comparing the growth of C. albicans with and 
without the test compound as the percentage of negative control (DMSO 1.5%). Positive 
control: miconazole. The dose-response curve was fitted using a five-parameter logistic model 
(GraphPad, Prism 5). Data were presented as the mean of two individual growth experiments, 
each performed in duplicate. SD values were omitted for clarity of graphs. 
 
The dose-response curves of the bis-benzylidene and bis-thienylidene derivatives of                    
N-methylpiperidin-4-one, cyclopentanone and cyclohexanone along with the reference 
control miconazole are shown in Figure 3.16. Compounds 22a and 24a both exhibited good 
inhibitory activity against C. albicans, with IC50 values of 128 and 138 μM and AUCs of 298 and 
288.5 respectively. Both of these compounds showed steep dose-response curves and 
therefore their Hill slopes were high (2.13 and 2.22) thus possibly showing aggregation. 
Compounds 22a and 24a both contain a central piperidine ring therefore giving an increase 
in their solubility compared to central cyclohexyl or cyclopentyl ring. Also the presence of N-
methyl in the central ring may lead to the formation of a hydrogen bond using the nitrogen 
lone pair. 
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Compound 24c showed moderate activity with an IC50 of 334 μM and AUC of 312. The shallow 
curve of 24c thus gave a low Hill slope value (0.40). In contrast, 2,5-bis[(E)-(2-
thienylidene]cyclopentanone (24b) displayed poor activity against C. albicans and was 
capable of inhibiting only a maximum 31% of growth. IC25 value of 24b was calculated as being 
437.9 μM. Although 24a, 24b and 24c all contain the thiophene rings, the only difference 
between them is the structure of the central ring; 24a has a piperidine ring 24b has a 
cyclopentyl ring and 24c has a cyclohexyl ring. As mentioned previously that cyclohexyl or 
piperidine rings can adopts more chair like conformation which facilitates the increase 
reactivity of molecule to the target enzyme whereas cyclopentyl ring are flatter and can’t 
form chair conformation. Thus 24b depicted lower activity than 24a and 24c. 
The antifungal activity of thirty-three symmetrical 1,4-diene-3-ones against C. albicans is 
presented in Table 3.2, page 119. The inhibitory activity values were expressed in terms of 
their Hill slope, AUC, IC10, IC25, IC50 and IC90. The most potent compound identified from the 
library of 1,4-diene-3-ones was bis-(pyridin-4-ylmethylene)cyclohexan-1-one (23h), based on 
its AUC (261 arbitrary unit), IC10, IC25, IC50 and IC90 (10.4, 32.9, 50.7 and 138 µM) values against 
C. albicans. In addition, both bis-(pyridin-4-ylmethylene)cyclopentan-1-one (23f) and bis-
(pyridin-3-ylmethylene)cyclohexan-1-one (23g) displayed good potency with low IC50 values, 
this being 68.5 and 57.6 µM. However, the Hill slopes of 23f-h were relatively high which 
suggests promiscuous aggregation at higher concentrations. Compounds 23a, 23b and 23c 
exhibited moderate activity against C. albicans. High Hill slope of compounds 23a, 23b and 
23c were due to steep curves and this may give rise to aggregation artefacts. 
Compounds which demonstrated >90% inhibitory action were determined to be 22a, 22f, 
23a-c, 23f-h and 24a. Most of the other compounds from the library of 1,4-diene-3-ones did 
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not achieve 90% growth inhibition of C. albicans. Compounds 22a and 22f both gave 
moderate inhibitory activity against C. albicans with IC50 values of 128 and 114 µM. However, 
both 22a and 22f displayed high Hill slopes these being 2.13 and 1.21 respectively. Compound 
22f being potent may be due to the presence of weak EWG (-Cl) at the meta-position of the 
aromatic ring which makes the β-carbon slightly more electrophilic so that nucleophiles (such 
as the cysteine -SH) can easily attack and form a C-S bond potentially inhibiting the H+-ATPase. 
However the meta-position for substitution would not give rise to a resonance structure 
facilitating enhanced electrophilicity at the β-carbon so any effect would be due to the 
aggregate change in electron withdrawing power of the meta-chloro benzene ring. However, 
good potency of compounds 22a could possibly be due to aggregation of the molecule as 
suggested by the high Hill slope (2.13).  
Certain compounds from the library did not reach 50% inhibition of the growth of C. albicans, 
these being 22h, 22i, 22j, 22k, 22l and 24b. Out of these compounds, 22j and 22k did not even 
reach 25% inhibition. All the synthesized 1,4-diene-3-ones exhibited wide range of AUC (261 
to 388 arbitrary units) between the concentrations of 0.1 and 1400 μM but miconazole gave 
an AUC of only 25.3 arbitrary unit. This shows that miconazole is a very potent inhibitor of            
C. albicans growth compared to all tested 1,4-diene-3-ones. 
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Table 3. 2. The antifungal activity of various 1,4-diene-3-ones against C. albicans.  
Compound IC10 ± SD (µM) IC25 ± SD (µM) IC50 ± SD (µM) Asymptotic I50 ± SD 
(µM) 
IC90 ± SD (µM) Hill slope  ± SD AUC ± SD 
22a 41.1 ± 9.14 85.4 ± 27.3 128 ± 28.3 125 ± 37.2 272 ± 4.24 2.13 ± 0.31 294 + 16.26 
22b 15.78 ± 12.5 112 ± 36.0 532 ± 43.1 630 ± 453 N/R 0.70 ± 0.02 341 ± 9.55 
22c 9.96 ± 6.83 104 ± 52.1 313 ± 25.5 696 ± 590 N/R 1.27 ± 0.99 329 ± 1.98 
22d 24.2 ± 6.61 161 ± 13.1 1112 ± 126.4 375 ± 55.2 N/R 0.60 ± 0.24 356 ± 0.78 
22e 14.9 + 1.92 192 ± 67.4 1148 ± 241 567 ± 208 N/R 0.68 ± 0.36 353 ± 1.84 
22f 22.1 ± 27.5 71.0 ± 22.7 114 ± 9.35 119 ± 10.7 677 ± 21.9 1.21 ± 0.21 288 ± 1.77 
22g 5.57 ± 4.07 37.7 ± 20.9 309 ± 99.8 133 ± 57.5 N/R 0.57 ± 0.09 316 ± 7.00 
22h 15.1 ± 5.05 407 ± 96.3 N/R 233 ± 290 N/R 0.20 ± 0.03 368 ± 3.61 
22i 73.8 ± 42.7 861 ± 14.0 N/R 636 ± 261 N/R 0.53 ± 0.37 385 ± 4.88 
22j 16.3 ± 10.9 N/R N/R 49.5 ± 4.45 N/R 0.84 ± 0.61 383 ± 0.71 
22k 45.4 ± 11.7 N/R N/R 49.6 ± 27.5 N/R 0.29 ± 0.37 387 ± 1.41 
22l 152 ± 173.6 3094 ± 825 N/R 2099 ± 2927 N/R 0.62 ± 0.31 389 ± 10.5 
22m 6.55 ± 0.74 59.6 ± 2.91 525 ± 33.9 3816 ± 1752 N/R 0.39 ± 0.00 335 ± 1.98 
22n 6.18 ± 1.98 49.9 ± 24.9 474 ± 7.78 149 ± 130 N/R 0.63 ± 0.21 327 ± 3.96 
22o 10.5 ± 12.8 59.6 ± 63.8 549 ± 115 229 ± 290 N/R 0.60 ± 0.28 329 ± 20.9 
22p 1.86 ± 0.12 20.0 ± 6.41 409 ± 10.6 62.0 ± 60.8 N/R 0.46 ± 0.10 314 ± 0.99 
22q 2.87 ± 1.97 26.4 ± 12.8 454 ± 66.3 476 ± 88.4 N/R 0.25 ± 0.18 321 ± 11.2 
22r 1.03 ± 0.36 11.15 ± 1.63 243 ± 11.9 386 ± 174 N/R 0.26 ± 0.02 302 ± 5.59 
22s 1.14 ± 1.21 29.9 ± 25.3 666 ± 70.7 682 ± 89.8 N/R 0.33 ± 0.08 316 ± 10.4 
22t 1.88 ± 0.09 59.4 ± 14.7 354 ± 361 361 ± 62.2 N/R 0.50 ± 0.11 319 ± 11.4 
22u 51.4 ± 5.01 320 ± 15.6 1604 ± 78 3336 ± 2062 N/R 0.55 ± 0.03 372 ± 1.27 
22v 5.65 ± 2.74 36.9 ± 12.4 263 ± 17.1 256 ± 88.8 N/R 0.67 ± 0.04 327 ± 3.18 
23a 257 ± 25.5 305 ± 59.2 367 ± 82.0 323 ± 18.4 820 ± 287.1 3.27 ± 0.04 329 ± 34.4 
23b 58.4 ± 78.6 158 ± 166.60 238 ± 177 928 ± 884 533 ± 202.9 1.36 ± 9.05 320 ± 49.9 
23c 76.8 ± 49.7 172 ± 3.25 249 ± 20.5 256 ± 29.7 557 ± 125.2 2.57 ± 4.01 314 ± 27.7 
23d 113 ± 69.9 524 ± 283 2196 ± 59.1 499 ± 453 N/R 0.99 ± 0.24 386 ± 15.4 
23e 70.4 ± 41.9 356 ± 239 1493 ± 881 3371 ± 3150 N/R 0.90 ± 0.14 379 ± 22.8 
23f 31.6 ± 1.03 46.3 ± 3.77 68.5 ± 3.27 70.7 ± 0.27 145 ± 19.1 2.33 ± 0.68 279 ± 4.45 
23g 19.8 ± 5.11 34.1 ± 9.33 57.6 ± 5.78 66.7 ± 1.34 215 ± 67.9 1.45 ± 0.51 273 ± 13.4 
23h 10.4 ± 1.19 32.9 ± 4.81 50.7 ± 3.50 56.0 ± 5.11 138 ± 9.19 2.21 ± 0.02 261 ± 0.42 
24a 43.3 ± 24.0 100 ± 82.6 138 ± 24.0 117 ± 4.95 276 ± 66.5 2.22 ± 0.28 288 ± 9.76 
24b 18.3 ± 12.1 438 ± 140.1 N/R 425 ± 289 N/R 0.36 ± 0.29 369 ± 3.46 
24c 1.66 ± 1.37 33.6 ± 3.83 334 ± 65.1 356 ± 64.4 N/R 0.40 ± 0.06 312 ± 12.2 
4 0.01 ± 0.01 0.01 ± 0.00 0.04 ± 0.02 0.03 ± 0.02 0.86 ± 1.08 0.95 ± 0.17 25.3 ± 9.64 
Note: N/R = Compounds not reached specified level of inhibition (10%, 25%, 50% or 90%). Data were presented as the mean ± SD of two individual experiment 
conducted in duplicates, n=4. 
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3.4 Discussion of macro-broth susceptibility assay 
The goal of the macro-broth susceptibility assay was to investigate the potential antifungal 
activity of 1,4-diene-3-one compounds (22a-v, 23a-h and 24a-c) against S. cerevisiae and          
C. albicans. Time based endpoint tests to identify the inhibitory potency of 1,4-diene-3-ones 
can sometimes give arbitrary results due to partial inhibition of fungal growth over the range 
of concentrations. For example, in the current set of experiments, some compounds showed 
an increase in inhibitory activity with a gradual increase in concentration represented by a 
shallow curve whereas some compounds showed a sudden rise in inhibitory activity with a 
steep curve at higher concentrations. Such results, associated with high Hill factors may be 
due to the concentration at which molecular aggregation becomes significant. 
The dose-response curves of 1,4-diene-3-ones varied extensively making it very easy to rank 
them into activity order over the range of concentrations. However the shape of the dose-
response curve varies significantly. Therefore, it is necessary to include and compare various 
inhibitory parameters. Hence the AUC, Hill coefficient, IC10, IC25, IC50, asymptotic I50 and IC90 
values were calculated and analysed. These values were presented in Table 3.1 and 3.2. The 
potency of the various compounds relates to the AUC enclosed within the rectangular portion 
between two concentrations (Odds & Abbott, 1984). The Hill slope is the reflection of the 
steepness of the curve. Differences in the Hill slope reflects potential interactions such as 
inhibitor aggregation or changes in cell structure or morphology (Rautenbach et al., 2006).  
3.4.1 Discussion of susceptibility assay of S. cerevisiae 
A library of 1,4-diene-3-ones demonstrated significant level of growth inhibition of S. 
cerevisiae (0.2 - 99% inhibition) over the concentration range between 0.10 to 3000 µM. In 
terms of the IC50, certain compounds (22c, 22e, 22f, 22g, 22m, 22n, 22o, 22r, 22s, 22t, 23b, 
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23c and 23e-h) displayed good potency against S. cerevisiae and their IC50 values were 
between 0.62 and 9.45 μM. While some compounds (22a, 22b, 22d, 22p, 22q, 23a and 23d) 
were considered to be moderate inhibitors based on their IC50 values ranged between 10 and 
100 μM. In contrast, compounds with IC50 values >100 μM were classified as moderate to 
poor inhibitor of S. cerevisiae and these being compounds 22h-l, 22u-v and 24a-c. 
The compound which exhibited the highest ability to inhibit the growth of S. cerevisiae was 
3,5-bis(4-trifluoromethylbenzylidene)-1-methylpiperidin-4-one (22n) having the lowest IC10, 
IC25, IC50 values as shown in Table 3.1, page 105. Additionally, 3,5-bis(3-chlorobenzylidene)-
1-methylpiperidin-4-one (22f), 3,5-bis(3-nitrobenzylidene)-1-methylpiperidin-4-one (22s) 
and 3,5-bis(3-trifluoromethylbenzylidene)-1-methylpiperidin-4-one (22m) have been 
identified as the second, third and fourth most potent inhibitors of S. cerevisiae growth based 
on their low AUC (97.4, 125 and 138) and IC50 (1.21, 1.87 and 2.22 μM) values.  
Although compound 22n depicted higher degree of potency (IC50 = 0.62 µM) and inhibited 
the growth of S. cerevisiae, it was 5-fold less potent than the clinically used miconazole nitrate 
(IC50 = 0.12 µM). Interestingly in this study, the IC50 of miconazole was 0.12 µM whereas in 
literature it was reported 3 µM (Ottilie et al., 2018), suggesting 25-fold difference between 
the two sets of experiments. The reason for this difference in susceptibility is not clear. 
Although variations between methodologies for determining antimicrobial potency are 
uncommon. The susceptibilities of microbes to anti-microbial agents is known to vary with 
the growth medium used for their assay (Ottilie et al., 2018) who performed their assay using 
YPD medium. They incubated S. cerevisiae at 30 °C until mid-log phase (absorbance at 600 
nm; 0.1 and 0.5), then the diluted cell suspension (absorbance at 600 nm; 0.01) and incubated 
with miconazole into a 96-well plate at 30 °C for 18 hours, followed by the absorbance 
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measurement. Thus this variation may also be due to the different growth procedure (i.e. 
Bijou in this study vs microtitre plate in the literature). 
The high activity of 22n is possibly suggesting the importance of the strong electron-
withdrawing group (EWG), trifluoromethyl attached at the para-position on the aromatic ring 
of this compound. Strong EWGs facilitate other atoms becoming more electrophilic in nature 
whereas strong electron-donating groups (EDG) facilitate other atoms becoming more 
nucleophilic in nature (Sivakumar, Muthu Kumar, & Doble, 2009). The presence of EWG (such 
as CF3, NO2, CCl3, halides) on the aromatic ring will increase the electrophilicity of the β-carbon 
of the 1,4-diene-3-ones, a representative example of compound 22n shown in Figure 3.17.  
 
Figure 3. 17. A representative example of a compound which shows an increase in the 
electrophilicity of β-carbon of the bis-benzylidene derivative of N-methylpiperidin-4-one. 
 
This suggests a possible mechanism of action, that the nucleophilic sulfhydryl (-SH) of a 
cysteine present in the fungal PM H+-ATPase could attack one of the electrophilic β-carbons 
present in the 1,4-diene-3-ones via a Michael addition reaction (Dao et al., 2016). The 
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presence of EDG (-H, -CH3, OCH3, -OH) on the aromatic rings will cause the β-carbons of 
dienone to become less electrophilic due to a higher electron density on the β-carbons, hence 
this would possibly result in a decrease in the reactivity of the compounds if it follows the 
above mention mechanism (Sivakumar et al., 2009). 
The second most potent inhibitor of S. cerevisiae growth was identified to be compound 22f 
(IC50 = 1.21 μM), which contain chloro-group at the meta-position on the aromatic rings. 
Likewise, the ortho-chloro substituted (22e) and para-chloro substituted (22g) bis-
benzylidene-piperidin-4-one also exhibited good potency with low IC50 values (3.90 and 5.56 
μM). However, compounds containing two chlorine atoms on the aromatic rings (22h; 2,4-di-
chloro and 22i; 3,4-di-chloro) gave moderate inhibitory activity against S. cerevisiae with IC50 
values of 153.6 and 153.9 μM (Figure 3.7b). This suggests that presence of di-chloro groups 
(22h and 22i) on the aromatic ring gives about 30-fold decrease in the activity compared to 
22e, 22f and 22g. It is more likely that the presence of two chlorine atoms increases the 
volume of the molecule sufficiently that although it is able to react, the molecule has less 
accessibility to the binding site (chlorine being quite large and there being four of them). In 
addition due to the di-chloro substitution there has been an increase in the molecular weight, 
clogP values, larger volume and increased surface area of the molecule than when a single 
chlorine atom is present on the aromatic rings. Compounds 22h and 22i both have the same 
clogP values (6.51), which is slightly greater than clogP values of 22e, 22f and 22g (5.25, 5.33 
and 5.25 respectively). In addition 22h and 22i have higher molecular mass (427.2 g/mole) 
than 22e, 22f and 22g (358.3 g/mole). Hence 22h and 22i exhibited less potency than 22e, 22f 
and 22g.  
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On the other hand, both compounds (24c) and (22l); 2,6-bis(thiophen-
2ylmethylene)cyclohexan-1-one and 3,5-bis(4-methylbenzylidene)-1-methylpiperidin-4-one 
failed to reach an IC50 value in the assay, possibly due to self-aggregation of the compounds 
(Giannetti et al., 2008). Giannetti et al., (2008) have mentioned that promiscuously binding 
compounds often form soluble or colloidal aggregates in solution. These aggregates can bind 
to proteins with high affinity and preventing the substrate accessing and thus binding to the 
target protein hence inhibiting the protein function. 
From the dose-response curves of bis-benzylidene derivative of N-methylpiperidin-4-one 
(22a), bis-pyridylidene derivatives of cyclopentanone (22u) or cyclohexanone (22v), it was 
identified that 22a was a more potent inhibitor than 22u or 22v. The IC50 values of 22a, 22u 
and 22v were 40.7, 1290 and 309 μM whereas their AUCs were 248, 320 and 313 respectively 
thus although the difference in the AUC are smaller than the differences between the IC50 
values the order was the same (Table 3.3, page 125). Thus in both measurements, compound 
22a displayed a higher degree of potency while 22v showed intermediate activity and 22u 
being the least active inhibitor of S. cerevisiae growth. As with the inhibitory effects of 22a 
and 22v, the high Hill slopes may indicate promiscuous aggregation of the molecule which 
may also contribute to the enhanced inhibitory activity commonly associated with such 
aggregations (Giannetti et al., 2008; Baell & Holloway, 2010; Ingólfsson et al., 2014).  
The difference in the activity of these compounds is related to the central ring structure. 
Compound 22a has a piperidone ring whereas 22u has a cyclopentyl ring and 22v has a 
cyclohexyl ring. Consequently they have different clogP values, these being 4.07, 4.77 and 
5.33 respectively. The lower clogP of 22a indicated a slightly better aqueous solubility and it 
is this which is believed to give contribute to the higher potency. 
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Table 3. 3. Ranking of bis-benzylidene derivatives of N-methylpiperidin-4-one, 
cyclopentanone and cyclohexanone based on their inhibitory activity against S. cerevisiae. 
Compounds Compound structures IC50 ± SD (µM) AUC ± SD ClogP 
22a 
 
40.7 ± 0.94 248 ± 1.67 4.07 
22u 
 
1290 ± 89.0 321 ± 12.3 4.77 
22v 
 
309 ± 48.5 314 ± 5.51 5.33 
 
Therefore the potency order of the central ring of the bis-benzylidene derivatives can be 
classified as N-methylpiperidin-4-one >cyclohexanone >cyclopentanone. When IC50 and AUC 
of 22a, 22u and 22v were compared with C. albicans, the rank order remains the same 
although specific values were different. Compounds 22a, 22u and 22v gave IC50 of 128, 1604 
and 263 μM against C. albicans whereas their AUCs were determined to be 294, 372 and 327, 
respectively (Table 3.2, page 119). Thus these compounds have same activity order against 
both S. cerevisiae and C. albicans. 
In addition to comparing the isosteric nitrogen-atom replacements in the aromatic ring of bis-
pyridylidene derivatives of N-methylpiperidin-4-one, cyclopentanone or cyclohexanone with 
the parent compound having an unsubstituted phenyl ring, it was identified that meta-N 
>para-N >ortho-N >phenyl ring for compounds with a central cyclohexyl ring and a piperidone 
ring however compounds with a cyclopentyl ring showed potency order of para-N >meta-N 
>ortho-N >phenyl ring. The six-membered ring structures of cyclohexyl and piperidine rings 
adapt a near chair conformation and larger bond angle whilst cyclopentyl ring is slightly flatter 
and has smaller bond angles in the ring. Therefore, it is possible that the chair conformation 
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might show an increase in the electrophilicity of the β-carbon and makes these compounds 
more reactive to the target site.  
The IC50 values of bis-pyridylidene derivative of compounds; 22a, 23a, 23b, 23c, 23d, 23e, 23f, 
23g and 23h were 40.7, 12.6, 8.84, 9.45, 20.3, 9.29, 8.46, 5.52 and 6.25 μM whereas their 
AUCs were 248, 207, 194, 194, 231, 206, 193, 164 and 177 respectively. Again the rank order 
is maintained irrespective of the method used to determine the potency. The clogP values of 
22a, 23a, 23b, 23c, 23d, 23e, 23f 23g and 23h were 4.07, 1.53, 1.83, 1.61, 1.90, 1.91, 1.60, 
2.34 and 1.60 respectively. Due to the presence of a nitrogen atom in the aromatic ring of 
compounds 23a-h their clogP values were significantly lower than 22a. However, the 
difference between the clogP of 23a-h is due to resonance effects. The lower degree of 
inhibitory action of compounds 22a, 22u and 22v than 23a-h is highly suggestive that the 
potency of these compounds is partly associated with their increased solubility. The N-
analogue of benzene (pyridine) is miscible with water whereas benzene is immiscible (Zafar 
et al., 2018). Because the pyridyl ring is amphipathic, the presence of the two-pyridine rings 
should increase both the solubility and permeability across membranes. This suggests that 
the introduction of a nitrogen atom on the aromatic ring has shown an increase in the 
solubility, and probably the permeability of compounds (23a-h) across the yeast (S. cerevisiae) 
plasma membrane.  
Most of the compounds from the library of 1,4-diene-3-ones exhibited Hill slopes <1, with the 
exception of certain compounds (22c, 22f, 23a, 23e and 23f) being between 1 and 2, and 
compounds 22a, 22s, 22t, 22v, 23b, 23c, 23g, 23h, 24b and 24c having Hill slopes >2. The 
highest Hill slope (2.97) was observed for (2E,6E)-2,6-bis(pyridine-4-ylmethylene)cyclohexan-
1-one (23h). Compounds with a Hill slope <2 reflects that they are active even at low 
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concentrations. In contrast, compounds with Hill slope >2 represents their activity is 
dependent on higher concentrations (Rautenbach et al., 2006). Interpretation of Hill 
coefficients is complex, Rautenbach et al., (2006) mentioned that self-association of peptide 
inhibitors may result in a lower than expected levels of inhibition. However other authors 
(Baell & Holloway, 2010; McGovern, Caselli, Grigorieff, & Shoichet, 2002; Pouliot & Jeanmart, 
2016; Seidler et al., 2003) argues that self-association/aggregation may lead to non-
competitive inhibition and higher than expected inhibition. Thus the situation regarding the 
Hill slope is both complex and confusing and incompletely understood.  
3.4.2 Discussion of susceptibility assay of C. albicans 
Compounds 22a-v, 23a-h and 24a-c have shown wide range of inhibition against C. albicans 
(0 - 99% inhibition) over the concentration range 0.1 to 1400 µM. Most of the test compounds 
from the library did not cause 90% inhibition of growth of C. albicans, except compounds 22a, 
22f, 23a-c, 23f-h and 24a. Compound 23h (2E,6E)-2,6-bis(pyridine-4-ylmethylene)cyclohexan-
1-one has been identified as the most potent inhibitor of C. albicans based on the lower IC10, 
IC25, IC50, IC90 and AUC values  (Table 3.2, page 119). Compounds 23f and 23g have also shown 
good inhibitory activity against C. albicans with their low AUC (279 and 273) and IC50 (68.5 
and 57.6 μM) values. 
The least active compounds against C. albicans were determined to be 22j, 22k and 22l, which 
exhibited a maximum of 16% inhibition of C. albicans growth at the highest concentration 
tested (1400 μM). Sivakumar et al., (2009) have mentioned in their QSAR studies on chalcones 
that usually the EWG at ortho, meta or para-position shows an increase in the electrophilicity 
of the β-carbon however, in this our research work, compounds 22j and 22k which contains 
COOH group at either ortho or para-position showed decrease in their activity. This could 
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possibly due to the presence of carboxylic acid groups either interacting with other target 
enzymes or there being a negative charge able to interact with the carboxyl group close to 
the potential drug-binding site on the target enzyme, which could thus act in a repulsive 
manner (Das et al., 2008). Compound 22l contains an EDG (CH3) at the para-position of the 
aromatic ring, which makes the compound less electrophilic so that the nucleophiles (-SH)  
can attack at the β-carbon but the rate of reaction will be slower due to the EDG  (Sivakumar 
et al., 2009). Compound 22l has shown a similar effect against S. cerevisiae in this study. 
Compounds 22e, 22f and 22g (containing mono-chloro group) exhibited some activity against 
C. albicans with IC50 of 1148, 114 and 309 μM. In addition, 22f exhibited higher potency than 
22e, 22g, 22h and 22i in S. cerevisiae study. However compounds 22h and 22i showed poor 
activity, which is possibly due to the presence of two halo atoms (e.g. dichloro) as EWGs on 
the aromatic ring of benzylidene derivatives of N-methylpiperidin-4-one. Halogens (F, Cl, Br 
and I) vary in their electronegativity from 9 to 53 (arbitrary units), which cause the withdrawal 
of electrons from the benzene rings causing ring deactivation. In addition, clogP for both 22h 
and 22i is 6.51 which makes these compounds very lipophilic. As mentioned previously in the 
S. cerevisiae study (in section 3.4.1, page 123) that due to the high molecular weight, large 
size and surface area of the molecule these compounds (22h and 22i) have less accessibility 
to the binding site of the target enzyme. 
From the dose-response curves it was identified that bis-benzylidene derivative of N-
methylpiperidin-4-one (22a) was more potent inhibitor of C. albicans growth than bis-
pyridylidene derivatives of cyclopentanone (22u) or cyclohexanone (22v). The IC50 values of 
22a, 22u and 22v were 128, 1604 and 263 μM whereas their AUCs were 294, 372 and 327 
respectively (Table 3.2, page 119). Again, the rank order is independent of the method of 
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analysis for both S. cerevisiae and C. albicans study. Compound 22a is capable of forming a 
hydrogen bond between the N-me lone pair of a piperidine ring and a hydrogen atom of the 
target enzyme whereas a cyclopentyl group of 22u or a cyclohexyl group of 22v cannot form 
such an interaction. As previously mentioned in the S. cerevisiae study, piperidine and 
cyclohexyl rings would adopt a near chair conformation, which facilitate the reactivity of 
molecule towards the target enzyme whilst the cyclopentyl ring is slightly flatter which 
facilitate sp2 delocalisation of the ring. Additionally, the N-methyl being both fairly polar and 
basic should increase the solubility possibly due to nitrogen forming a hydrogen bond using 
its lone pair of electrons. 
As mentioned earlier that the nitrogen-containing aromatic rings increases compound 
solubility when compared to their phenyl analogs. Therefore the potencies of bis-pyridylidene 
derivatives (23a-h) were compared to each other based on their IC50 and AUCs. Although 23d, 
23e and 23f were similar in structures the difference in the position of nitrogen atom in the 
aromatic ring will cause variability in activity and this ultimately depends on the interaction 
of the nitrogen atom with the target protein(s). It was identified that the bis-pyridylidene 
derivatives of cyclohexanones were more potent than bis-pyridylidene derivatives of 
cyclopentanone or N-methylpiperidin-4-one. The reason for better potency of compounds 
(23g-h) with a central cyclohexyl ring is possibly due to the steep curve and associated high 
Hill slopes, which suggests, and is consistent with, the increase in inhibition being due to 
promiscuous aggregation. 
When comparing the inhibitory activities of 23a-h between C. albicans and S. cerevisiae study, 
it has been identified that these compounds exhibited a higher level of potency against              
S. cerevisiae than C. albicans. This is probably due to differences in the genetic and 
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morphological profiles of S. cerevisiae compared to C. albicans. Dimorphic nature of                      
C. albicans can change it structure from mycelium to hyphae growth and might form a biofilm. 
On the other hand S. cerevisiae can change its ploidy state from haploid to diploid and vice a 
versa whereas C. albicans is obligate diploid.  
Moreover, all of the synthesized compounds (22a-v, 23a-h and 24a-c) demonstrated their 
inhibitory activities were significantly less potent than miconazole nitrate (IC50 = 0.04 μM) 
against C. albicans and in literature, Isham & Ghannoum, (2010) have reported the IC50 of 
miconazole was 0.016 µg/ml which is equivalent to 0.04 µM.  
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3.5 Conclusions 
From the library of 1,4-diene-3-ones, the four most potent compounds capable of inhibiting 
the growth of S. cerevisiae were the 4-trifluoromethyl (22n, IC50 = 0.62 µM), 3-chloro (22f,                           
IC50 = 1.21 µM), 3-nitro (22s, IC50 = 1.87 µM) and 3-trifluoromethyl (22m, IC50 = 2.22 µM) 
substituted bis-benzylidene derivatives of N-methylpiperidin-4-one. All of these compounds 
contain an electron-withdrawing group present at either the meta- or para-position of the 
aromatic ring. The presence of EWGs will increase the electrophilicity of the β-carbon of these 
compounds.  However, 22n exhibited a 5-fold less potency than miconazole nitrate (IC50 = 
0.12 µM), while 22f, 22s and 22m exhibited 10 to 19-fold lower potency than miconazole 
nitrate against S. cerevisiae.  
Overall, the bis-benzylidene and bis-pyridylidene derivatives of N-methylpiperidin-4-one, 
cyclopentanone and cyclohexanone exhibited good potency against S. cerevisiae with IC50 
values between 0.62 to 23 µM. However, the thienyl derivatives of N-methylpiperidin-4-one, 
cyclopentanone or cyclohexanone (24a, 24b and 24c) were not effective inhibitors of                   
S. cerevisiae growth. 
In terms of the 1,4-diene-3-ones activity against C. albicans, the most potent compounds 
identified were 4-pyridylidene cyclohexanone (23h, IC50 = 50.7 µM), 3-pyridylidene 
cyclohexanone (23g, IC50 = 57.6 µM), 4-pyridylidene cyclopentanone (23f, IC50 = 68.5 µM) and 
3,5-bis(3-chlorobenzylidene)-1-methylpiperidin-4-one (22f, IC50 = 114 µM). Compounds 23f, 
23g and 23h depicted 8, 10 and 8-fold more potent against S. cerevisiae than C. albicans, 
whereas 22f exhibited 94-fold higher potency against S. cerevisiae than C. albicans. However, 
all of these compounds were significantly less potent than the clinically used drug miconazole 
nitrate (IC50 = 0.04 µM) against C. albicans.  
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The thienyl derivatives of N-methylpiperidin-4-one, cyclopentanone or cyclohexanone (24a, 
24b and 24c) gave low to poor inhibitory activity against C. albicans. Moreover, compounds 
22j and 22k (carboxylic acid substituted bis-benzylidene derivatives of N-methylpiperidin-4-
one) have been identified as the least active inhibitors of C. albicans growth. 
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4 Proton extrusion assay 
4.1 Introduction 
The plasma membrane (PM) H+-ATPase is an essential enzyme for the growth of fungi 
(Portillo, 2000; Kjellerup et al., 2017). The presence of an electrogenic proton pump                          
(H+-ATPase) in fungal and plant plasma membranes had been hypothesized based on the 
measurements of the membrane potentials using a micro pH electrode (Serrano, 1980 & 
1983; Perlin, Brown, & Habern, 1988; Ben-Josef, Manavathu, Platt, & Sobel, 2000). According 
to Petrov & Slayman, (1995), the PM H+-ATPase of fungi contains three cysteine residues in 
the transmembrane segment and six cysteine residues in the cytoplasmic domains. The PM 
H+-ATPase pumps protons from the cytosol to the exterior of the cell by hydrolysing ATP. This 
results in an increase in the cytoplasmic pH (pHi) causing alkalization of the cytoplasm which 
results in stimulation of cell growth (Serrano, 1993). The proton (H+) gradient generated by 
the PM H+-ATPase facilitates secondary uptake of nutrients into cells (Portillo, 2000).  
Given both the essential and unique nature of the H+-ATPase, this enzyme represents a 
potential novel antifungal target for novel classes of the therapeutic agent (Monk & Perlin, 
1994; Monk et al., 1995). It has been reported that NEM, a sulfhydryl reactant binds to 
cysteine-532 in the cytoplasmic region causing inhibition of the PM H+-ATPase as shown in 
Figure 1.14 (Petrov & Slayman, 1995). An interesting study conducted by Portillo & Gancedo, 
(1984) demonstrated that miconazole inhibits the mitochondrial (FoF1) ATPase of S. cerevisiae. 
They demonstrated that miconazole inhibits ATP synthesis without affecting the oxidation of 
NADH. This suggests that miconazole may have some membrane disrupting or uncoupling 
activity as well as inhibiting FoF1-ATP(synth)ase activity. Miconazole blocks ATP synthesis via 
mitochondrial oxidative phosphorylation, which could result in a decrease of proton pumping 
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from the S. cerevisiae cell due to cytoplasmic depletion of substrate ATP concentration 
(Portillo & Gancedo, 1984). Other H+-ATPase inhibitors which have been shown to inhibit the 
P-type H+-ATPase include dicyclohexyl carbodiimide, omeprazole, ebselen and 
diethylstilbestrol (Serrano, 1980).  
It has also been reported that curcumin (11) a natural product which contains α,β-
unsaturated enone structures, inhibited the Ca2+-ATPase of skeletal muscle sarcoplasmic 
reticulum (Logan-Smith et al., 2001). The logP of curcumin is 2.92, which is within the limit set 
by Lipinski, Lombardo, Dominy, & Feeney, (1997) and the logP of the molecule should be <5 
for drug-likeness. However curcumin has some drawback like low solubility and rapid 
metabolism (Sharma, Manoharlal, Puri and Prasad, 2010). Curcumin is also not considered as 
a potential drug candidate due to its poor bioavailability as mentioned in the chapter 1. 
However due to some structural similarities of curcumin to 1,4-diene-3-ones it was 
considered worthwhile to investigate the ability of curcuminoids to inhibit proton pumping 
by S. cerevisiae. 
Having synthesized various 1,4-diene-3-ones (detailed in Chapter-2) and identified their 
antifungal activity (described in Chapter-3) there is a need to identify the possible 
mechanism(s) of action of these compounds. Therefore, a library of 1,4-diene-3-ones (22a-v, 
23a-h and 24a-c) have been screened against S. cerevisiae with the aim of determining if they 
inhibit proton pumping. Compounds containing the 1,4-diene-3-one pharmacophore have 
the potential to react with cysteine(s) found in transmembrane loops M1 and M2 (Monk et al., 
1995) and/or the cysteine residue found in the nucleotide binding site of the H+-ATPase 
(Brooker & Slayman, 1982; Katz & Sussman, 1987). The β-carbon of the 1,4-diene-3-one is 
electrophilic in nature which can be attacked by the nucleophilic sulfhydryl-containing amino 
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acid, cysteine, located in the membrane segment of the ATPase (Manavathu et al., 1999). This 
approach has been used by other workers in studying proton transport across the plasma 
membrane of S. cerevisiae (Dao et al., 2016; Kjellerup et al., 2017; Tung et al., (2017). 
Glucose-induced medium acidification allows comparison of H+ pumping by the H+-ATPase of 
S. cerevisiae under different conditions (Perlin, Brown & Habern, 1988). The acidification of 
the medium was studied by measuring the pH of the external medium of carbon-starved                 
S. cerevisiae by activating the H+ pump with glucose (Manavathu et al., 1999; Ben-Josef et al., 
2000). Glucose induces a high rate of H+ efflux from yeast cells, about 20 nmol H+/min/mg 
fresh weight. The first few minutes of acidification are almost solely due to the activity of the 
plasma membrane ATPase and not with other aspects of acid generating metabolism 
(Serrano, 1983). This H+ transport has been shown to be sensitive to arsenate which acts as a 
phosphate analogue and which depletes the cell of ATP. Brooker & Slayman, (1982) 
demonstrated that addition of glucose to carbon-starved yeast cells led to a five to ten-fold 
increase in ATPase activity within minutes. This activation is associated with a glucose 
activated protein kinase cascade which results in a several fold decrease in Km for MgATP2- 
and an alkaline shift in the pH optimum of the ATPase (Brooker & Slayman, 1982). 
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4.2 Materials and Methods 
4.2.1 Materials, growth medium and growth condition for proton extrusion assay 
YPD (bacteriological peptone 20%, yeast extract 10% and glucose 20%) broth (Sigma-Life 
Science, Y1375, Lot: SLBS2093V) was used to grow S. cerevisiae in the planktonic form. YPD 
powder (50 g) was dissolved in distilled water to a final volume of 1 litre. Aliquots of 100 ml 
of YPD broth was prepared into 250 ml conical flasks, autoclaved at 121 °C/15 psi for 15 
minutes and subsequently stored at 4 °C until used. Potassium chloride powder (for molecular 
biology ≥ 99%, Sigma Life Science, P9541, Lot: BCBQ0895V) was prepared at 50 mM by 
dissolving in distilled water and autoclaved as mentioned earlier. D-glucose powder (Fisher 
Scientific UK Limited, G/0500/61, Lot: 1156267) was dissolved in sterile distilled water to 
prepare a 40 % solution which was filter sterilised using a 0.2-micron membrane filter. D-
glucose solution was prepared fresh daily and stored at 4 °C until required.  
A few colonies of S. cerevisiae from a working culture were inoculated into 100 ml YPD broth 
and the yeast was grown to late log phase at 30 °C, 120 rpm for 16 hours (Monk et al., 1995). 
The late log phase cells were collected by centrifugation at 3500 x g for 10 minutes at 4 °C and 
washed with 100 ml each of sterile distilled water and 50 mM KCl. The pellet was re-
suspended into 50 mM KCl (100 ml), followed by incubation at room temperature overnight 
(approximately 16 hours) by supplying filtered air (via a 0.2 µm filter) using an aquarium pump 
at a flow rate of 2 ml air pumped per minute to deplete the cells carbon reserves. Cell counts 
were performed to identify the number of viable cells present in the carbon starved cell 
suspension using methylene blue dye and a Naubauer haemocytometer (identical to the 
methodology described in section 3.2.1.6). The carbon-starved cells were harvested by 
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centrifugation at 3500 x g for 10 mins at 4 °C after which the pellet was re-suspended in            
50 mM KCl to a final cell density of 1 x 108 cells/ml.  
4.2.2 Stock solution of test compounds and controls 
N-ethyl maleimide (NEM) powder (ThermoFisher Scientific, PierceTM, 23030) was used as a 
positive control inhibitor. In addition, miconazole nitrate powder (azole antifungal) and 
curcumin powder (Sigma-Aldrich, C1386) were tested to determine their effect on the proton 
pumping activity of S. cerevisiae. Stock solutions of NEM, miconazole and curcumin were 
prepared in DMSO (Hybri-Max; D2650) at 12.5 mM. Stock solutions were diluted with DMSO 
to obtain the standard concentrations of 3.13 mM, 6.25 mM and 10 mM, respectively. From 
the library of 1,4-diene-3-ones, compound 23b was selected to test a range of concentrations 
because of its increased solubility and probable enhanced membrane permeability profile 
with optimal clogP value (1.827), and an IC50 value (8.84 μM) against S. cerevisiae. A stock 
solution of compound 23b (12.5 mM) was prepared in DMSO. The stock solution was serially 
diluted by 2 and 2x2-fold and 1.25fold to achieve 6.25, 3.13 and 10 mM. The 10 mM was 
subsequently diluted to achieve 5 and 2.5 mM. The test compounds were all freshly prepared 
on the day of the experiment.  
Stock solutions of all the 1,4-diene-3-ones (22a-v, 23a-h and 24a-c) were prepared in DMSO 
at 12 mM followed by diluting 1:1 with DMSO to obtain a working stock concentration of 6 
mM. For each experiment, 15 µl of appropriate concentration of 1,4-diene-3-one was added 
to cell suspension (1.5 ml) giving a final concentration of 60 µM. DMSO (15 µl) was used as a 
negative control (1%) when treating yeast cells with a solution of the test compounds. 
Similarly, NEM (15 µl, 60 µM) was used as a positive control. 
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4.2.3 Measurement of glucose-induced acidification of the external medium 
The proton pumping activity of S. cerevisiae was evaluated by monitoring the glucose-induced 
acidification of the external medium by measuring the pH of the extracellular KCl medium 
using a microelectrode (Mettler Toledo Ultra Micro-ISM pH Electrode; MultiPin, code: 
30244732). Preliminary H+ extrusion studies were performed to establish the optimal 
parameters, which can be used for the final efficacy studies. The setup of the proton extrusion 
assay is shown in Figure 4.1. 
 
 
Figure 4. 1. Set up of the proton extrusion assay. 
The experimental set up of the H+ extrusion assay was displayed in Figure 4.1. The 
temperature of the water reservoir was maintained at 36 °C and warm water from the 
reservoir was supplied via a peristaltic pump to the water-jacketed glass chamber to maintain 
a constant temperature of 30 °C. Both the pH probe and the pH meter were connected to the 
data logger computer. Experimental data were saved in the LabX direct software. After each 
experiment, the waste yeast suspension was transferred to a waste container via a vacuum 
suction tube and the water-jacketed glass chamber was extensively washed with 50 mM KCl 
solution.   
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Method optimisation was implemented using various concentrations of N-ethyl maleimide 
(31.3, 62.5, 100 and 125 μM) for various pre-incubation times. A carbon starved cell 
suspension (1.5 ml at a cell density of 1 x 108 cells/ml) of S. cerevisiae was loaded into a water-
jacketed glass chamber maintained at 30 °C. Subsequently, 15 µl of the NEM solution was 
added and incubated at 30 °C with gentle stirring using a glass-covered metal flea (made in 
house from glass pipettes and metal wire from a paper clip) for various periods of time (10, 
30, 45, 60, 75, 90 and 120 minutes). After appropriate preincubation with NEM, the H+ pump 
was activated by adding D-glucose solution (150 µl, 4% final concentration) with continuous 
stirring. A micro pH electrode was immediately placed into the cell suspension and the pH of 
the external medium was monitored for 30 minutes with automated recording every 3 
seconds.  
Control experiments were performed using 1.5 ml of cell suspension and 15 µl of 50 mM KCl 
(no-drug) or 15 µl of DMSO (solvent control) to measure the effect of DMSO on the 
acidification of the external medium. The positive control was included to determine the 
extent if any of inter-day variability using NEM as an internal standard -SH reagent to inhibit 
the H+ pumping by S. cerevisiae. NEM (62.5 µM) pre-incubated with carbon starved                               
S. cerevisiae cells for 60 mins showed optimum response by inhibiting the H+ pumping ability 
of S. cerevisiae.  
The method was further optimised and validated using NEM (60 µM), where the cells were 
pre-incubated with NEM at 30 °C for 60 mins. The NEM validated method was applied to all 
further experiments using the 1,4-diene-3-one compound library. All compounds (22a-v, 23a-
h and 24a-c) were tested at a single concentration of 60 µM. Each compound was tested 
independently at least three times to compare the time of day and inter-day variability.
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4.3 Results of proton extrusion assay 
4.3.1 Effect of N-ethyl maleimide on the proton pumping activity by S. cerevisiae 
The carbon starved S. cerevisiae cells were tested for their ability to pump protons to the 
external medium in the presence of variable concentrations of NEM (31.3, 62.5, 100 and 125 
μM). The ability of S. cerevisiae to extrude protons in the presence of NEM (9a) is shown in 
Figure 4.2 and is expressed as the pH of the external medium varying with time. 
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Figure 4. 2. Effect of N-ethyl maleimide on the H+ pumping ability of S. cerevisiae. 
Effect of N-ethyl maleimide on glucose-induced medium acidification of carbon starved              
S. cerevisiae cells. Each data point represents the mean of three individual experiments.  
 
A decrease in the pH of the external medium of concentrated cell suspension was observed 
(Figure 4.2). N-ethyl maleimide inhibited proton pumping by S. cerevisiae in a concentration-
dependent manner. NEM at 125 μM gave maximum response by inhibiting the initial rate of 
proton pumping compared to the glucose control. In addition, NEM at 62.5 and 100 μM 
showed near complete inhibition of both rate proton pumping and extent of acidification of 
the medium. At 100 and 125 μM, steady state of proton flux was seen within 5 mins of 
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medium acidification. NEM at 62.5 μM was selected as optimal concentration as it exhibited 
good response by inhibiting both the initial rate of proton pumping and the extent H+ pump 
after 10 mins. NEM at 31.3 μM depicted limited inhibitory activity against proton pumping by 
S. cerevisiae.  
The inhibitory activity of NEM was calculated by comparing the difference in the pH (ΔpH) of 
the NEM with control (carbon-starved cells in 1% DMSO) using Equation 5.  
ΔpH (initial rate) of the external medium = pH(t0) – pH(tn)                                (Eq.5) 
Where, t0 = time (min) at glucose added and  
               tn = time (min) after addition of glucose. 
Besides this, the initial rates of H+ pumping by S. cerevisiae was also calculated which include; 
ΔpH/0.5 min, ΔpH/1 min, ΔpH/1.5 min and ΔpH/2 min, respectively [Data not shown]. 
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Figure 4. 3. Effect of N-ethyl maleimide on proton pumping of S. cerevisiae. 
N-ethyl maleimide induced inhibition of glucose-dependent H+ pumping by S. cerevisiae. The 
difference in the pH of the external medium of cell suspension containing NEM was compared 
with glucose control (no drug). The initial rate of H+ pumping measured as ΔpH for first 3 mins 
[a] and the ΔpHmin to max [b]. Each data point represents the mean of the three experiments.  
 
NEM at 62.5, 100 and 125 µM exhibited effective inhibition of the proton pumping activity by 
S. cerevisiae both in terms of the initial rate after 3 mins (46%, 69% and 75% inhibition, Fig. 
4.3a) and the total extent of the change in the pH (ΔpHmax) after 30 mins (51%, 62% and 67% 
inhibition, Fig. 4.3b). In addition, NEM at 100 and 125 µM inhibited the proton pump after 5 
mins of medium acidification while 62.5 µM displayed inhibition after 10 minutes of pump 
activation, no further change in the pH was observed due to a steady state of proton flux (H+ 
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in = H+ out). In contrast at 31.3 µM, NEM only exhibited 25% inhibition of the proton pump in 
terms of the initial rate (after 3 mins) and only 8% inhibition after 30 mins when compared to 
the glucose control. This demonstrates NEM (>62.5 µM) is a potent inhibitor of the H+ efflux 
from S. cerevisiae. Therefore, NEM 62.5 μM was rounded to 60 μM for simplicity when used 
as a control in further experiments. 
4.3.2 Investigation of the effect of curcumin and miconazole on the H+ pumping 
activity by S. cerevisiae 
Curcumin (11) and miconazole (4) were also investigated for their ability to inhibit the H+ 
pumping by S. cerevisiae using range of concentrations (31.3, 62.5, 100 and 125 µM, 
respectively). The ΔpH of the external medium was obtained by using Eq. 5 mentioned in 
section 4.3.1. In addition, the initial rate of proton pumping by S. cerevisiae was calculated as 
ΔpH/min for the 2.5 mins after pump activation. Both miconazole (4) and curcumin (11) 
exhibited good inhibition of proton pumping from S. cerevisiae in a concentration-dependent 
manner (Fig. 4.4a, b).  
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Figure 4. 4. Analysis of miconazole [a] and curcumin [b] susceptibility of the H+ pumping in 
S. cerevisiae. 
Effect of miconazole and curcumin on medium acidification by carbon starved S. cerevisiae 
cells. The difference in the pH measured for 30 mins after proton pump activation. The ΔpH 
of miconazole and curcumin was calculated every 2.5 mins and presented in the above 
figures. Each data point represents the mean of the three individual experiments, glucose 
control (without compounds).  
 
Miconazole at 31.3 µM displayed the lowest level of inhibition (7%) after 30 mins, whilst at 
62.5, 100 and 125 µM miconazole gave 44%, 57% and 65% inhibition of H+ pumping after 30 
mins of medium acidification (Figure 4.4a). However, it should be noted that in growth 
inhibition study in chapter-3, miconazole (0.12 µM) gave 50% inhibition of S. cerevisiae 
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growth. This shows that miconazole requires 1000-fold higher concentration to inhibit the H+ 
pump compared to inhibiting the 4α and 14α demethylase enzymes. In addition, miconazole 
exhibited inhibition of the H+ pumping ability by S. cerevisiae within 7.5 minutes of glucose-
induced pump activation at 62.5, 100 and 125 µM respectively. Further acidification of the 
medium ceased after 7.5 mins and a steady state of proton flux was achieved.  
Curcumin showed poor solubility over the concentration range tested, which is also reported 
in the literature. Considering this fact and the structural similarity of curcumin with 1,4-diene-
3-ones, we have decided to investigate its activity to inhibit the proton pump. Curcumin 
exhibited effective potency by inhibiting proton export (36%, 51%, 58% and 60% inhibition) 
at 31.3, 62.5, 100 and 125 µM respectively in Figure 4.4[b]. The ΔpHmax (change in pH in terms 
of the total extent after 30 mins) values of curcumin were 1.79, 1.36, 1.16 and 1.11 
respectively at 31.3, 62.5, 100 and 125 µM compared to glucose control (ΔpHmax = 2.79).  
4.3.3 Effect of 1,4-diene-3-ones on the H+ pumping activity by S. cerevisiae 
It has been identified from the results of NEM optimisation experiments that 62.5 μM gives 
good level of inhibition of proton pumping by S. cerevisiae. Therefore the library of thirty-
three symmetrical 1,4-diene-3-ones (22a-v, 23a-h and 24a-c) was tested at a single 
concentration of 60 µM against late log phase carbon starved cells of S. cerevisiae. This is also 
a concentration commonly used in single concentration high throughput screening systems 
(McGovern et al., 2002; Odds, 1992). The inhibitory activity of each compound was obtained 
by comparing their ΔpH with control (carbon-starved cells in 1% DMSO and 4% glucose 
solution). The initial rate of proton pumping of S. cerevisiae was calculated as ΔpH/min for 
the first 2.5 minutes. Similarly, the ΔpHmax of each 1,4-diene-3-one was measured after 30 
minutes of medium acidification.  
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The statistical significance for each compound compared to the control was determined by 
comparing the ‘t’ ratio with the ‘t’ distribution for the number of differences shown using a 
two-way ANOVA using the Bonferroni correction (which lowers the P value that is considered 
to be significant to 0.05, divided by the number of comparisons). The Bonferroni correction 
ensures that the 5% probability applies to the entire data of comparisons and not seperately 
to each individual comparison (Dao et al., 2016). The activity of bis-benzylidene derivatives of 
N-methylpiperidin-4-one on the inhibition of proton efflux from S. cerevisiae is shown in 
Figure 4.5. 
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Figure 4. 5. Effect of bis-benzylidene derivatives of N-methylpiperidin-4-one on the H+ pumping by S. cerevisiae. 
Data were displayed as ΔpH of the external medium measured after the H+ pump activation. The R-substituents attached to the aromatic ring 
on bis-benzylidene derivatives of N-methylpiperidin-4-one includes: Hydrogen, 2-methoxy, 3-methoxy, 4-methoxy and 4-methyl [a]; 3-
trifluoromethyl, 4-trifluoromethyl, 3-trifluoromethoxy and 4-trifluoromethoxy [b]; 2-chloro, 3-chloro, 4-chloro, 3-nitro and 4-nitro [c]; 2-iodo, 3-
iodo, 2-carboxylic acid, 4-carboxylic acid, 2,4-di-chloro, 3,4-di-chloro [d]. NEM was used as a positive control and DMSO was used as negative 
control in all experiments. Each data point represents the mean of three individual experiments. Two-way repeated measures ANOVA 
(Bonferroni correction): *, p<0.05; **, p<0.01; ***; p<0.001 relative to glucose control (without compounds).  
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Compounds 22a-t (at 60 µM) in Figure 4.5 exhibited a wide range of inhibitions (8.7% to 52%) 
in terms of the initial rate of proton pumping by S. cerevisiae. Measurement of pH changes of 
22a-t in terms of the initial rate of H+ pumping after 1 min (ΔpHir) ranged from 0.33 to 0.66 
pH units, while the glucose control gave the ΔpHir of 0.69 arbitrary pH units. Additionally, 
compounds 22a-t inhibited between 4.6% and 32% in terms of the total pH change (ΔpHmax) 
after 30 mins. The ΔpHmax values of 22a-t ranged from 2.23 to 3.23 pH units whilst NEM (60 
µM) gave a ΔpHmax of 2.23 and glucose control gave 3.26. The most potent compounds in 
terms of the inhibition of the total extent of the change in pH were compounds 22f, 22s, 22g 
and 22t, which showed 29% to 33% inhibition of the H+ efflux from S. cerevisiae. Moreover, 
compounds 22f, 22g, 22s, 22t showed similar activity as the NEM control (32% inhibition) and 
they were significantly different from the glucose control (P<0.05 and P<0.01). Compounds 
22f, 22g, 22s and 22t all have EWGs (either chloro or nitro) attached to the aromatic ring at 
meta or para position. The higher potency of these compounds suggesting the importance of 
the electronic property associated with the β-carbon atoms. This suggests that the inhibition 
of H+-ATPase is responsible for the inhibition of proton efflux via the Michael reaction 
between the compounds and PMA1.  
On the other hand, compounds 22o, 22e, 22a, 22j, 22k, 22c, 22r, 22i, and 22b exhibited low 
to moderate activity by inhibiting 10% to 18% of the proton efflux from S. cerevisiae after 30 
mins of medium acidification. The ΔpHmax values after 30 mins of these compounds ranged 
from 2.67 to 2.93. However, these compounds showed slightly better activity in terms of 
inhibiting the initial rate of proton efflux after 1 min, these being 10-32% inhibition. 
Compounds 22h, 22q, 22d, 22m, 22p, 22n and 22l exhibited poor activity (<10% inhibition) 
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against proton pumping by S. cerevisiae and their ΔpHmax values ranged between 2.95 and 
3.17 arbitrary units, which was very close to the glucose control (ΔpHmax = 3.26). 
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Figure 4. 6. Effect of bis-pyridylidene derivatives of N-methylpiperidin-4-one on the H+ 
pumping by S. cerevisiae.  
Data were presented as the ΔpH of the external medium measured after the activation of 
proton pump. Each data point represents the mean of three individual experiments. SD values 
were omitted for clarity of graphs. Two-way repeated measures ANOVA (Bonferroni 
correction): *, p<0.05; **, p<0.01; ***, p<0.001 relative to glucose control (without 
compounds). 
 
The effect of bis-benzylidene and bis-pyridylidene derivatives of N-methylpiperidin-4-one on 
inhibition of proton efflux from S. cerevisiae is shown in Figure 4.6. After 30 minutes of 
medium acidification, the ΔpHmax of 22a, 23a, 23b and 23c were 2.56, 2.07, 2.09 and 2.08 
whilst NEM and the glucose control were 2.07 and 3.26 respectively. Compounds 23a, 23b 
and 23c at 60 µM exhibited good activity in terms of inhibiting the initial rate (48%, 46% and 
49% inhibition) and the total extent (33%, 32% and 34% inhibition) of proton efflux by                 
S. cerevisiae. This is comparable to NEM control at the same concentration exhibited 49% and 
33% inhibition of the initial rate and the total extent of proton pumping by S. cerevisiae. 
Compounds 23a, 23b and 23c exhibited inhibition of H+ pumping ability by S. cerevisiae within 
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10 minutes of glucose-induced medium acidification and no further change in the pH 
representing a steady state of proton flux was achieved (JH+in = JH+out). This possibly suggests 
that compounds 23a-c work by a similar mechanism to NEM, by interacting with either the 
nucleotide-binding site in the cytoplasmic region or at the omeprazole binding site in the 
membrane segment of the H+-ATPase enzyme (Brooker & Slayman, 1982).   
However the bis-benzylidene (22a) derivative exhibited slightly lower activity in decreasing 
the proton efflux from S. cerevisiae, showing 32% inhibition of initial rate and only 18% 
inhibition of the total extent of proton efflux. Following statistical analysis it has been 
identified that there was no significant difference (p>0.05) between 23a-c, NEM and control 
(no drug) for initial 2.5 mins of medium acidification. This is due to the Bonferroni correction 
because this equation lowers the P value that is considered significant to 0.05 divide by the 
number of comparisons. However, between 5 and 30 mins of medium acidification, 
compounds 23a-c and NEM displayed significant difference from the glucose control with 
p<0.05, p<0.01 and p<0.001 respectively. 
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Figure 4. 7. Effect of bis-pyridylidene derivatives of cyclopentanone and cyclohexanone on 
the H+ pumping by S. cerevisiae.  
Data were shown as the ΔpH of the external medium measured after activation of proton 
pumping with 4% glucose. Each data point represents the mean of three individual 
experiments. SD values were omitted for clarity of graphs. Two-way repeated measures 
ANOVA (Bonferroni correction): *, p<0.05; **, p<0.01; ***, p<0.001 relative to glucose control 
(without compounds). 
 
The ΔpHmax (after 30 mins) of NEM, 23d, 23e, 23f, 23g and 23h were 3.24, 3.23, 3.13, 2.76, 
and 2.84 respectively while glucose control has 3.46 (Figure 4.7). When comparing the total 
extent of the change in pH after 30 mins, the bis-pyridylidene derivatives of cyclohexanone 
(23g and 23h) exhibited better inhibitory potency (20% and 18% inhibition) than the bis-
pyridylidene derivatives of cyclopentanone (23d, 23e and 23f; 6%, 7% and 10% inhibition) 
although neither class exhibited reasonable to moderate levels of inhibition. NEM, 23g and 
23h either completely inhibited proton pumping by S. cerevisiae within 10 mins of medium 
acidification or the in/out flux (JH+in = JH+out) reached a steady state of the proton (ΔJH+ = 0). In 
addition, compounds 23g and 23h both displayed significant difference from the glucose 
control between 5 and 30 mins of pump activation, their P values were p<0.001, p<0.01 and 
p<0.05 respectively. 
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Figure 4. 8. Effect of bis-benzylidene or thienylidene derivatives of N-methylpiperidin-4-one, 
cyclopentanone and cyclohexanone on the H+ pumping by S. cerevisiae.  
Data were displayed as the difference in the pH of the external medium measured after 
activation of proton pumping with 4% glucose. Each data point represents the mean of three 
individual experiments. SD values were omitted for clarity of graphs. Two-way repeated 
measures ANOVA (Bonferroni correction): *, p<0.05; **, p<0.01; ***, p<0.001 relative to 
glucose control (without compounds). 
 
As shown in Figure 4.8, compounds 22a, 22u, 22v, 24a, 24b and 24c have all demonstrated 
minimal inhibitory activity of H+ pumping by S. cerevisiae. The ΔpHmax of 22a, 22u, 22v, 24a, 
24b and 24c were 2.67, 2.73, 3.06, 3.02, 3.13 and 3.02 respectively and they were not 
significantly different from the glucose control (ΔpHmax = 3.26) using the Bonferroni 
correction. After 30 mins of pump activation, compounds 22a, 22u, 22v, 24a, 24b and 24c 
exhibited only 18%, 15%, 5%, 6%, 3% and 6% inhibition of proton efflux from S. cerevisiae 
respectively although NEM demonstrated a significant difference from the glucose control 
(P<0.001). On the other hand, compounds 22a, 22u, 22v, 24a, 24b and 24c exhibited 
significant inhibition after 10 mins of medium acidification (P<0.01). 
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4.3.4 Effect of (3E, 5E)-1-methyl-3,5-bis(pyridine-3-ylmethylene)piperidin-4-one on 
the proton pumping activity by S. cerevisiae 
From the results of macro-broth susceptibility assay against S. cerevisiae in chapter-3, it has 
been identified that the pyridyl group of compounds exhibited better solubility than the 
equivalent benzyl group of compounds. This change in solubility associated with the change 
of benzyl to pyridyl is observed in many classes of compound. Because the pyridyl is 
amphipathic whereas benzene is hydrophobic. Additionally, pyridyl group of compounds has 
lower clogP (between 1.60 and 2.34) whereas benzyl group has higher clogP (4.07).  
From the pyridyl group of compounds, bis-(pyridine-3-ylmethylene)-1-methylpiperidin-4-one 
(23b) exhibited lower AUC (194) and IC50 (8.84 μM) values against S. cerevisiae, which makes 
this compound a good example to investigate its effect against proton pumping by  S. 
cerevisiae. Therefore, 23b was examined for its effect on proton export using range of 
concentrations such as 25, 31.3, 50, 62.5, 100 and 125 μM respectively. The bis-(pyridine-3-
ylmethylene)-1-methylpiperidin-4-one (23b) inhibited H+ pumping by S. cerevisiae in a 
concentration-dependent fashion (Figure 4.9). 
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Figure 4. 9. Effect of Bis-(pyridine-3ylmethylene)-1-methylpiperidin-4-one on the H+ 
pumping by S. cerevisiae. 
Each data point represents the mean of the three individual experiments, displaying the ΔpH 
measured every 2.5 mins after activation of the proton pumping with glucose (4%) against 
time.  
 
Compound 23b at 25 µM gave only 2% inhibition both in terms of the initial rate and the 
ΔpHmax (30 mins). However at 31.3, 50 and 62.5 µM, the ΔpHmax values of 23b were 2.29, 2.00 
and 1.94 respectively whilst the glucose control was 3.18: thus exhibiting 28%, 37% and 39% 
inhibition of proton efflux from S. cerevisiae after 30 mins of medium acidification. At higher 
concentrations (100 and 125 µM), 23b exhibited 50% and 64% inhibition of proton efflux from 
S. cerevisiae exhibiting low final ΔpHmax values 1.59 and 1.16, respectively. This suggests that 
23b is a good inhibitor of proton pumping by S. cerevisiae. 
The effect of N-ethyl maleimide, miconazole, curcumin and various synthesized 1,4-diene-3-
ones on proton pumping ability by S. cerevisiae is shown in Table 4.1, page 158. After glucose-
induced acidification of external medium, the difference in the pH due to proton pumping by 
S. cerevisiae is expressed as ΔpH after 1 and 2.5 mins (initial rate), 5 mins (degree of pH 
change), and at 30 mins (total extent of the pH change represented as the ΔpHmax). The most 
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potent compounds identified from the library of 1,4-diene-3-ones were 22e, 22f, 22g, 22s, 
22t, 22u, 23a, 23b and 23c, which exhibited 40-52% inhibition of the initial rate of proton 
efflux from S. cerevisiae. Conversely, in terms of inhibition of the total extent of the change 
in pH (ΔpHmax after 30 mins), the most potent compounds identified were 22f, 22g, 22s, 22t, 
23a, 23b and 23c exhibiting 29-34% inhibition of proton efflux. In contrast, the least active 
inhibitors (<20% inhibition) in terms of initial rate of H+ pumping by S. cerevisiae were 22b, 
22c, 22h, 22i, 22k, 22l, 22n, 22p, 22q, 22r, 23d, 23e and 24a-c. Subsequently, the least active 
inhibitors (<10% inhibition) based on ΔpHmax values after 30 mins were 22d, 22h, 22l, 22m, 
22n, 22p, 22q, 22v, 23d-f and 24a-c.  
Overall, 22s [3,5-bis(3-nitrobenzylidene)-1-methylpiperidin-4-one] and 23c [bis-pyridin-4-
ylmethylene)-1-methylpiperidin-4-one] have been identified as the two most potent 
inhibitors of H+ efflux with its lowest initial rate ΔpH over the first minute (0.33 and 0.35) and 
ΔpHmax after 30mins (2.15 and 2.23). It is believed that the increased potency of compounds 
23a-c is due to their increased permeability and amphipathic nature as suggested by their low 
clogP values (1.53, 1.83 and 1.61 respectively) and which are within the logP range suggested 
by Lipinski et al., (1997). Thus compounds 23a-c appears to be very effective at inhibiting H+ 
pumping by S. cerevisiae.  
In addition the good inhibitory activity of compounds 22f, 22g, 22s and 22t due to low ΔpHmax 
suggests the importance of an electron-withdrawing group attached at either the meta- or 
para-position on the aromatic ring of bis-benzylidene derivatives of N-methylpiperidin-4-one. 
In comparison and from the ΔpHmax perspective, compound 22a (un-substituted bis-
benzylidene-N-methyl-piperidin-4-one) exhibited poor activity by inhibiting only 18% of the 
Chapter 4: Proton extrusion assay 
 
157 
 
proton efflux from S. cerevisiae with ΔpHmax value of 2.67 as compared to the glucose control 
ΔpHmax value of 3.26.  
Compound 22f contains a meta-chloro group, whereas compound 22g contains a para-chloro 
group. Similarly compound 22s contains a meta-nitro group and compound 22t contains a 
para-nitro group on the aromatic ring of the bis-benzylidene derivatives of N-methylpiperidin-
4-one. When comparing the difference between compounds 22f and 22g, it has been 
identified that the 22f was more potent than 22g possibly due to resonance effects induced 
by the electron-withdrawing group (refer to figure 3.17 for representative example of tri-
fluoromethyl group at para-position).  
Similar effects were seen for compounds 22s and 22t. The presence of a EWG at the meta-
position of the aromatic ring increases the electrophilicity of the β-carbon compared to the 
para-position. This observation is consistent with the lower AUCs and IC50 values of 22f, 22g, 
22s and 22t against S. cerevisiae shown in the 24 hour growth inhibition experiments (chapter 
3). Compounds containing EWG at meta-position (22f and 22s) exhibited higher potency than 
compounds with EWG at para-position (22g and 22t). This is because compound 22g and 22t 
has electronegative atom adjacent to the π system, which deactivate the aromatic ring by 
decreasing the electron density on the ring through resonance withdrawing effect. In 
addition, some property of the enzyme which may interfere with compounds binding 
effectively when para-substituted EWG is present. Overall this suggests the presence of an 
electron-withdrawing group on an aromatic ring increases the electrophilicity of the β-carbon 
of this molecule and therefore their reactivity towards system involved in the H+ pumping.  
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Table 4. 1. Effect of NEM and various 1,4-diene-3-ones on the H+ pumping by S. cerevisiae.  
Compounds 
ΔpH at 1 
min 
% 
inhibition 
after 1 
min 
ΔpH at 2.5 
mins 
% 
inhibition 
after 2.5 
mins 
ΔpH at 5 
mins 
% 
inhibition 
after 5 
mins 
ΔpHmax at 30 
mins 
% 
inhibition 
after 30 
mins 
Glucose 
control 0.69 ± 0.06 0.00 1.47 ± 0.36 0.00 2.19 ± 0.54 0.00 3.26 ± 0.31 0.00 
4 (MIC) 0.33 ± 0.16 52.17 0.73 ± 0.14 50.34 1.02 ± 0.22 53.42 1.83 ± 0.15 43.87 
9a (NEM) 0.35 ± 0.11 49.28 0.87 ± 0.18 40.82 1.24 ± 0.25 43.38 2.23 ± 0.50 31.60 
11 (CUR) 0.11 ± 0.13 84.06 0.20 ± 0.31 86.39 0.32 ± 0.26 85.39 1.36 ± 0.59 58.28 
22a 0.47 ± 0.26 31.88 1.09 ± 0.20 25.85 1.56 ± 0.20 28.77 2.67 ± 0.39 18.10 
22b 0.60 ± 0.05 13.04 1.13 ±  0.11 23.13 1.54 ± 0.19 29.68 2.93 ± 0.15 10.12 
22c 0.57 ± 0.11 17.39 1.15 ± 0.08 21.77 1.55 ± 0.11 29.22 2.71 ± 0.34 16.87 
22d 0.49 ± 0.18 28.99 1.12 ± 0.20 23.81 1.66 ± 0.20 24.20 2.98 ± 0.14 8.59 
22e 0.40 ± 0.25 42.03 0.88 ± 0.35 40.14 1.34 ± 0.38 38.81 2.67 ± 0.70 18.10 
22f 0.38 ± 0.24 44.93 0.77 ± 0.36 47.62 1.11 ± 0.37 49.32 2.19 ± 0.66 32.82 
22g 0.40 ± 0.28 42.03 0.91 ± 0.50 38.10 1.30 ± 0.58 40.64 2.30 ± 0.64 29.45 
22h 0.57 ± 0.11 17.39 1.23 ± 0.35 16.33 1.75 ± 0.49 20.09 2.95 ± 0.16 9.51 
22i 0.61 ± 0.17 11.59 1.30 ± 0.28 11.56 1.84 ± 0.37 15.98 2.86 ± 0.16 12.27 
22j 0.55 ± 0.12 20.29 1.25 ± 0.29 14.97 1.75 ± 0.30 20.09 2.68 ± 0.28 17.79 
22k 0.57 ± 0.09 17.39 1.27 ± 0.13 13.61 1.78 ± 0.13 18.72 2.68 ± 0.30 17.79 
22l 0.61 ± 0.04 11.59 1.22 ± 0.13 17.01 1.76 ± 0.26 19.63 3.17 ± 0.18 2.76 
22m 0.54 ± 0.07 21.74 1.13 ± 0.26 23.13 1.69 ± 0.50 22.83 3.04 ± 0.33 6.75 
22n 0.63 ± 0.07 8.70 1.18 ± 0.24 19.73 1.71 ± 0.37 21.92 3.11 ± 0.15 4.60 
22o 0.52 ± 0.12 24.64 1.06 ± 0.32 27.89 1.57 ± 0.55 28.31 2.66 ± 0.81 18.40 
22p 0.61 ± 0.08 11.59 1.23 ± 0.30 16.33 1.77 ± 0.50 19.18 3.07 ± 0.33 5.83 
22q 0.62 ± 0.06 10.14 1.26 ± 0.14 14.29 1.79 ± 0.33 18.26 2.98 ± 0.58 8.59 
22r 0.62 ± 0.19 10.14 1.22 ± 0.18 17.01 1.69 ± 0.26 22.83 2.78 ± 0.56 14.72 
22s 0.33 ± 0.23 52.17 0.78 ± 0.41 46.94 1.19 ± 0.55 45.66 2.23 ± 0.73 31.60 
22t 0.38 ± 0.18 44.93 0.90 ± 0.16 38.78 1.23 ± 0.24 43.84 2.31 ± 0.33 29.14 
22u 0.41 ± 0.19 40.58 1.17 ± 0.30 20.41 1.74 ± 0.43 20.55 2.73 ± 0.72 16.26 
22v 0.46 ± 0.19 33.33 1.22 ± 0.20 17.01 1.82 ± 0.35 16.89 3.05 ± 0.32 6.44 
23a 0.36 ± 0.22 47.83 0.77 ± 0.25 47.62 1.10 ± 0.22 49.77 2.17 ± 0.58 33.44 
23b 0.37 ± 0.21 46.38 0.74 ± 0.38 49.66 1.05 ± 0.45 52.05 2.21 ± 0.60 32.21 
23c 0.35 ± 0.24 49.28 0.70 ± 0.34 52.38 1.09 ± 0.30 50.23 2.15 ± 0.55 34.05 
23d 0.58 ± 0.06 15.94 1.10 ± 0.12 25.17 1.58 ± 0.13 27.85 3.24 ± 0.10 0.61 
23e 0.61 ± 0.07 11.59 1.16 ± 0.13 21.09 1.67 ± 0.11 23.74 3.23 ± 0.17 0.92 
23f 0.53 ± 0.08 23.19 0.98 ± 0.15 33.33 1.40 ± 0.19 36.07 3.13 ± 0.13 3.99 
23g 0.47 ± 0.11 31.88 0.89 ± 0.17 39.46 1.30 ± 0.21 40.64 2.76 ± 0.31 15.34 
23h 0.48 ± 0.09 30.43 0.87 ± 0.12 40.82 1.24 ± 0.16 43.38 2.83 ± 0.17 13.19 
24a 0.63 ± 0.06 8.70 1.19 ± 0.13 19.05 1.64 ± 0.26 25.11 3.01 ± 0.04 7.67 
24b 0.62 ± 0.09 10.14 1.18 ± 0.13 19.73 1.70 ± 0.19 22.37 3.12 ± 0.26 4.29 
24c 0.62 ± 0.10 10.14 1.18 ± 0.11 19.73 1.72 ± 0.21 21.46 3.02 ± 0.32 7.36 
 
  
Note: The difference in the pH (ΔpH) of the external medium was expressed as an initial rate (1 and 2.5 mins), ΔpH 
after 5 mins (degree of pH change) and ΔpHmax at 30 mins. MIC: miconazole, CUR: curcumin and NEM: N-ethyl 
maleimide. Each data point represents the mean ± SD of three individual experiments. Glucose and NEM were used 
as controls in all experiments. Glucose control stands for S. cerevisiae cells (108 cells/ml) in DMSO (1%) without any 
inhibitor. 
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4.4 Discussion of H+ extrusion assay 
The 1,4-diene-3-one compounds are tentatively thought to act by forming a C-S (thio-ether) 
bond with cysteine amino acid in the plasma membrane and inhibiting ATPase, thus changing 
the membrane structure and integrity (Manavathu et al., 1999; Khan et al., 2012). The effect 
of thirty-three symmetrical 1,4-diene-3-ones (22a-v, 23a-h, 24a-c) on inhibiting the initial rate 
and overall level of H+ pumping by S. cerevisiae was measured at a single inhibitor 
concentration of 60 µM. This is also a concentration usually employed in single concentration 
high throughput screening systems (McGovern et al., 2002; Odds, 1992).  
From the library of 1,4-diene-3-ones, it has been identified that bis-pyridylidene derivatives 
of N-methylpiperidin-4-one (23a-c, 60 µM) either completely inhibited H+ pumping ability by 
S. cerevisiae within 10 minutes of medium acidification being initiated or the proton in/out 
flux (JH+in = JH+out) reached a steady state (net JH+ = 0). This indicates that flux out (ATPase 
pumping) is equal to the flux in possibly due to leakage in the membrane. Moreover, 
compounds 23a-c were as potent as NEM at 60 µM, which exhibited 49% inhibition of initial 
rate of H+ efflux and 32% inhibition of the total extent of H+ efflux by S. cerevisiae. NEM has 
been shown to inhibit the PM H+-ATPase of both Neurospora crassa (Brooker & Slayman, 
1982) and Avena sative root cells (Katz & Sussman, 1987). For this reason that NEM was 
investigated for its action against proton export by S. cerevisiae and used as a control. When 
NEM and 23b were compared at various concentrations (62.5, 100 and 125 µM), NEM 
inhibited 46%, 69% and 75% of proton export (in terms of ΔpHmax at 30 mins) from S. 
cerevisiae while 23b exhibited 39%, 50% and 64% inhibition.  
From the bis-benzylidene derivatives of N-methylpiperidin-4-one, the most potent 
compounds identified were 22f, 22g, 22s and 22t; based on their low ΔpHir values (0.38, 0.40, 
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0.33 and 0.38) and ΔpHmax values (2.19, 2.30, 2.23 and 2.31). NEM control also depicted 
similar ΔpHir and ΔpHmax values and these being 0.35 and 2.23, respectively whereas glucose 
control values for ΔpHir and ΔpHmax were 0.69 and 3.26 respectively. Compounds 22f, 22g, 
22s and 22t exhibited 44.9%, 42%, 52.2% and 44.9% inhibition of the initial rate of proton 
efflux after 1 min, which was fairly close to the activity of NEM (49.3% inhibition). 
Subsequently, in terms of inhibition of the total extent ΔpHmax, 22f, 22g, 22s and 22t exhibited 
32.8%, 29.5%, 31.6% and 29.1% inhibition, again their activity is fairly similar compared to 
NEM (32% inhibition). 
It seems probable that high potency of compounds 22f, 22g, 22s and 22t compared to the 
other compounds from the library is due to the presence of EWGs (e.g. Cl or NO2) at either 
the meta- or para-position of the aromatic rings. As mentioned previously in chapter 2, such 
EWGs enhance the electrophilicity of the β-carbon atom so that the nucleophilic S- (cysteine 
thiolate) anion of the plasma membrane H+-ATPase can easily attack and form a C-S thio-ether 
bond an inhibit the H+-ATPase (Sivakumar et al., 2009; Jackson et al., 2017). The inhibition of 
the H+ pump will thus cause an internal acidification of the cell which will eventually lead to 
cell death. Other benzene ring substituted benzylidene derivatives of N-methylpiperidin-4-
one exhibited a lower degree of potency against H+ pumping by S. cerevisiae in terms of both 
the initial rate after 1 min (8.7-40.6% inhibition) and the total extent over 30 mins (0.61-18.4% 
inhibition). 
It has been reported by Fonyo, (1979) that H+/Pi- carrier and cytochrome oxidase are very 
sensitive to enones such as NEM, therefore it is possible that 1-3-diene-2-ones have some 
effect on mitochondrial function by either inhibiting the H+/Pi- carrier or cytochrome oxidase 
activities. This would need to be tested using either a mitochondrial swelling technique to 
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measure the activity of the phosphate or other organic acid carriers (Fonyo, 1979) or to 
measure electron transport activities using an oxygen electrode (Casey, Thelen, & Azzi, 1980; 
Helmerhorst, Murphy, Troxler, & Oppenheim, 2002). In addition, it will be necessary to purify 
the PM H+-ATPase enzyme and assay the potency of these compounds. This should also 
provide some indication of any polypharmacological effect of the enone compounds i.e. to 
what extent is compound potency and antifungal activity associated with a particular set of 
assays (Ma, Lv, & Zhang, 2018).  
It is known that the ADP/ATP nucleotide transporter, cytochrome c oxidase and the 
proton/phosphate transporter are all susceptible to sulfhydryl reagents such as NEM, 
omeprazole, curcumin, etc (Fonyo, 1979; Monk et al., 1995; Schultz et al., 2007; Dao et al., 
2016). The sulphenamide of omeprazole affects growth of S. cerevisiae in a pH dependent 
manner (Monk et al., 1995). Monk et al., (1995) have mentioned that acid-activated 
omeprazole inhibits the H+ efflux by S. cerevisiae by forming a di-sulphide bond with cysteine 
present on the transmembrane segment of the H+-ATPase. 
Many researchers have reported that miconazole has multiple activities besides inhibiting the 
enzymes involved in ergosterol biosynthesis, alteration of membrane permeability and 
interaction with the cell wall (Portillo & Gancedo, 1984; Abbott & Odds, 1989). Miconazole 
(4) targets mainly 4α-demethylase but also 14α-demethylase and thus inhibits ergosterol 
synthesis in fungal cells. The literature IC50 value for miconazole (3 μM) was based on the 
growth inhibitory assay against S. cerevisiae (Ottilie et al., 2018). However, Portillo & 
Gancedo, (1984) have demonstrated that miconazole required 50 μM to inhibit the 
mitochondrial ATPase by interfering with the Fo component but had no effect on F1-ATPase 
activity. Thus the inhibition of FoF1-ATPase by miconazole is unlikely to be of any therapeutic 
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or clinical relevance since a 20 fold excess is needed to inhibit FoF1-ATPase compared to the 
IC50 for growth.  
Miconazole may have a more complex effect since in the 50 μM range it inhibits (FoF1) ATPase 
which is significantly higher than the concentration required to inhibit ergosterol synthesis. 
Inhibition of the FoF1-ATPase synthase will result in a decrease in both mitoplasmic and 
cytoplasmic ATP concentrations. The build-up of mitochondrial ΔpH will also result in protonic 
such pressure in the electron transport system and a subsequent decrease in electron 
transport chain activity. This will result in decrease cytoplasmic ATP and thus lower PM H+-
ATPase activity due to substrate depletion. Additionally lack of ergosterol in the plasma 
membrane will result in this membrane becoming leakier to H+ and the extent and ratio of 
back-flux of H+ into the cell will increase. This will result in the pH vs time graph being both 
shallower and lower in extent. In this study, miconazole exhibited good activity by inhibiting 
the initial rate and the total extent (ΔpHmax) of H+ efflux from S. cerevisiae. Miconazole 
exhibited 44%, 57% and 65% inhibition of the ΔpHmax at 62.5, 100 and 125 µM, respectively. 
In this study, curcumin (11) activity was also investigated to determine its effect on H+ efflux 
from S. cerevisiae because of it structural similarities with dienones. It has been reported that 
curcumin inhibits the P-type Ca2+-ATPase of skeletal muscle sarcoplasmic reticulum (Logan-
Smith et al., 2001). In many studies it has been reported that curcumin exhibits poor 
bioavailability (Nelson et al., 2017). Curcumin is also known for its stability issue in solution 
form but Dao et al., (2016) have shown in their experiments that lack of methoxy group in 
demethoxycurcumin makes this compound more stable. Dao et al., (2016) have reported that 
demethoxycurcumin is a potent inhibitor of AHA2, Ca2+-ATPase and Pma1p PM H+-ATPase. 
The activity of the H+-ATPase AHA2 was reduced by demethoxycurcumin with an IC50 of 18.7 
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µM, Pma1p with IC50 of 28.9 µM and Ca2+-ATPase with IC50 of 2.6 µM. A study conducted by 
Khan et al., (2012) have shown that curcumin (MIC90 ranging from 250 – 650 µg/ml) exhibited 
38%, 48% and 50% inhibition of H+ efflux from three different C. albicans isolates; standard, 
clinical and fluconazole-resistant.  
To gain insight into mechanism of action of curcumin and its effect on proton extrusion by 
PM H+-ATPase has been investigated in this study against carbon-starved cells of S. cerevisiae. 
Curcumin exhibited good activity and revealed 36%, 43%, 51%, 58% and 60% inhibition of H+ 
efflux from S. cerevisiae (in terms of its ΔpHmax) over the range of concentrations (31.3, 50, 
62.5, 100 and 125 μM). However, curcumin routinely displayed turbidity in the aqueous 
medium at all tested concentrations. The true nature of its activity remain suspect due to 
turbidity or aggregation of molecule when added to the cell suspension. 
The bis-pyridylidene derivatives of cyclohexanone (23g and 23h) exhibited poor to moderate 
activity, inhibiting only 32% and 30% of the initial rate (after 1 min) of H+ efflux with their 
ΔpHir values of 0.47 and 0.48 respectively. In terms of inhibiting the total extent of change in 
the pH after 30 mins, 23g and 23h exhibited only 15 and 13% inhibition of H+ pumping by S. 
cerevisiae and their ΔpHmax were measured as 2.76 and 2.83 pH units respectively compared 
to glucose control (3.26 pH units). In contrast the bis-pyridylidene derivatives of 
cyclopentanone (23d-f) exhibited even lower potency (15.9%, 11.6% and 23% inhibition) than 
23g and 23h in terms of the initial rate of H+ pumping by S. cerevisiae. In addition 23d, 23e 
and 23f exhibited poor activity in terms of inhibiting the total extent of ΔpHmax over 30 mins 
(0.61%, 0.92% and 4% inhibition).  
The difference in the activity of 23a-c, 23d-f and 23g-h is therefore apparently linked to the 
structure of the central ring. Compounds 23a-c have a piperidine ring whilst 23d-f have a 
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cyclopentyl ring, and 23g-h have a cyclohexyl ring. The presence of the piperidine structure 
influences the inhibitory action possibly by increasing the aqueous solubility of the compound 
at least as measured by clogP values. As mentioned in previous chapters that piperidine ring 
structure are able to form a hydrogen bond between the N-methyl lone pair and a hydrogen 
atom associated with the target site whereas a cyclopentyl or cyclohexyl ring structure are 
unable to form such an interaction. Therefore, compounds 23a-c (central piperidine ring) 
were more effective at inhibiting the proton efflux from S. cerevisiae than 23d-f (central 
cyclopentyl ring) or 23g-h (central cyclohexyl ring). This is consistent with the results exhibited 
by the bis-benzylidene derivatives such as compounds 22a (a piperidine ring) 22u (a 
cyclopentyl ring) and 22v (a cyclohexyl ring). In terms of total extent of the change in pH after 
30 mins, compound 22a exhibited better potency by inhibiting 18.1% of proton efflux whereas 
22u showed 16.3% inhibition and 22v revealed only 6.44% inhibition. 
The bis-thienylidene derivatives of N-methylpiperidin-4-one and cycloalkanones (24a, 24b 
and 24c) exhibited little inhibition in terms of either the initial rate (8.70, 10.1 and 10.1% 
inhibition) or the ΔpHmax (7.67, 4.29 and 7.36% inhibition) of H+ pumping by S. cerevisiae cells. 
The result of the proton extrusion assay using the bis-thienyl derivatives against S. cerevisiae 
is in agreement with their higher IC50 values and AUCs obtained from the general growth 
susceptibility assay. These collective results are all consistent with this group of compounds 
being less effective at inhibiting H+ pumping by S. cerevisiae. 
The decrease in inhibitory potency of most of the compounds from the library in proton 
extrusion assay compared to the broth susceptibility assay is possibly due to the difference in 
the timing of the assay. In the growth inhibitory assay, compounds have more time to interact 
with other components of the cells because it was performed over a 24 hour period whereas 
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in the proton extrusion assay, compounds have only 90 minutes to interact with cells. 
Therefore, it is possible that the decrease in the activity of some compounds when comparing 
the two assay formats may be due to an increase in the number of interacting components 
or the time required to access the cytoplasmic side of the ATPase. 
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4.5 Conclusions 
The bis-pyridylidene derivatives of N-methylpiperidin-4-one (23a, 23b and 23c, 60 µM) 
exhibited higher levels of inhibition of H+ efflux from S. cerevisiae, in terms of  inhibiting the 
initial rate (48, 46 and 49% inhibition) and the ΔpHmax (33, 32 and 34 % inhibition). In addition, 
23a-c showed similar activity as the control inhibitor NEM (initial rate; 49% inhibition and 
ΔpHmax; 32% inhibition). Furthermore this is consistent with 23a-c exhibiting good potency in 
the macro-broth susceptibility assay against S. cerevisiae with their IC50 values being 12.6, 
8.84 and 9.45 μM. 
Moreover, the most effective compounds from the bis-benzylidene derivatives of N-
methylpiperidin-4-one were 22f, 22g, 22s and 22t, all of which exhibited good potency in 
terms of inhibiting both the initial rate and ΔpHmax of H+ pumping by S. cerevisiae. Additionally, 
22f, 22g, 22s and 22t also exhibited good potency in macro-broth susceptibility assay with 
their IC50 values being 1.21, 5.56, 1.87 and 3.37 μM. In contrast, the bis-pyridylidene 
derivatives of cycloalkanones (23d-h) exhibited poor activity against proton pumping by              
S. cerevisiae.  
The bis-thienylidene derivatives of N-methylpiperidin-4-one and the cycloalkanones (24a, 24b 
and 24c) did not inhibit H+ pumping by S. cerevisiae. These results were consistent with their 
higher AUCs and IC50 values against S. cerevisiae shown in the 24 hour growth inhibition 
experiments (chapter 3). This confirms that compounds containing thienyl group (24a-c) were 
not effective inhibitors of S. cerevisiae cells and no further derivative with this ring structure 
should probably be synthesized. 
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In conclusion, the antifungal activity of 22f, 22g, 22s, 22t, 23a, 23b and 23c may be originating 
from the inhibition of the plasma membrane H+-ATPase of S. cerevisiae and drop of internal 
pH leading to membrane damage.  
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5 Structure-activity relationship 
5.1 Introduction - Structure-activity relationship 
As stated in chapter-1 section 1.3.2, the frequency of invasive fungal infections has increased 
significantly in recent decades and the treatments for invasive fungal infections are limited  
despite the increase in our understanding of the molecular basis of antifungal drug therapy 
(Giraud et al., 2009).  
Over past decades, quantitative structure-based drug discovery and design has become 
increasingly important. Such advances are linked to an increased knowledge of structural 
biology and protein structure (De Cesco et al., 2017). This approach indicates possible 
structural modifications which may be made to a lead molecule in order to optimise ligand 
interactions with the target enzyme.  
In 1997 Lipinski et al., (1997) reviewed the literature related to computational approaches for 
evaluating the permeability and solubility of molecules in the process of drug discovery and 
development. They developed four rules and discussed how they could be applied to evaluate 
drug-likeness in the discovery process. These being: a molecular mass <500 Daltons, log P 
(octanol/water partition coefficient) <5, the number of hydrogen bond donors being fewer 
than five and the number of hydrogen bond acceptors being fewer than ten. 
Based on what is known about inhibitors of the fungal H+-ATPase, a library of 1,4-diene-3-one 
compounds have been synthesized where both the nature and substituent groups of aromatic 
rings, and the size and nature of the core ring carbonyl structure have been varied. The 
synthesized compounds will act in the same fashion and be consistent with Lipinski’s rule. A 
library consist of the bis-benzylidene derivatives of N-methylpiperidin-4-ones with various 
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substituents attached to the aromatic rings (22a-t), bis-benzylidene derivative of 
cyclopentanone (22u), bis-benzylidene derivative of cyclohexanone (22v), bis-pyridylidene 
derivatives of N-methylpiperidin-4-one and cycloalkanones (23a-h) and bis-thienylidene 
derivatives of N-methylpiperidin-4-one and cycloalkanones (24a-c). The compounds in this 
library were tested for their antifungal activities (details and results of which are given in 
Chapters 3 and 4). This class of compounds are synthetic αα’-dimethylene ketone 
homologues of curcumin where aromatic rings such as pyridine or benzene or pseudo-
aromatic structures, such as thiophene are attached to a methylene group α or α’ to the 
carbonyl group such as N-methylpiperidin-4-one, cyclopentanone or cyclohexanone. In the 
library developed for this project, various heterocycles were introduced in order to increase 
both the solubility and bioavailability. 
Enones or dienones are both able to undergo a Michael addition reaction with intracellular 
thiol containing compounds (e.g. glutathione, protein cysteines) with the olefinic C=C double 
bond of the enone. Chemically it was expected that conjugated enones/dienones could inhibit 
glutathione-S-transferase which could improve the general cytotoxicity of 3,5-
bis(benzylidene)-4-piperidone compounds along with other proteins containing essential 
cysteine residue (Lagisetty, Vilekar, Sahoo, Anant, & Awasthi, 2010).  
The evidence from this study suggest that 1,4-diene-3-ones (22a-v and 23a-h) possess a good 
level of antifungal activity against S. cerevisiae but are only poor to moderately active against 
C. albicans. This was established using in vitro macro-broth susceptibility assay against both 
S. cerevisiae and C. albicans (Chapter-3) and proton extrusion assays on S. cerevisiae 
(Chapter-4). It was identified that compounds 24a-c were not effective inhibitors of either         
S. cerevisiae or C. albicans.  
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The magnitude of their hydrophobic, electrophilic, volumetric and steric properties has been 
altered and tested for potential SAR. SAR attempts to investigate the influence of various 
psychochemical properties of the molecule such as the nature and pattern of ring substitution 
on the electrophilicity of the β-carbon, or the presence of pyridine rings having a direct 
relationship with the solubility and lipophilicity of a molecule. The benzene ring will be more 
lipophilic whereas a pyridine ring will be more amphipathic in nature. 
Initial analysis of the relationships between the structure and biological activity of the 
synthesized 1,4-diene-3-ones was performed in order to identify physicochemical features of 
the 1,4-diene-3-ones which could lead to improved antifungal properties of this class of 
compounds or alternatively be incorporated into other potentially more targeted 
compounds. Information obtained from the SAR analysis offers a useful starting point for 
further chemical modification of the pharmacophore structure (1,4-diene-3-one), which 
hopefully would result in compounds having higher bioavailability and target specificity thus 
hopefully leading to more potent compounds.
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5.2 Methods – Structure activity-relationship  
5.2.1 Structure-activity relationships of 1,4-diene-3-ones 
Structure-activity relationship (SAR) studies were performed by selecting two parameters 
namely; the lipophilic and electronic properties of various sub-libraries of the 1,4-diene-3-one 
compounds. Correlation plots were constructed to determine whether any correlations 
existed between either the activity (e.g. compound which inhibited 50% of S. cerevisiae 
growth; IC50) or its derivative parameter (log 1/IC50), clogP or 1H-NMR δ-values of olefinic 
protons present on the β-carbon of the 1,4-diene-3-ones. This latter property was chosen as 
a good descriptor for both electron density and shielding of the β-carbon. Individual clogP 
values were calculated for each compound using the software programme Molecular Orbital 
Environment 2014.09 Software (MOE). For the purpose of this study, calculated log P (clogP) 
was used as a lipophilic parameter. 
The clogP of various 1,4-diene-3-ones ranged between 1.53 and 6.94 (Table 5.1 and 5.2, page 
174 and 176). Pyridine-containing compounds (23a-h) have lower clogP values (between 1.53 
and 2.34). Compounds (23a and 23d) containing nitrogen atom at the ortho-position of 
aromatic ring have clogP values of 1.53 (N-methylpiperidin-4-one derivative) and 1.90 
(cyclopentanone derivative). While compounds (23b, 23e and 23g) with a nitrogen-atom at 
the meta-position of the aromatic ring have clogP values of 1.83 (N-methylpiperidin-4-one 
derivative), 1.91 (cyclopentanone derivative) and 2.34 (cyclohexanone derivative). In addition 
compounds (23c, 23f and 23h) with a N-atom at the para-position of aromatic ring have the 
same clogP values of 1.60 for N-methylpiperidin-4-one, cyclopentanone and cyclohexanone 
derivatives. 
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The 1H-NMR δ-value of proton on the β-carbon of 1,4-diene-3-ones was selected as an 
indicator of electron density and thus electrophilicity. The δ-values of proton of 1,4-diene-3-
ones was obtained from individual 1H-NMR spectra and ranged from 7.47 to 7.98 ppm. Out 
of which, the δ-values of proton on the β-carbon of bis-benzylidene, bis-pyridylidene and bis-
thienylidene derivatives of N-methylpiperidin-4-one varied from 7.65 to 7.98 ppm (Table 5.1, 
Page 174). Similarly the δ-value of the carbon atom from the carbonyl (C=O) group of each 
compound was obtained from the 13C-NMR spectra. The δ-value of the 13C carbon C=O groups 
for the bis-benzylidene, bis-pyridylidene and bis-thienylidene derivatives of N-
methylpiperidin-4-one ranged from 167.3 to 187.1 ppm (Table 5.1, Page 174). 
The inhibitory activities of the 1,4-diene-3-ones compounds described as either IC50s or AUCs 
against S. cerevisiae (data taken from Table 3.1, Page 105) were converted to log (1/IC50) and 
log(1/AUC). Transformations of the data to a logarithmic scale were implemented to linearize 
the relationships. The values of clogP, 1H-NMR δ-values of proton on the β-carbon, 13C-NMR 
δ-value of C=O, log (1/IC50) and log (1/AUC) with various substituent groups attached to the 
aromatic rings or the position of nitrogen in the pyridine rings are shown in Table 5.1, page 
174. The log (1/IC50) of the bis-benzylidene, bis-pyridylidene and bis-thienylidene derivatives 
of N-methylpiperidin-4-ones varied between 2.65 and 6.21. Similar calculations for the log 
(1/AUC) gave values ranging from 1.99 to 2.50. Compounds containing the pyridine 
functionality were lowest in terms of their clogP values and were within the Lipinski range (1-
5).   
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Table 5. 1. Electronic and lipophilic properties of bis-benzylidene, bis-pyridylidene and bis-
thienylidene derivatives of N-methylpiperidin-4-ones and their anti-fungal activity against 
S. cerevisiae. 
Compounds Groups attached 
at R1 and R2
 
ClogP  1H-NMR, δ 
value of 
protons on 
the β-carbon 
(ppm) 
13C-NMR, 
δ value of 
C=O 
(ppm) 
log 
(1/IC50) 
log 
(1/AUC) 
22a H-Ar 4.07 7.88 186.7 4.39 2.39 
22b 2-OCH3-Ar 3.71 7.82 187.1 4.64 2.41 
22c 3-OCH3-Ar 4.06 7.76 187.0 5.49 2.16 
22d 4-OCH3-Ar 3.98 7.54 186.7 4.65 2.36 
22e 2-Cl-Ar 5.25 7.75 186.7 5.41 2.27 
22f 3-Cl-Ar 5.33 7.56 186.7 5.92 1.99 
22g 4-Cl-Ar 5.25 7.57 186.4 5.26 2.20 
22h 2, 4-diCl 6.51 7.90 185.9 3.81 2.43 
22i 3, 4-diCl 6.51 7.65 186.1 3.81 2.46 
22j 2-COOH 3.42 7.85 170.1 3.90 2.41 
22k 4-COOH 3.42 7.91 167.3 3.65 2.47 
22l 4-CH3-Ar 4.67 7.79 187.0 N/R 2.50 
22m 3-CF3-Ar 6.01 7.76 186.2 5.82 2.14 
22n 4-CF3-Ar 5.94 7.81 186.4 6.21 2.02 
22o 3-OCF3-Ar 6.94 7.75 186.5 5.55 2.24 
22p 4-OCF3-Ar 6.87 7.81 186.1 4.89 2.25 
22q 2-I-Ar 6.45 7.81 185.9 4.72 2.34 
22r 3-I-Ar 6.52 7.71 186.5 5.18 2.29 
22s 3-NO2-Ar 4.01 7.60 186.0 5.73 2.10 
22t 4-NO2-Ar 3.94 7.80 186.2 5.47 2.16 
23a 2-pyridine 1.53 7.72 186.0 4.90 2.32 
23b 3-pyridine 1.83 7.68 185.9 5.05 2.29 
23c 4-pyridine 1.61 7.70 186.0 5.03 2.29 
24a 2-thiophene 3.13 7.98 185.9 2.65 2.50 
Note: Ar= Six membered aromatic ring. N/R means compound did not give 50% inhibition of S. cerevisiae growth and 
therefore log (1/IC50) was not calculated. 
 
The electronic and lipophilic properties of the bis-benzylidene, bis-pyridylidene and bis-
thienylidene derivatives of cyclopentanone and cyclohexanone, together with their antifungal 
activity against S. cerevisiae, expressed as either log (1/IC50) or log (1/AUC), are given in Table 
5.2, page 176. For the bis-benzylidene, bis-pyridylidene and bis-thienylidene derivatives of 
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cyclopentanone, compounds containing pyridine rings with the varying position of nitrogen-
atom (ortho, meta or para) have low clogP values (1.60 to 1.91) whilst thiophene rings (3.43) 
or benzene rings (4.77) have higher clogP values. The bis-benzylidene, bis-pyridylidene and 
bis-thienylidene derivatives of cyclohexanone also effect the clogP values, such as displayed 
in compounds with pyridine rings having clogP values of 1.60 and 2.34 compared to thiophene 
rings (3.87) or benzene rings (5.33). Compound 2-pyridylcyclohexan-1-one was not included 
in the entire study as the final “purified” product contained impurities such as a putative 
dimeric form and the presence of hydrochloride salts in the mixture (Data not shown in 
chapter 2). 
The 1H-NMR δ-value of proton on the β-carbon of the bis-benzylidene, bis-pyridylidene and 
bis-thienylidene derivatives of cyclopentanone ranged from 7.47 to 7.79 ppm whereas the 
bis-benzylidene, bis-pyridylidene and bis-thienylidene derivatives of cyclohexanone ranged 
from 7.65 to 7.97 ppm. Compounds containing a central cyclohexyl ring gave slightly higher 
1H δ-values compared to the compounds with a cyclopentyl ring.  
The bis-benzylidene, bis-pyridylidene and bis-thienylidene derivatives of cyclopentanone 
gave their 13C-NMR δ-value of the 13C carbon C=O groups ranged between 195.1 and 197.8 
ppm and inhibitory potencies of 2.89-5.08 (log (1/IC50)) and 2.29-2.51(log (1/AUC)). 
Subsequently the bis-benzylidene, bis-pyridylidene and bis-thienylidene derivatives of 
cyclohexanone gave their 13C-NMR δ-value of the 13C carbon C=O groups varied from 189.1 
to 190.4 ppm, while their log (1/IC50) values were between 3.51 to 5.25 and log (1/AUC) values 
were 2.22 to 2.52 respectively. 
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Table 5. 2. Electronic and lipophilic properties of bis-benzylidene, bis-pyridylidene and bis-thienylidene derivatives of cyclopentanone and 
cyclohexanone and their anti-fungal activity against S. cerevisiae. 
 
 
Groups attached at 
R1 and R2 
Compounds  ClogP  1H-NMR, δ values of 
proton  on the β-
carbon (ppm) 
13C-NMR, δ 
value of 
C=O (ppm) 
log (1/IC50) log (1/AUC) 
 
H-Ar 22u 4.77 7.62 196.6 2.89 2.51 
2-pyridine 23d 1.90 7.53 195.3 4.69 2.36 
3-pyridine 23e 1.91 7.53 197.8 5.08 2.32 
4-pyridine 23f 1.60 7.47 195.4 5.07 2.29 
2-thiophene 24b 3.43 7.79 195.1 3.21 2.50 
 
H-Ar 22v 5.33 7.80 190.4 3.51 2.50 
3-pyridine 23g 2.34 7.73 189.1 5.25 2.22 
4-pyridine 23h 1.60 7.65 189.2 5.07 2.25 
2-thiophene 24c 3.87 7.97 189.1 N/R 2.52 
Note: Ar= six membered aromatic ring. N/R represents that compound did not give 50% inhibition of S. cerevisiae growth and therefore log (1/IC50) was not calculated. 
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Only 31 compounds were analysed for SAR since only these compounds have exhibited 
inhibitory activity greater than 50% against S. cerevisiae. Compounds 22l (3,5-bis(4-
methylbenzylidene)-1-methylpiperidin-4-one) and 24c (2,6-bis-(thiophene-2-
ylmethylene)cyclohexan-1-one) were excluded from the data set due to a lack of potency. 
The inhibitory activities against S. cerevisiae by 1,4-diene-3-ones were expressed as either log 
(1/IC50) or log (1/AUC) and compared with both the clogP and the δ-values of proton on the 
β-carbon of 1,4-diene-3-ones.  
Certain compounds in the library contain electron withdrawing groups e.g. I, Cl or COOH 
whereas some compounds contain electron donating groups such as CH3 or OCH3 attached to 
the aromatic ring while few other compounds consist of either aromatic pyridine rings or a 
pseudo aromatic sulphur containing five membered ring. SAR analyses were conducted by 
dividing compounds into several groups based on the different substituents and rings, such 
as a full data set (containing 31 compounds), bis-benzylidene derivatives of N-
methylpiperidin-4-ones (18 compounds) and bis-pyridylidene derivatives of N-
methylpiperidin-4-one and cycloalkanones (pyridine ring containing 8 compounds).  
The Hammett equation sometimes fails when substituents and other functionalities or 
reaction centres have the potential to interact with each other (e.g. substituents that are 
ortho to each other). For example in some cases the electronic effect of a substituent ortho 
to the first substituent increases or decreases the substituent effect (Hansch & Leo, 1979). In 
some SAR analyses, the ortho-substituted group of compounds were removed because of the 
potential for interactions (Figure 5.1). For example, some ortho-substituents (e.g. COOH, OH) 
can interact with the olefinic hydrogen atom present at the β-carbon or hydrogen atom of 
central piperidine structure and cause either volumetric or steric clashes between hydrogen 
atoms.   
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Figure 5. 1. A representative example of potential interaction of ortho-substituent with 
either olefinic proton or protons of central pyridyl ring. 
 
SAR was performed after grouping compounds based on their chemical structures: 
1) SAR of 31 compounds (22a-k, 22m-v, 23a-h and 24a-b),  
2) SAR of reduced data set excluding ortho-substituents compounds – 19 compounds 
analysed (22a, 22c-d, 22f-g, 22k, 22m-p, 22r-t, 23b-c and 23e-h), 
3) SAR of bis-benzylidene derivatives of N-methylpiperidin-4-ones – 18 compounds analysed 
(22a-k and 22m-t). 
4) SAR of reduced data set of bis-benzylidene derivatives of N-methylpiperidin-4-ones 
excluding ortho-substituents compounds – 13 compounds analysed (22a, 22c-d, 22f-g, 
22k, 22m-p and 22r-t), and  
5) SAR of bis-pyridylidene derivatives of N-methylpiperidin-4-one and cycloalkanones – 8 
compounds analysed (23a-h). 
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Correlation analysis was performed using the following selections:  
(i) log (1/IC50) against clogP of 1,4-diene-3-ones,  
(ii) log (1/IC50) against the δ-values of proton on the β-carbon of 1,4-diene-3-ones,  
(iii) log (1/IC50) against the δ-values of the carbon atom of carbonyl (C=O) group of 1,4-
diene-3-ones,  
(iv) log (1/AUC) against clogP of 1,4-diene-3-ones, 
(v) log (1/AUC) against the δ-values of proton on the β-carbon of 1,4-diene-3-ones, 
(vi) log (1/AUC) against the δ-values of the carbon atom of carbonyl (C=O) group of 1,4-
diene-3-ones, 
(vii) log (1/AUC) against log (1/IC50) of 1,4-diene-3-ones,   
(viii) The δ-values of the carbon atom of C=O against δ-values of protons on the β-carbon 
of 1,4-diene-3-ones and 
(ix) The δ-values of proton on the β-carbon of 1,4-diene-3-ones against their clogP. 
(x) The δ-values of proton on the β-carbon of 1,4-diene-3-ones against clogP and 
(xi)  The δ-values of the carbon atom of C=O of 1,4-diene-3-ones against clogP. 
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5.3 Results – Structure activity-relationship 
Structure-activity relationship analysis of full data, the set containing 31 compounds (22a-k, 
22m-v, 23a-h and 24a-b) were analysed using two possible combinations; log (1/IC50) vs clogP 
and log (1/IC50) vs the δ-values of proton on the β-carbon of the 1,4-diene-3-ones. Correlation 
coefficients (R2 values) derived from the various plots indicates the goodness of fit between 
the equation of physicochemical parameter and the biological activity of the particular set of 
compounds. Initial SAR was performed using log (1/IC50) vs clogP and log (1/IC50) vs the δ-
values of proton on the β-carbon of the 1,4-diene-3-ones on full data set of 31 compounds by 
fitting a linear model using the equation (Eq. 6). However the R2 values of the linear 
correlations of the data set was very low (0.004; clogP plot and 0.135; δ-values of protons). 
𝒚 = 𝒃𝒙 + 𝒄                              (𝑬𝒒. 𝟔) 
Further SAR was conducted using a second order polynomial equation (Eq. 7) as this provided 
a better fit to the data. 
𝒚 = 𝒂𝒙𝟐 + 𝒃′𝒙 + 𝒄                 (𝑬𝒒. 𝟕) 
Polynomial regression is a special case of multiple linear regression (MLR) and it can be used 
to fit a variety of models such as linear, quadratic, cubic or quartic. In addition polynomial 
regression is used to fit a nonlinear relationship between independent and dependent 
variables (e.g. clogP and log (1/IC50)). The aim of this study was to correlate the biological 
properties [log (1/IC50) or log (1/AUC)] with the chemical properties (lipophilic or electronic) 
of the molecule. 
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Figure 5. 2. SAR of log (1/IC50) against clogP [a] and log (1/IC50) against the δ-values of the 
protons on the β-carbon [b] of the 1,4-diene-3-ones. 
 
Correlation analysis of 31 compounds plotting log (1/IC50) against clogP in Fig 5.2[a] shows a 
parabolic curve with a correlation coefficient (R2) of 0.0553 whereas the correlation analysis 
of log (1/IC50) against the δ-values of proton on the β-carbon of the 1,4-diene-3-ones 
generates a hyperbolic curve with the correlation coefficient of 0.2795 in Fig 5.2[b]. The R2 
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values in Fig 5.2[a and b] were very poor, however Fig 5.2[b] show slightly better R2 value, 
which possibly suggests better correlation between the electrophilicity and the inhibitory 
activity. When comparing the coefficient value of 2nd order polynomial (b’x = -0.5857) with 
linear equation (bx = 0.0327) it was identified that these two models have a 0.61 fold 
difference between them in Figure 5.2[a]. Similarly the plot of log (1/IC50) vs the δ-values of 
protons on the β-carbon in the Figure 5.2[b] showed 299 fold difference between the 2nd 
order polynomial (b’x = 297.16) and linear (bx = -2.628). This evidence confirms that second 
order polynomial provide a bitter fit of the data compared to the linear equation. 
However, low values of R2 could possibly the result of three different groups of compounds 
analysed together in this data set. Additionally, it was clearly observed that the electrophilic 
parameter (δ-values of proton on the β-carbon of the 1,4-diene-3-ones) correlates reasonably 
with log (1/IC50) compared to the lipophilic parameter (clogP). Subsequent correlation 
analysis of log (1/AUC) against clogP was performed and this gave a correlation coefficient of 
0.0208 whereas the plot log (1/AUC) against δ-values of proton on the β-carbon of the 1,4-
diene-3-ones gave a correlation coefficient of 0.1791 (Data not shown).  
The full data set was reduced by removing various sub-sets of compounds to determine 
whether removing a particular property will give a better fit of the data or better correlation 
coefficient and to see whether this has a beneficial or detrimental effect on the correlation. 
Therefore SAR analysis was performed by removing the ortho-substituted compounds from 
the library (detailed reasoning for this explained in section 5.2.1, page 172-179). The reduced 
dataset contains 19 compounds from the library. These were compounds 22a, 22c, 22d, 22f, 
22g, 22k, 22m-p, 22r-t, 23b, 23c, and 23e-h, respectively. The reason for removing the ortho-
substituted compounds is because ortho-substitution is well known to give rise to interactions 
between groups such as: hydrogen bonding, volumetric or steric clashes (representative 
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example in Figure 5.1). An example of this is found in ortho-hydroxybenzoic acid but not in 
the meta or para-hydroxybenzoic acid. Other possible interaction is due to the interaction of 
substituent by volumetric or other atom/group interaction, which potentially cause rotations 
around the phenyl to olefinic C-C bond. 
 
Figure 5. 3. SAR of log (1/IC50) against clogP [a] and log (1/IC50) against the δ-values of 
protons on the β-carbon [b] of the 1,4-diene-3-ones (excluding ortho-substituents). 
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SAR was performed on the remaining 19 compounds excluding the ortho-substituted 
molecules from the library. By removing the ortho-substituent groups from the full data set, 
the R2 value increase marginally from 0.0553 to 0.1071 (Fig. 5.2a and 5.3a) and 0.2795 to 
0.4513 (Fig. 5.2b and 5.3b). This clearly indicates that excluding the ortho-substituted group 
of compounds from the library has generated a slightly better relationship between the 
activity and physicochemical properties of the compounds. Although some improvement 
would be expected since the number of compounds included in this data set is lower 
compared to the Figure 5.2. This suggests that a volumetric ‘clash’ between the ortho group 
and the proton of the β-carbon may be important in compound potency. So, there is probably 
some interaction between the ortho-substituent and one or more of the hydrogen atoms 
present on either of the olefinic carbon or methylene group of N-methylpiperidin-4-one or 
cycloalkanones. In addition, it is obvious that the biological activity of this group of 
compounds has a better correlation with the electronic term electron density compared to 
the lipophilicity. This suggests that the electrophilicity of the β-carbon of 1,4-diene-3-ones is 
important for the inhibitory activity of these compounds. 
SAR analysis of the bis-benzylidene derivatives of N-methylpiperidin-4-one was performed to 
determine which substituent (or position of substituent) is giving rise to correlation between 
the inhibitory activity and lipophilic or electrophilic parameters. This dataset contains only 18 
compounds, these being 22a-k and 22m-t, respectively.  
Chapter 5: Structure activity-relationships 
 
185 
 
 
Figure 5. 4. SAR of log (1/IC50) against clogP [a] and log (1/IC50) against the δ-values of 
protons on the β-carbon [b] of bis-benzylidene derivatives of N-methylpiperidin-4-one. 
 
A better fit was obtained when bis-benzylidene derivatives of N-methylpiperidin-4-one 
compounds were analysed for both the lipophilic and electronic properties. Additionally, SAR 
of log (1/IC50) vs clogP shows a hyperbolic curve with a significant improvement in the 
correlation coefficient value, these being 0.4138 in Figure 5.4[a] whereas previous two SAR in 
both the Figure 5.2[a] (full data set) and Figure 5.3[a] (excluding ortho-substituents) 
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presented a parabolic curve. This could be due to compounds with different functionalities 
have been grouped together in one data set and analysed as shown in Figure 5.2 and 5.3 [a]. 
On the other hand, the SAR derived from filling log (1/IC50) and δ-values of protons on the β-
carbon of bis-benzylidene derivatives of N-methylpiperidin-4-one displayed a substantial 
increase in the correlation coefficient value, (R2 = 0.6746; Fig 5.4b) which demonstrates a 
significant relationship between the activity and the electronic property. This suggests that 
bis-benzylidene derivatives of N-methylpiperidin-4-one were dependent on the 
electrophilicity of the β-carbon for their activity against S. cerevisiae. Lipophilicity has some 
influence but it does not appear to play a major role in the activity of this class of compounds.  
The higher correlation coefficient for this group of compounds is possibly due to the presence 
of the nitrogen atom in the central ring, which is believed to cause an increase in the solubility 
of the compound based on clogP values and decrease the likelihood of molecules forming 
aggregates. If cyclopentanone or cyclohexanone derivatives were included in these data sets 
then the R2 values decreases significantly, therefore these compounds were removed for this 
particular analysis. 
Certain isomeric pairs of compounds with substituents such as 3-chloro or 4-chloro,                       
3-trifluoromethyl or 4-trifluoromethyl, 3-trifluoromethoxy or 4-trifluoromethoxy, 3-nitro or 
4-nitro were very close together. These compounds were associated very well with their            
clogP irrespective of their position, whether is at meta or para their clogP values were similar. 
This is consistent with many other studies (Hansch & Leo, 1979). Therefore, if there was a 
major difference between compounds then it could be due to the structural property of these 
isomeric sets of compounds. The low differences here are unlikely due to the positioning of 
those particular groups. However in the correlation plot of log (1/IC50) against the δ-values of 
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proton on the β-carbons these isomeric pairs of substituents showed significant difference in 
their positions (Figure 5.4[b]). Thus the δ electronic (electron density on the β-carbon) 
parameter appears to be very important.  
 
Figure 5. 5. SAR of log (1/IC50) against clogP [a] and log (1/IC50) against the δ-values of 
proton on the β-carbon [b] of bis-benzylidene derivatives of N-methylpiperidin-4-one 
(excluding ortho-substituents). 
 
SAR analyses of only 13 compounds excluding ortho-substituents from bis-benzylidene 
derivatives of N-methylpiperidin-4-one shows a moderate to good relationship between 
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activity and lipophilic/electronic properties of compounds. Figure 5.5[a] shows moderate 
relationship between the activity log (1/IC50) and clogP with a correlation coefficient of 
0.5312, which is slightly better than previous SAR (including ortho-substituted compounds). 
In contrast, SAR of log (1/IC50) and δ-values of proton on the β-carbon of these compounds 
depict a reasonably good relationship with a correlation coefficient of 0.6286 (Figure 5.5b). It 
has been observed that removing compounds having an ortho-substituent from the data set 
give rise to a better relationship between activity and lipophilicity. However it should be noted 
that simply decreasing the number of compounds in a data set will, for fundamental 
mathematical and statistical reasons give rise to some improvement in the R2 value. The 
presence of an ortho-substituent potentially twists the aromatic rings out of a 2D plane. 
However, the relationship between activity and the electrophilic parameter showed a slight 
deviation in the R2 values. This could be due to the fact that substituents such as 2-iodo, 2-
chloro and 2,4-dichloro were very close to the hyperbolic curve and removal of these has 
shown some effect on the correlation coefficient. 
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Figure 5. 6. SAR of log (1/IC50) against clogP [a] and log (1/IC50) against the δ-values of the 
proton on the β-carbon [b] of bis-pyridylidene derivatives of N-methylpiperidin-4-one and 
cycloalkanones. 
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compounds). Compounds containing pyridine rings are known to increase the solubility of the 
homologs compounds and the clogP values of this group of compounds suggests that the 
activity of these compounds should correlate better with their lipophilic properties. The 
correlation coefficient of the log (1/IC50) vs clogP plot (R2 = 0.4790) was greater than log 
(1/IC50) vs δ-values of proton on the β-carbon (R2 = 0.1447). This is exactly the opposite of 
what is found in the other plots suggesting that inhibition linked to the extended time period 
of growth assays possibly involves a complex series of interactions.  
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Figure 5. 7. SAR of log (1/IC50) against the δ-values of the carbon atom of the carbonyl [a] 
and log (1/AUC) against the δ-values of the carbon atom of the carbonyl [b] of bis-
pyridylidene derivatives of N-methylpiperidin-4-one and cycloalkanones. 
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parabolic curve in Figure 5.7[b]. However SAR in both cases displayed a very good relationship 
between the activity of compounds and carbonyl group with high R2 values (0.9131 and 
0.8508). This suggests that carbonyl group have some influence on the activity of this set of 
compounds. In order to attempt to understand the different plots shown in Fig. 5.7, the 
correlation analysis of two inhibition parameters log (1/AUC) and log (1/IC50) for the full data 
set of various 1,4-diene-3-ones containing 31 compounds were plotted (Figure 5.8). 
 
Figure 5. 8. Comparison of log (1/AUC) with log (1/IC50) of the 1,4-diene-3-ones against S. 
cerevisiae (full data set containing 31 compounds). 
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correlation plot was constructed using 1/(log (1/AUC)) vs log (1/IC50) and this gave an R2 of 
0.8098 for linear equation and R2 of 0.9267 for second order polynomial equation. Similarly 
correlation plot of log (1/AUC) vs 1/(log (1/IC50)) gave an R2 of 0.6977 for linear equation and 
R2 of 0.8986 for second order polynomial equation. In all cases, the second order polynomial 
equation gave better R2 values compared to the linear equation. This confirms that data 
generated in different ways from the susceptibility assays were reliable and robust.    
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Figure 5. 9. Comparison of the δ-values of the carbon atom of the carbonyl with the δ-values 
of the proton on the β-carbons; full data [a], bis-pyridylidene derivatives of N-
methylpiperidin-4-one [b] and bis-pyridylidene derivatives of N-methylpiperidin-4-one and 
cycloalkanones [c]. 
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The correlation plots of the δ-values of proton on the β-carbons with the δ-values of the 
carbon atom of the carbonyl group was performed to compare the relationship between 
these two electronic parameters (Figure 5.9). The correlation plot of full data sets includes 31 
compounds showed a poor correlation coefficient with R2 of 0.2820 (Fig. 5.9a). Subsequently 
correlation plot was constructed again by removing any compounds with Hill slope greater 
than 2.0 from the data set to decrease the influence of molecular aggregation on the analysis 
(therefore only 23 compounds were analysed) and this resulted in an increase in the R2 value 
(0.3988). However this is still a low level of correlation. The information obtained from the 
chapter 3 suggest that the inhibitory action of compounds having high Hill slopes is possibly 
enhanced in a non-specific fashion due to the level of aggregation of the molecules. The above 
correlation plot indicates that those compounds with high Hill slope showed a 1.5 fold 
increase in the R2 value.  
The correlation plot of bis-benzylidene derivatives of N-methylpiperidin-4-one (18 
compounds) gave an R2 value of 0.3412. It is expected that the correlation of the δ-values of 
the proton and the δ-values of the carbon atoms of the carbonyl should be close to linear thus 
giving a good correlation of data. However in this case such a correlation was not observed. 
This could be because in the full data set (Fig 5.9a) three different functionalities have been 
grouped together and analysed which resulted in low R2 value in figure 5.9[b]. This is probably 
due to the δ-proton being associated with the point of reaction whereas the 13C of the 
carbonyl is not associated with the reaction centre. 
Interestingly in figure 5.9[c], the bis-pyridylidene derivatives of N-methylpiperidin-4-one and 
cycloalkanones (only 8 compounds) displayed very good correlation with R2 value of 0.8169. 
This could be due to a low numbers of compound being analysed in the data sets. In addition, 
Chapter 5: Structure activity-relationships 
 
196 
 
compounds analysed in this plot (Fig 5.9c) were aggregators as all of them (23a-h) have a Hill 
slope greater than 1. 
SAR analyses of various 1,4-diene-3-ones describing the relationships between the activity 
with lipophilicity and electrophilicity were shown in Table 5.3, page 198. Only two parameters 
have been used to generate SAR these being clogP and electrophilicity as defined by 1H-NMR 
although many more are available in the programme MOE. Bis-benzylidene derivatives of N-
methylpiperidin-4-one shown a reasonably good relationship between log (1/IC50) and the δ-
values of proton on the β-carbons (R2 = 0.6746). However SAR of this group of compounds for 
log (1/IC50) against clogP generated a correlation coefficient of only 0.4138. This collective 
information suggests that the inhibitory activity of bis-benzylidene derivatives of N-
methylpiperidin-4-one is predominantly dependent on the electronic property of this class of 
compounds. In addition this group of compounds demonstrated a good relationship between 
the two selected activity parameters namely log (1/IC50) and log (1/AUC) with an R2 value of 
0.9092. 
SAR analysis of the δ-values of proton on the β-carbons against the δ-values of carbonyl 
displayed good relationship for bis-pyridylidene derivatives (R2 = 0.8169) but this was for a 
very small subset of compounds. SAR of the full data set or bis-benzylidene derivatives gave 
a poor correlation coefficient (R2 = 0.2820 and 0.3412 respectively). Even when SAR was 
performed by excluding ortho-group of compounds from both the full data set or the bis-
benzylidene derivatives the improvement in the correlation coefficient values obtained were 
limited (R2 = 0.4364 and 0.5558).  
SAR of bis-pyridylidene derivatives of N-methylpiperidin-4-one and cycloalkanones for log 
(1/IC50) against clogP generated a reasonable relationship with an R2 of 0.4790 but a very poor 
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correlation for log (1/IC50) against the δ-values of proton on the β-carbons (R2 = 0.1447). This 
suggests that the inhibitory activity of bis-pyridylidene derivatives of N-methylpiperidin-4-one 
and cycloalkanones is highly dependent on its lipophilic property rather than electrophilic. 
This appear to be contrary to the previous data when electrophilicity appear to be dominant. 
This difference may be due to the pyridyl derivatives being more soluble (but aggregating an 
effect confirmed by the high Hill coefficients) than their phenyl equivalents (which showed 
less aggregating effect confirmed by their lower Hill coefficient values).
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Table 5. 3. Comparison of the correlation coefficients of the lipophilic and electronic parameters of various 1,4-diene-3-ones with the inhibitory 
activities obtained from S. cerevisiae study.  
List of various correlation analyses 
Correlation coefficient (R²) 
Full dataset with 
31 compounds 
Reduced dataset -
excluding ortho 
substituents                         
(19 compounds) 
Bis-benzylidene 
derivatives of N-
methylpiperidin-4-
one (18 
compounds) 
Bis-benzylidene 
derivatives of N-
methylpiperidin-4-
one (Excluding ortho 
substituents - 13 
compounds) 
Bis-pyridylidene 
derivatives of N-
methylpiperidin-
4-one and 
cycloalkanones  
(8 compounds) 
log (1/IC50) vs clogP 0.0553 0.1071 0.4138 0.5312 0.4790 
log (1/IC50) vs δ-value of olefinic proton 0.2795 0.4513 0.6746 0.6286 0.1447 
log (1/IC50) vs δ-value of 13C of C=O 0.1828 0.2783 0.3777 0.4933 0.9131 
log (1/AUC) vs clogP 0.0208 0.1318 0.3809 0.5004 0.6416 
log (1/AUC) vs δ-value of olefinic proton 0.1791 0.2363 0.4493 0.4014 0.3034 
log (1/AUC) vs δ-value of 13C of C=O 0.1875 0.2906 0.2221 0.3273 0.8508 
log (1/AUC) vs log (1/IC50) 0.9371 0.8906 0.9092 0.9102 0.8989 
δ of 13C of C=O vs δ value of olefinic proton 0.2820 0.4364 0.3412 0.5558 0.8169 
δ-value of olefinic proton vs clogP 0.1183 0.1230 0.2692 0.2747 0.2749 
clogP vs δ-value of olefinic proton 0.1183 0.1230 0.2692 0.2747 0.2749 
clogP vs δ-value of 13C of C=O 0.0634 0.1628 0.4730 0.4254 0.2640 
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5.4 Discussion – Structure-activity relationship 
The antifungal properties of the 1,4-diene-3-one compounds were compared using structural 
and physicochemical features to establish the relative importance of either hydrophobicity, 
or electron density at the β-carbons. Two parameters namely lipophilic (expressed as clogP) 
and the electrophilic parameter (expressed as the δ-value of proton on the β-carbon) of 1,4-
diene-3-ones were selected to use in the analysis although many other parameters are also 
available from MOE software. Similarly, the IC50 and area under the curve (AUC) for each 
compound were selected as their biological activity obtained from the macro-broth 
susceptibility assay against S. cerevisiae. 
The reason for selecting IC50 as one parameter is that most of the compounds gave 50% 
inhibition of growth of S. cerevisiae. However measurement of the IC50 alone can often give 
ambiguous results. As mentioned by Odds & Abbott, (1984) that by measuring the AUC, better 
reproducibility of the inhibitory potency of compounds can be obtained. Therefore, AUC of 
each compound was used as a second parameter to possibly identify any differences between 
compound potency.  
For SAR analysis, compounds which shown greater than 50% inhibition of S. cerevisiae growth 
in the macro-broth susceptibility assay were selected. Therefore only 31 compounds (22a-k, 
22m-v, 23a-h and 24a-b) were analysed. The correlation coefficient (R2) values from the 
correlation analysis of log(1/IC50) vs clogP and log(1/IC50) vs δ-value of proton on the β-carbon 
of 1,4-diene-3-ones were poor (0.0553 and 0.2795). However, the difference between 
lipophilic and electronic properties was very high in terms of their R2 values. This evidence 
suggests that the electrophilic property of 1,4-diene-3-ones play a significant role in the 
inhibitory action of these compounds rather than the lipophilicity. This simply suggests that 
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the electron density (or lack thereof) at the β-carbon of 1,4-diene-3-ones is important in 
potency. 
The Hammett equation sometimes fails when substituents and reaction centres have the 
potential to interact with each other such as an ortho substituents (Hansch & Leo, 1979). 
Taking this point into consideration further investigation was performed by arranging the 
library of compounds into several groups as mentioned in the result section 5.3 and their 
values were displayed in Table 5.3, page 198. Based on the possibility that the ortho-
substituted groups may interact either with the hydrogen atom present on either of the                       
β-carbons or the methylene group at position 2 or 5 in the N-methylpiperidin-4-one group (or 
equivalently in cyclopentanone or cyclohexanone) and interact or ‘clash’. Consequently, 
compounds that contain an ortho-substituent group were removed from the data set and the 
remaining 19 compounds (22a, 22c-d, 22f-g, 22k, 22m-p, 22r-t, 23b-c and 23e-h) analysed. 
Correlation analysis of log (1/IC50) vs clogP gave an R2 value of 0.1071 whereas for log (1/IC50) 
vs δ-value of proton on the β-carbon of 1,4-diene-3-ones gave an improved R2 value of 0.4513. 
The correlation coefficient values for log (1/IC50) vs δ-value or proton on the β-carbon of 1,4-
diene-3-ones data set has shown a considerable increase in the correlation coefficient 
compared to the full data set. This indicates that ortho-substituents may have secondary 
effects related to the atom or atom ‘clashes’ with consequential distortion of the molecule. 
However the R2 value of 0.4513 indicating that the correlation between biological activity and 
electrophilicity is still less than 50%, therefore further SAR was performed using reduced a 
data set. 
Further SAR was conducted on a sub-group containing the bis-benzylidene derivatives of N-
methylpiperidin-4-one (18 compounds, 22a-k and 22m-t). This has shown an improvement in 
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the correlation coefficient (R2 = 0.4138) for the correlation plot between log (1/IC50) and 
clogP. On the other hand, the correlation analysis of log (1/IC50) vs the δ-value of proton on 
the β-carbon of bis-benzylidene derivatives of N-methylpiperidin-4-ones gave a good 
correlation coefficient (R2 = 0.6746). This sub-set of data has shown significant improvement 
in the correlation and it clearly implies that the electrophilic property of bis-benzylidene 
derivatives of N-methylpiperidin-4-ones plays an important role in their inhibitory activity 
against S. cerevisiae. 
Reanalysis of log (1/IC50) against clogP plot of bis-benzylidene derivatives of N-
methylpiperidin-4-ones by removing ortho-substituted groups has shown a slight 
improvement in the correlation coefficient (R2 = 0.5312) as compared to the SAR of data with 
ortho-substituted groups gave the R2 = 0.4138. This possibly suggests some form of atomic 
‘bumping’ causing distortion from the molecular plane may be occurring and in silico model 
building may prove useful in this context. Similarly SAR of bis-benzylidene derivatives of N-
methylpiperidin-4-ones excluding compounds with ortho- groups gave a correlation 
coefficient of 0.6286, which was slightly lower than the R2 value of compounds including 
ortho- groups. The reason for this decrease in R2 is unclear. 
However, the SAR analysis of log (1/AUC) against clogP or the δ-value of proton on the β-
carbon gave a slightly lower correlation values for bis-benzylidene derivatives of N-
methylpiperidin-4-ones whether analysed both with or without ortho-substituents, the R2 
being 0.3809 (including ortho-substituted compounds) or 0.5004 (excluding ortho-substituted 
compounds). Similarly the correlation coefficient values for log (1/AUC) vs δ-values of proton 
were 0.4493 (including ortho-substituents) and 0.4014 (excluding ortho-substituents). 
Differences between the correlation coefficient values of the SAR data of log (1/IC50) and 
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equivalent log (1/AUC) is because the IC50 values obtained manually at the point of inflection 
(50%) of the dose-response curve whereas AUC includes a rectangle portion of the curve 
between two sets of concentrations.   
Given the differences in the SAR results in S. cerevisiae of both log (1/IC50) and equivalent log 
(1/AUC).  A correlation plot of the two inhibitory parameters was performed to identify any 
possible differences between log (1/AUC) and log (1/IC50). These two inhibitory parameters 
correlated significantly with each other. Cross-correlation of the IC50 with AUC was conducted 
on various subsets of data including: (1) the full data set of 31 compounds (R2 = 0.9371), (2) 
compounds excluding ortho-substituents from full data set (R2 = 0.8906), (3) the bis-
benzylidene derivatives of N-methyl-piperidin-4-one including ortho-substituents (R2 = 
0.9092), (4) set 3 excluding compounds with ortho-substituents (R2 = 0.9102) and (5) the bis-
pyridylidene derivatives of N-methylpiperidin-4-one and cycloalkanone (R2 = 0.8989). Given 
the high R2 values between log (1/AUC) and log (1/IC50), it is not obvious why the differences 
in the R2 values for the previous data analysis are occurring.   
In contrast SAR of bis-pyridylidene derivatives of N-methylpiperidin-4-one and 
cycloalkanones for log (1/IC50) vs clogP gave a correlation coefficient of 0.4790 whereas SAR 
of log (1/IC50) vs δ-value of the olefinic proton on the β-carbon gave a correlation coefficient 
of 0.1447. Similarly SAR of log (1/AUC) against clogP of bis-pyridylidene derivatives of N-
methylpiperidin-4-one and cycloalkanones gave an R2 of 0.6416 while log (1/AUC) vs clogP 
gave an R2 of 0.3034. This demonstrates that the activity of pyridine containing compounds is 
influenced by solubility/lipophilicity rather than the electrophilic property of this class of 
compounds.  
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SAR studies in S. cerevisiae revealed that the antifungal activity of the 1,4-diene-3-ones is 
dependent on structural features including the presence of a heterocyclic moiety, the nature 
of the substituents attached to the aromatic rings and their associated effects particularly due 
the electrophilicity of the β-carbon atom. High antifungal activity of 1,4-diene-3-ones against                  
S. cerevisiae appears to be due to the presence of a strong electron-withdrawing group such 
as -CF3, -OCF3, -NO2 or -Cl on the aromatic ring of bis-benzylidene derivatives of N-
methylpiperidin-4-one. In contrast, the presence of electron donating group (e.g. -CH3) on the 
aromatic rings of bis-benzylidene derivatives of N-methylpiperidin-4-one leads to a decrease 
in the potency of the compounds. It has been reported previously in the QSAR study on 
chalcones that presence of that EDG on the aromatic rings of chalcones shown reduction in 
the antifungal activity (Sivakumar et al., 2009).
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5.5 Conclusions – Structure-activity relationship 
Analysis of the various sub-sets of 1,4-diene-3-ones demonstrates that the electrophilic 
nature of the β-carbon on the compounds (22a-k, 22m-v, 23a-h and 24a-b) is important in 
modulating the antifungal activity of this class of compounds (Sivakumar et al., 2009). This is 
consistent with what has been observed with chalcones and another class of cysteine reactive 
enone compounds. SAR analysis of log (1/IC50) vs δ-values of proton on the β-carbon of bis-
benzylidene derivatives of N-methylpiperidin-4-one gave a significantly higher correlation 
coefficient (R2 = 0.6746) compared to the plot of log (1/IC50) vs clogP (R2 = 0.4138). This 
suggests that the inhibitory activity of bis-benzylidene derivatives of N-methylpiperidin-4-one 
was influenced by the electronic rather than the lipophilic descriptor. The poor R2 value of log 
(1/IC50) vs clogP suggests that other properties beside hydrophobicity are important for the 
activity of these compounds (22a-k, 22m-v). This includes, but is not limited to the 
electrophilicity of the reacting carbon and volumetric constituents (not analysed). Based on 
the changes in R2 values, when ortho-substituted compounds were removed from the data 
set it was believed that the improvement in R2 was due to the removal of compounds that 
might give rise to stereo-chemical or volumetric bumping.   
SAR of bis-pyridylidene derivatives of N-methylpiperidin-4-one and cycloalkanones exhibited 
hyperbolic curves for both plots in Figure 5.6 between log (1/IC50) vs δ-values of proton and 
log (1/IC50) vs clogP, their correlation coefficient values being 0.1447 and 0.4790 respectively. 
This indicates that the activity of the pyridyl derivatives were dependent on lipophilicity 
rather than electronic property. This speculatively suggests that the pyridyl group of 
compounds may be facilitating the targeting of multiple sites of the enzyme, multiple 
enzymes or causing some change(s) in cellular morphology.  
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Although improvement in the R2 values were obtained when analysing subsets of compounds 
some (or even all) of this improvement may simply be due to the decrease in the size of the 
data set. In order to determine if such problem exist it would be necessary to study the 
distribution of individual residuals across the graphs and to perform more complex statistical 
analyses. Additionally further compounds would need to be synthesized in order to bring the 
data sets to the same size thus eliminating potential’ improvements’ caused by different 
group sizes. 
In conclusion, it has been identified that the two activity parameters, log (1/IC50) and log 
(1/AUC) correlate well with each other with excellent R2 values for all data sets analysed. 
However the correlation analysis of log (1/IC50) vs clogP and log (1/IC50) vs δ-values of proton 
showed better fit of the data compared to the SAR of log (1/AUC) vs clogP and log (1/AUC) vs 
the δ-values of proton. This suggests that log (1/IC50) is a better parameter than log (1/AUC) 
when constructing SAR relationships for this class of compounds. Given that log (1/IC50) 
correlates well (R2 = 0.9371) with log (1/AUC) for full data set of 1,4-diene-3-ones, the reason 
for the difference in correlation when comparing each inhibitory parameter with the δ-values 
of proton is unclear and requires further investigation. 
Most of the sub-set of 1,4-diene-3-one analysed for SAR using either log 1/IC50 or log 1/AUC 
demonstrated decreased correlations suggesting that the 1,4-diene-3-one compounds may 
have poly-pharmacological effect (i.e. it may be affecting more than one system). However, 
SAR of the 1,4-diene-3-one compounds also suggests that the β-carbon electron density (or 
lack thereof) is a good predictor of potency. 
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6 General discussions and conclusions  
Over the past twenty years, many pathogenic fungi have developed various forms of 
resistance to currently available clinically used antifungal agents (Chakrabarti, 2011; Cannon 
& Holmes, 2015; Schelenz et al., 2016; Zhao et al., 2016; Canela et al., 2018). Although there 
has been an increase in the number of antifungal agents available both in a class (e.g. 
triazoles) or of novel classes (e.g. echinocandins), the choice of a suitable antifungal agent 
remains limited. This limitation is due to poor pharmacokinetics, pharmacodynamics and 
toxicological profiles of many of the presently used antifungal agents. There is thus an 
increased interest, and need, for the identification of novel drug targets within the mycota, 
along with the development of novel antifungal drug structures targeted to these targets.  
 Using various molecular biological techniques the fungal PM H+-ATPase has been identified 
as a potential antifungal drug target (Portillo, 2000). Although identified as a potential drug 
target some twenty years ago there has been, until recently, very limited attempts to develop 
drugs targeted to this enzyme (Seto-Young et al., 1997; Dao et al., 2016; Kjellerup et al., 2017; 
Tung et al., 2018). The PM H+-ATPase enzyme has been shown to be inhibited by various thiol-
reactive compounds such as maleimides, omeprazole, curcumin, chalcones, ebselen, caffeic 
acid and other α,β-unsaturated carbonyls (Brooker & Slayman, 1982; Monk et al., 1995; 
Manavathu et al., 1999; Batovska et al., 2007; Chan et al., 2007; Dao et al., 2016). An α,β-
unsaturated carbonyl is electrophilic in nature and therefore it is readily attacked by a 
nucleophile. However the cysteine containing antioxidant glutathione commonly prevents 
damage to cellular components by reacting with electrophiles since it contains a sulfhydryl 
group which acts as a nucleophile and attacks the β-carbon of α,β-unsaturated carbonyl 
compounds (Das et al., 2007).  
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The pharmaceutical and agrochemical industries have, over the last two decades, shown 
significant interest in bis(substituted-benzylidene)cycloalkanones as therapeutic and 
agrochemical agents (Amoozadeh et al., 2011). It has also been identified that various enone 
compounds such as styryl ketones, dienones or curcumin exhibit low toxicity to mammalian 
cells (Manavathu et al., 1999; Dao et al., 2016; Kjellerup et al., 2017). The aim of this study 
was to investigate compounds with the potential to inhibit the fungal PM H+-ATPase enzyme 
in the cell. Given the general safety of chalcones and related compounds (Dimmock et al., 
1998; Manavathu et al., 1999) it was decided to synthesize a library of 1,4-diene-3-ones 
containing 33 symmetrical compounds (22a-v, 23a-h, and 24a-c). These compounds were 
synthesized as described in Chapter 2. Certain compounds in the library have a heterocyclic 
ring containing a nitrogen atom either in the aromatic ring present at either the ortho, meta 
or para-position or in the central piperidone ring. The presence of nitrogen atom has shown 
an increase in the amphipathicities of such compounds. 
In this research work, 3,5-bis(3-nitrobenzylidene)-1-methylpiperidin-4-one (22s) and 3,5-
bis(4-nitrobenzylidene)-1-methylpiperidin-4-one (22t) have been successfully synthesized 
using the method described by El-Subbagh et al., (2000). The synthesis of 3,5-bis(2-
nitrobenzylidene)-1-methylpiperidin-4-one has not previously been reported in the literature. 
In this study, various attemps were made to synthesize 3,5-bis(2-nitrobenzylidene)-1-
methylpiperidin-4-one using variations of the Claisen-Schmidt reaction. However, we were 
unsuccessful in synthesizing this compound and the desired product was not obtained. The 
reasons for this are still unclear. 
The inhibitory potencies of the synthesized compounds (22a-v, 23a-h and 24a-c) were 
investigated by conducting in vitro macro-broth susceptibility assays against S. cerevisiae and 
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C. albicans (described in Chapter-3). Significant levels of antifungal activity were seen for most 
of the compounds tested against S. cerevisiae (0.2 to 99% growth inhibition) over the range 
of concentration tested. However, compounds 22a-v, 23a-h and 24a-c exhibited considerably 
less potency when screened against C. albicans although the levels of inhibition displayed still 
covered the range 0 to 99% inhibition. 
Certain compounds (22c, 22e, 22f, 22g, 22m, 22n, 22o, 22r, 22s, 22t, 23b, 23c and 23e-h) 
exhibited very good potency against S. cerevisiae with IC50 values between 0.62 and 9.45 μM 
(Table 3.1, page 105). The higher potency of these compounds is due to the presence of EWG 
at either meta or para-position of the aromatic ring which increases the electrophilicity of the 
β-carbon thus making it more reactive to nucleophiles such as the sulfhydryl of cysteine which 
reacts via a Michael addition reaction (Dao et al., 2016). In addition, compounds 23b, 23c and 
23e-h exhibited high potency due to the presence of pyridine ring. This increase in potency is 
probably due to an increase in solubility in both aqueous and organic systems and thus there 
is a probable increase in the bioavailability of these compounds although this remains to be 
confirmed (Moore et al., 2014). 
Other compounds (22a, 22b, 22d, 22p, 22q, 23a and 23d) were identified as moderate 
inhibitors of S. cerevisiae with their IC50 values ranging from 10 to 100 μM. Most of the 
compounds in this group have electron-donating group attached to the aromatic rings which 
makes the β-carbon less electrophilic and therefore less reactive, except 22q; iodo (EWG), 
23a and 23d that contain pyridine rings. Compound 22q is likely to be less effective than 
bromo or chloro equivalent isomers due to its higher electronegativity. In contrast, 
compounds 22h-l, 22u-v and 24a-b exhibited lower inhibitory activity against S. cerevisiae 
growth (IC50 values >100 μM).  
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The most potent compound identified from the 1,4-diene-3-ones library against S. cerevisiae 
was 3,5-bis(4-trifluoromethylbenzylidene)-1-methylpiperidin-4-one (22n) with the lowest 
IC10, IC25 and IC50 values, these being 0.10, 0.22 and 0.62 μM, respectively. The second, third 
and fourth potent inhibitor of S. cerevisiae cells were 22f, 22s and 22m with their IC50 values 
of 1.21, 1.87 and 2.22 μM, respectively. The IC50 values of compound 22f and 22n showing 
only a two-fold difference in their inhibitory potencies. The presence of a strong EWG (-CF3) 
at the para-position of the aromatic ring of compound (22n) results in an increase in the 
electrophilicity of the β-carbon of this compound. Compound 22n has three fluorine atoms 
whereas 22f contain only a single chlorine atom on the aromatic ring, therefore the increase 
in the electrophilicity of the β-carbon is greater in 22n than 22f. Consequently 22n shows 
higher potency than 22f. 
The inhibitory activity of the para-substituent groups on bis-benzylidene derivatives of N-
methylpiperidin-4-one against S. cerevisiae were shown in Table 6.1, page 211. Compounds 
22n, 22p and 22t contain a strong electron-withdrawing group (EWG) at the para-position of 
the aromatic ring and their Hammett substituent constant (σ) values were 0.54, 0.35 and 0.78 
respectively (Hansch & Leo, 1979). These compounds showed very good IC50 values (0.62, 12.9 
and 3.37 μM) which suggests a relationship between the strength of the EWGs, the associated 
electron densities at the β-carbon atoms of the compound and their antifungal potencies. 
Similarly, compound 22g also gave a good IC50 value (5.56 μM) which contains an EWG (-Cl) 
at the para-position of the aromatic ring. Compound 22g has a low Hammett substituent 
constant (σ) value (0.23) compared to 22n, 22p and 22t.  
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Table 6. 1. Comparison of the inhibitory activity of para substituted bis-benzylidene 
derivatives of N-methylpiperidin-4-ones against S. cerevisiae. 
Compounds R-substituents 
 
Hammett’s 
substituent 
constants 
(σ)  
 IC50 ± SD (μM) 
 
AUC ± SD 
22d -OCH3 -0.27  27.9 ± 18.4  230 ± 16.1  
22g -Cl +0.23  5.56 ± 8.01  160 ± 49.1 
22k -COOH +0.73  218 ± 26.4 299 ± 14.4 
22l -CH3 -0.17  N/R 314 ± 10.5 
22n -CF3 +0.54  0.62 ± 0.26 104 ± 6.73 
22p -OCF3 +0.35  12.9 ± 0.91 180 ± 44.8 
22t -NO2 +0.78  3.37 ± 2.01  146 ± 48.5 
Note: N/R represents that compound did not gave 50% inhibition. 
On the other hand compound 22k, which has a moderate EWG at the para-position of the 
aromatic ring exhibited moderate inhibitory activity (IC50 = 218 μM) although it has a very 
high σ value (0.73). In contrast, compound 22l was unable to inhibit the 50% growth of                     
S. cerevisiae. The presence of an electron-donating group (-CH3) shows a plus inductive (+I) 
effect on the structure resulting in a lack of antifungal activity. Compound 22d contains a 
methoxy group (weak EDG) which shows a negative inductive (-I) effect at the para-position 
and exhibited fairly good inhibitory activity against S. cerevisiae with IC50 value of 27.9 μM. 
The increase in the activity of 22d compare to 22l is due to the presence of a methoxy group 
rather than a methyl group. This shows that the presence of oxygen has some influence on 
the inhibitory activity of this compound. Compound 22d has clogP of 3.98 whereas 22l has 
clogP of 4.67. Speculatively this could be due to an increase in the solubility of 22d as well as 
a negative inductive (-I) effect since oxygen is more electronegative than carbon but a positive 
mesomeric (+M) effect due to the lone pair (Kerber, 2006). 
This suggest a possible mechanism of action of bis-benzylidene derivatives of N-
methylpiperidin-4-one is the interaction of olefinic carbon (β-carbon) with a sulfhydryl (-SH) 
groups present in a cysteine residue of the fungal PM H+-ATPase. The library of synthesized 
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1,4-diene-3-ones will all give rise to the Michael reactions. Due to the highest potency of 
compound 22n, it was selected as an example for the Michael addition reaction mechanism 
with cysteine as shown in Figure 6.1. 
 
Figure 6. 1. A possible mechanism of cysteine and 3,5-(E)-bis-(4-
trifluoromethylbenzylidene)-1-methylpiperidin-4-one (22n) reaction kinetics. 
 
The sulfhydryl group (thiol, -SH) of a cysteine residue present in proteins such as the fungal 
plasma membrane H+-ATPase may form a thio-ether bond by reacting with the α,β-
unsaturated carbonyl group of 3,5-bis-(4-trifluoromethylbenzylidene)-1-methylpiperidin-4-
one (Figure 6.1). The SH group of cysteine acts as a nucleophile (S-) while the β-carbon 
(HC=CHCO group) of 3,5-bis-(4-trifluoromethylbenzylidene)-1-methylpiperidin-4-one acts as 
electrophile. The reaction of cysteine and 3,5-bis-(4-trifluoromethylbenzylidene)-1-
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methylpiperidin-4-one forms a covalent C-S bond and the reaction could thus potentially 
cause an irreversible inhibition of the plasma membrane H+-ATPase as suggested by proton 
pumping experiments described in the chapter 4. 
From the results of macro-broth susceptibility assays of 1,4-diene-3-ones against C. albicans, 
compounds 23f, 23g and 23h exhibited the highest inhibitory activity with IC50 values of 68.5, 
57.6 and 50.7 μM respectively. The higher potency of these compounds is possible associated 
with some degree of promiscuous aggregation because their dose-response curves were 
steep and the associated Hill slopes were high (2.33, 1.45 and 2.21 respectively). Most of the 
compounds were unable to reach 90% inhibition of C. albicans growth. However a few 
compounds demonstrated >90% inhibition of C. albicans growth these being 22a, 22f, 23a-c, 
23f-h and 24a respectively.  
In this study, the inhibitory activities of all compounds tested against C. albicans displayed 
significantly lower potency than miconazole nitrate (IC50 = 0.04 μM). Although certain 
compounds (22f, 22m, 22n, 22o, 22s, and 22t) exhibited good potencies against S. cerevisiae 
(IC50; 1.21, 2.22, 0.62, 2.83, 1.87 and 3.37 μM) due to the presence of EWGs, their activity was 
limited against C. albicans (IC50; 114, 525, 474, 549, 666 and 354 μM). This suggests that the 
inhibitory action of these compounds is probably specific to particular species (e.g.                          
S. cerevisiae) although a range of fungal species need to be screened in order to confirm this 
conclusion. 
The comparative potencies of various 1,4-diene-3-ones against S. cerevisiae and C. albicans 
were compared by using a discrimination ratio of their IC50 and AUC values (Table 6.2, page 
217). The threshold for discrimination ratio between 0 and 2 is generally considered to be 
good. Anything above this value suggests that a compound is less capable of targeting 
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multiple species. The discrimination ratio was obtained by dividing the antifungal activity of 
compounds against C. albicans with the antifungal activity of compounds against S. cerevisiae. 
The discrimination ratio based on the inhibitory action of compounds against S. cerevisiae and 
C. albicans vary significantly in terms of their IC50 values (0.06 to 764). However, the difference 
in the discrimination ratio is far less when comparing their AUC values (0.59 to 3.14). 
Compound 22n exhibited highest potency against S. cerevisiae (IC50 = 0.62 μM) but gave 
moderate potency against C. albicans with the IC50 value of 474 μM therefore the ratio of its 
activity was very high (764.5) indicating that the activity of 22n is limited to particular species. 
Additionally 22n displayed the highest discrimination ratio (3.14) based on its AUC values.  
The difference in the activities of compounds against S. cerevisiae and C. albicans is due to 
differences in the genetic or physiological profiles of these two species. A study conducted by 
Tebung, Choudhury, Tebbji, & Morschhäuser, (2016) described the difference between                     
S. cerevisiae and C. albicans. They used ChIP-chip (Chromatin Immunoprecipitation 
Microarray) analysis to identify the transcriptional profiling of Ppr1 protein and found that in 
S. cerevisiae Ppr1 controls the building of pyrimidines whereas in C. albicans Ppr1 controls the 
degrading of purines. S. cerevisiae can exist either in haploid or diploid variants. In contrast C. 
albicans are dimorphic in nature means C. albicans can change from yeast to hyphae form 
under certain environmental conditions. Therefore it is possible that compounds showing 
good potency against S. cerevisiae may not show similar potency against C. albicans. 
Compounds 22u and 22v displayed low discrimination ratios (1.24 and 0.85) which suggests 
they have the ability to target multiple species. However 22u exhibited low inhibitory 
activities against both S. cerevisiae and C. albicans (IC50 = 1290 and 1604 μM respectively) 
whilst 22v exhibited moderate activities against both S. cerevisiae and C. albicans (IC50 = 263 
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and 309 μM respectively). Similarly, compound 22a has a discrimination ratio of 3.14, which 
can be considered reasonable. Compounds 22a, 22u and 22v have un-substituted aromatic 
rings attached via di-methylene bridge to either piperidine, cyclopentyl or cyclohexyl ring. 
Higher potency of compounds 22a and 22v compared to 22u suggests the influence of central 
six membered ring which adopts more a chair conformation which facilitate an increase in the 
reactivity of molecule to the target enzyme (H+-ATPase) whereas five membered ring 
compound ring is flatter and can’t form chair conformation.   
Compounds 22b, 23f, 23g and 23h gave the discrimination ratios of 9.91, 8.10, 10.4 and 8.11 
respectively, which denotes these compounds have some capacity to inhibit multiple species 
however a 10-fold increase is required in the dose to inhibit the growth of C. albicans cells. 
On the other hand some compounds displayed discrimination ratio between 10 and 100; 
these being 22c, 22d, 22f, 22g, 22p, 22q, 22r, 23a, 23b, 23c and 23g whereas other 
compounds (22e, 22m, 22o, 23d and 23e) displayed very high ratio (100-300) indicating                
S. cerevisiae cells were more susceptible to these group of compounds than C. albicans cells 
and probably could not be taken forward for further development.  
Although the discrimination index of 1 is perfect by comparing one inhibitory parameter (IC50) 
it is insufficient to decide whether to take this compound forward for future drug 
development or not. It would be useful to screen more species to cover a wide variety of types 
(e.g. yeasts or other forms) and that the discrimination ratio for all pairwise combinations or 
all other species compared to one standard species could be generated. Because a compound 
with a discrimination index of 1 is able to target multiple species, compounds with higher 
discrimination indexes are very specific to particular species tested. 
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Nevertheless, when comparing the discrimination ratio of the reference control compound 
miconazole nitrate based on their IC50 and AUC values, its 0.33 and 0.59, which shows a three-
fold difference in its activity against C. albicans over S. cerevisiae. This confirms that 
miconazole is capable of targeting multiple species. Although this would normally not be a 
problem indeed it would be preferred because C. albicans is pathogenic whilst S. cerevisiae is 
only occasionally pathogenic. However, individuals suffering from various cancers or 
immunocompromised individuals are often susceptible to S. cerevisiae and it is becoming an 
opportunistic pathogen and an increase in the clinical dose may be needed. This could lead 
to toxicological problem depending on the therapeutic window of miconazole nitrate. 
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Table 6. 2. Discrimination ratio of the inhibitory activities of various 1,4-diene-3-ones 
against S. cerevisiae and C. albicans. 
Compound 
 
 
C. albicans S. cerevisiae Ratio of C. albicans / 
S. cerevisiae 
IC50 (µM) (AUC) IC50 (µM) (AUC) (IC50) (AUC) 
22a 128 294 40.7 248 3.14 1.19 
22b 532 341 53.7 249 9.91 1.37 
22c 313 329 3.24 144 96.60 2.28 
22d 1112 356 27.9 230 39.86 1.55 
22e 1148 353 3.9 188 294.36 1.88 
22f 114 288 1.21 97.3 94.21 2.96 
22g 309 316 5.56 160 55.58 1.98 
22h N/R 368 154 269 * 1.37 
22i N/R 385 153 289 * 1.33 
22j N/R 383 124 258 * 1.48 
22k N/R 387 218 299 * 1.29 
22l N/R 389 N/R 314 * 1.24 
22m 525 335 2.22 138 236.49 2.43 
22n 474 327 0.62 104 764.52 3.14 
22o 549 329 2.83 176 193.99 1.87 
22p 409 314 12.9 180 31.71 1.74 
22q 454 321 21.4 221 21.21 1.45 
22r 243 302 7.64 196 31.81 1.54 
22s 666 316 1.87 125 356.15 2.53 
22t 354 319 3.37 146 105.04 2.18 
22u 1604 372 1290 321 1.24 1.16 
22v 263 327 309 314 0.85 1.04 
23a 367 329 12.6 208 29.13 1.58 
23b 238 320 8.84 194 26.92 1.65 
23c 249 314 9.45 194 26.35 1.62 
23d 2196 386 20.3 231 108.18 1.67 
23e 1493 379 9.29 207 160.71 1.83 
23f 68.5 279 8.46 194 8.10 1.44 
23g 57.6 273 5.52 164 10.43 1.66 
23h 50.7 261 6.25 178 8.11 1.47 
24a 138 288 2233 315 0.06 0.91 
24b N/R 369 619 319 * 1.16 
24c 334 312 N/R 328 * 0.95 
4 0.04 25.3 0.12 43 0.33 0.59 
Note: Data were displayed as the mean of three (S. cerevisiae) and two (C. albicans) individual experiments each 
conducted in duplicates. N/R represents compounds not reaching 50% inhibition. *means ratio not calculated.
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Subsequent to these studies, it is necessary to identify the possible mechanisms of action of 
1,4-diene-3-one compounds. It is possible that these compounds act on various cellular 
targets accessible either externally due to presence of EWG or certain compounds containing 
pyridine rings which may penetrate the cell membrane and cytoplasmically inhibit the                
H+-ATPase enzyme by forming a thio-ether bond with cysteine residue of H+-ATPase. Several 
authors have reported that NEM and other α,β-unsaturated carbonyls inhibited the                     
H+-ATPase (Brooker & Slayman, 1982; Kongstad et al., 2014; Tung et al., 2018). The goal of 
this research work was to examine compounds with the ability to inhibit the fungal PM             
H+-ATPase enzyme. 
Therefore, a library of 1,4-diene-3-ones was investigated to identify the possible mechanisms 
of action by measuring the glucose-induced acidification of the extracellular medium of                 
S. cerevisiae using a modification of the method described by Ben-Josef et al., (2000). Ben-
Josef et al., (2000) have studied the effect of CAN-296 (a complex carbohydrate isolated from 
the cell wall of Mucor rouxii) on C. albicans, C. krusei, C. glabrata, C. guilliermondii and                      
S. cerevisiae. The effect of 1,4-diene-3-ones on H+-ATPase mediated proton pumping by intact 
cells of S. cerevisiae was conducted by measuring the change in pH of the external medium 
(detailed in Chapter 4). Interestingly within 10 minutes of medium acidification, the steady 
state of proton flux (JH+in = JH+out) has been achieved by bis-pyridylidene derivatives of                  
N-methylpiperidin-4-one (23a-c, 60 µM) while most of the other compounds from the library 
reached a steady state after about 15 mins after medium acidification was initiated. This 
suggests compounds (23a-c) penetrate the cell membrane and makes the membrane leaky 
thus inhibits the H+-ATPase.  
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Certain compounds with strong EWGs (22f; meta-chloro, 22g; para-chloro and 22s; meta-
nitro, 22t; para-nitro) exhibited good potency by inhibiting the H+ pumping ability of                       
S. cerevisiae. The presence of a powerful EWG will make the compound more reactive to all 
nucleophiles however that external and PM nucleophiles/SH groups will be the first to come 
into contact with the drug. As these compounds block the formation of transmembrane 
electrochemical proton gradient by inhibiting the PM H+-ATPase enzyme they were termed 
‘membrane active antifungal agents’. On the basis of SAR study of log (1/IC50) vs δ-values of 
proton on the β-carbon plots of the initial activity it is believed that these compounds most 
likely interact with membrane associated cysteines possibly at or close to the omeprazole 
binding site. However further experiments need to be conducted to confirm this statement. 
These compounds form a covalent C-S bond with a cysteine residue within the protein which 
results in the inhibition of the H+-ATPase. In order uniquely prove this, it will be necessary to 
both purify and assay the enzyme along with determining the residue that is modified using 
e.g. MALDI-MS (Matrix-assisted laser desorption ionization mass spectrometry). 
The bis-thienylidene derivatives of N-methylpiperidin-4-one and cycloalkanones (24a, 24b 
and 24c), and the bis-pyridylidene derivatives of cyclopentanone (23d-f) were not effective 
inhibitors of H+ pumping by S. cerevisiae. This result was consistent with the susceptibility 
assays against S. cerevisiae that also gave very poor inhibition for these above-mentioned 
compounds. 
When comparing the inhibitory activity of compounds from susceptibility assays with the H+ 
extrusion assay there was some differences in their comparative potencies. For example, 
compounds (22c, 22m, 22n and 22o) exhibited good potency against S. cerevisiae with low 
micromolar range of the IC50 values. However these compounds were less effective at 
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inhibiting proton pumping by S. cerevisiae. A possible reason for this difference is due to 
variations in the time period of the experiment. The H+ extrusion assay was conducted only 
for 1.5 hours (60 mins pre-incubating cells with test compound followed by 30 mins of pH 
measurement subsequent to the addition of glucose) whereas the susceptibility assay was 
performed over a 24-hour duration. This difference in time period possibly gives rise to a 
greater ability to have multiple targeting effects. 
The H+ extrusion assay is associated with the initial part of metabolism prior to the significant 
production of glycolytic intermediates while the macro-broth susceptibility assay occurs over 
24 hours (Roos & Luckner, 1984). Therefore the compounds have more time to interact with 
other enzymes in the growth assay. It is possible that some compounds need a longer time 
period to interact with cellular constituents to exhibit their full potency which may be due to 
a polypharmacological effect rather than to targeting a single enzyme.  
In this study, certain compounds have displayed good potency against S. cerevisiae in macro-
broth susceptibility assay, exhibiting IC50 values in the low μM range (1-10 μM). However, 
when compared to miconazole they were still considerably less active.  
A 60 μM (one point) assay is a standard protocol for primary screening of compound libraries 
in drug discovery and on this basis the inhibitory activity of a library of 1,4-diene-3-ones on 
H+ pumping of S. cerevisiae was investigated. A 60 μM concentration is also commonly 
employed in single concentration high throughput screening systems (McGovern et al., 2002). 
Only a few compounds gave full inhibition of H+ pumping by S. cerevisiae within 10 mins of 
pump activation. 
Low IC50 values for compounds 22f, 22m, 22n and 22s against S. cerevisiae in macro-broth 
susceptibility assays make the pharmacophore (1,4-diene-pentan-3-one) a useful fragment to 
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integrate into a more site-targeted molecule. Additionally certain compounds with pyridine 
rings such as 23a, 23b and 23c exhibited the highest capacity to inhibit H+ pumping in                   
S. cerevisiae. Additionally, in macro-broth susceptibility assays, these compounds exhibited 
good activity against S. cerevisiae (IC50 = 12.6, 8.84 and 9.45 µM respectively) but only low to 
moderate activity against C. albicans (IC50 = 367, 238 and 249 µM). This suggests that the 
pyridine (or pyrazine or pyrimidine) ring structure might be a useful fragment to include in 
future molecules due to their ability to increase the amphipathic nature of the molecule and, 
even possibly with the pyrimidine structure, to increase specificity towards ATP binding 
proteins. 
The current studies reveal that the presence of an amphipathic group, such as pyridine, in 
1,4-diene-3-ones gives rise to an increase in the solubility of the compounds. It can reasonably 
be suggested that the ability of the 1,4-diene-3-ones to act as antifungals by inhibiting the 
growth of yeast (S. cerevisiae) and to inhibit the efflux of protons from the cell is associated 
with their inhibitory effects on the PM H+-ATPase. It is therefore useful to compare the 
antifungal activities of these compounds with their electrophilic and lipophilic properties. This 
can be achieved by performing both basic and complex structure-activity studies.  
The preliminary structure-activity analysis of 1,4-diene-3-ones indicated that the electrophilic 
nature of the β-carbon of compounds (generated from data containing all or subsets of 31 
compounds; 22a-k, 22m-v, 23a-h and 24a-b) is a significant contributor for its antifungal 
activity. The structure-activity analysis of various bis-benzylidene derivatives of N-
methylpiperidin-4-one suggested that the potency of this group of compounds (22a-k and 
22m-v) is dependent on their electronic property rather than their lipophilic property. The 
presence of strong EWGs at either meta or para-position increases the electrophilicity of the 
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β-carbon of these compounds (22a, 22c-d, 22f-g, 22k, 22m-p and 22r-t). However, SAR 
analysis of bis-pyridylidene derivatives of both N-methylpiperidin-4-one and cycloalkanones 
(23a-h) indicated that potencies of these compounds is dependent on their lipophilic rather 
than the electrophilic property. This could be possibly due to lower clogP values of this group 
of compounds or less data points included in SAR (8 compounds were analysed, which is very 
low) or that the data obtained for this group of compounds are unexpected and may be 
aberrant (Hansch & Leo, 1979). 
The results obtained from this study suggests that the interaction of the synthesized 
compound with the fungal plasma membrane is, by itself, insufficient for complete inhibition 
of the H+-ATPase enzyme. However, these 1,4-diene-3-ones can be considered as lead 
compounds which will aid further optimization towards highly selective H+-ATPase inhibitors 
as a new class of antifungal agents and aiding in the drug design process. Compounds 
containing the 1,4-diene-3-one pharmacophore targeting the membrane segment would not 
have to cross the plasma membrane. Hence these compounds will not be susceptible to the 
action of multidrug resistance pumps such as ABC efflux pump, which act to pump drugs out 
from the cell. Alternatively molecules or drugs which have a better aqueous or organic 
solubility profile, along with a high specificity for the nucleotide binding site of the H+-ATPase 
would be a useful development. 
In conclusion, this work has produced a set of probes which has helped to define some of the 
parameters required to design a molecule targeting the plasma membrane H+-ATPase and 
which could possibly be included in such a future covalent drug acting to possibly eliminate a 
fungal infection.  
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7 Speculations on future work and development  
The encouraging results from this study suggest it may be useful to synthesize further 
compounds. These could include structures asymmetric around the 1,4-diene-3-one 
pharmacophore and/ or to introduce such structures into site-targeted compounds such as 
molecules targeted to the nucleotide-binding site or to the omeprazole binding site of the H+-
ATPase. For example, introduction of the most potent group (e.g. -CF3) on one side of the 
aromatic ring whilst also introducing a nitrogen-containing aromatic ring (e.g. pyridine) on the 
other side of the 1,4-diene-3-one pharmacophore could be useful. Such changes could 
potentially increase both the overall solubility and permeability of the compound across the 
plasma membrane and the specificity towards nucleotide binding sites thus hopefully its 
potency against the H+-ATPase.  
A potential problem of using this pharmacophore (1,4-diene-3-one) is that it may not be 
sufficiently specific to the fungal plasma membrane H+-ATPase. Therefore, other possibilities 
include altering the pharmacophore such that it can have different levels of reactivity to 
different cysteine sulfhydryls. For example, it might be possible to synthesize some 
compounds which could possibly initially act as prodrugs, which are then activated to an 
enone by a reverse Michael reaction to form the active drug which would finally react at the 
target site. It might therefore be possible to synthesize some compounds which could act as 
reverse Michael reactors, which can act as prodrugs facilitating the generation of an α,β-
unsaturated enone from a compound which already contains a carbonyl group but having a 
good leaving group beta to the carbonyl, such as chloro or trimethyl ammonium (Figure 7.1). 
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Figure 7. 1. A potential example of the mechanism for a reverse Michael reaction. 
 
Moreover, compounds containing the 1,4-diene-3-one pharmacophore have the potential to 
target sulfhydryl (-SH) groups at multiple sites of interaction on the ATPase, such as the 
omeprazole binding site in the membrane segment (M1/M2) as well as the nucleotide binding 
site.  
Additionally, it would be useful to model the plasma membrane H+-ATPase enzyme in 3D and 
to prepare both open and closed (E1/E2) models using the Ca2+-ATPase or other P-type 
ATPases of known 3D structures (Griffiths and Kirton, unpublished data).  
Molecular modelling coupled with developing further quantitative structure-activity 
relationships will need to be performed in order to improve the preliminary pharmacophore 
model. In silico compound screening against 3D structures of the open (E1) and closed (E2) 
forms of the H+-ATPase and other P-type ATPases such as Na+/K+, Ca2+, Cu2+ and H+/K+-ATPase 
could be performed in order to maximise the levels of discrimination between the PMA H+-
ATPase and other P-type ATPase enzyme. Hopefully this would help to minimise the potential 
toxicity of future molecules.  
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There is also need to consider the potential effects of novel compounds on membrane 
stability particularly within the host cells and to study the action of the compounds on lipid 
and membrane stability. Moreover, it is essential to perform further experiments to examine 
the integrity of the cytoplasmic membrane in the presence of 1,4-diene-3-ones in the intact 
cells by studying the leakage rate of fluorescent molecules such as Rhodamine 123 from 
preloaded cells with or without drug over time (De Cesco et al., 2017). 
In both the design and screening of future compounds, it would be useful to have significant 
amount of easily produced H+-ATPase enzyme. Although this enzyme has been extracted and 
purified previously from various fungi and plants, yields were not high (Ben-Josef et al., 2000; 
Dao et al., 2016). Previous attempts by other workers to produce the whole recombinant 
protein in Escherichia coli were unsuccessful (Rosano & Ceccarelli, 2014). This could possibly 
be due the ATPase acting as a toxic protein due to the high rates of ATP hydrolysis and thus 
pumping protons out of the E. coli cell (Rosano & Ceccarelli, 2014). This could potentially 
deplete the ATP concentration, especially at high ATPase expression levels. However, recent 
work has shown that it is possible to express the cytoplasmic ATP hydrolysing domain as a 
soluble recombinant protein in E. coli (Dylan Patel and D. Griffiths, unpublished data). This 
may potentially lead to a high throughput screening system based on a soluble ATPase 
fragment. 
Finally, it may be possible to improve the specificity or selectivity by including a 
phosphoramidate structure (Figure 7.2). Such structures are found in drugs used in the 
treatment of osteoporosis (Gledhill et al., 2007). More recently various diphenylphosphane 
derivatives of antifungal drugs has been synthesized having both oxyphosphate (P=O) or 
thiophosphate (P=S) centres (de Almeida et al., 2019).  
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Figure 7. 2. A potential example of attachment of dienone or phosphoramidate to the ATP. 
 
A study by Kappler & Hampton (1990) has shown that it is possible to actually design ATP 
analogs by introducing non-hydrolysable groups that would potentially increases the 
selectivity for different enzymes such as thymidine kinase, adenylate kinase, pyruvate kinase 
or methionine adenosyltransferase, etc. This can be achieved either by replacing/modifying 
the nitrogen atom on the adenine ring of ATP or by modifying the triphosphate group to 
introduce either phosphoramidate or replacing the oxygen with CH2 or NH groups. The 
phosphoramidate structure of ATP molecule are not hydrolysable so in theory, if 1,4-diene-3-
one pharmacophore were coupled with one or other of two hydroxyl groups in the ribose (via 
a dehydration reaction). Alternatively either (di)enone or reverse Michael group could be 
introduced at positions labelled ‘A’ in Fig 7.2 where they might be placed would depend on 
the relationship of the nucleotide binding site cysteine to the various parts of the ATP 
molecule. 
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Appendix 1 - Full spectra of synthesized dienones 
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Compound 22b 
Proton spectrum of 3,5-bis[(E)-2-methoxybenzylidene]-1-methylpiperidin-4-one (22b)
N
CH3
O O
CH3
O
CH3
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
0
0.25
0.50
0.75
1.00
A
b
s
o
lu
te
 I
n
te
n
s
it
y
3.004.086.174.162.032.042.00
2
.3
7
3
.6
5
3
.6
6
3
.8
4
6
.9
0
6
.9
0
6
.9
2
6
.9
6
6
.9
6
7
.1
8
7
.2
07
.2
5
7
.3
38
.0
5
Carbon spectrum of 3,5-bis[(E)-2-methoxybenzylidene]-1-methylpiperidin-4-one (22b)
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Compound 22c 
Proton spectrum of 3,5-bis[(E)-3-methoxybenzylidene]-1-methylpiperidin-4-one (22c)
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Carbon spectrum of 3,5-bis[(E)-3-methoxybenzylidene]-1-methylpiperidin-4-one (22c)
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Compound 22d 
Proton spectrum of 3,5-bis[(E)-4-methoxybenzylidene]-1-methylpiperidin-4-one (22d)
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Carbon spectrum of 3,5-bis[(E)-4-methoxybenzylidene]-1-methylpiperidin-4-one (22d)
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Compound 22e 
Proton spectrum of 3,5-bis[(E)-2-chlorobenzylidene]-1-methylpiperidin-4-one (22e)
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Carbon spectrum of 3,5-bis[(E)-2-chlorobenzylidene]-1-methylpiperidin-4-one (22e)
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Compound 22f 
Proton spectrum of 3,5-bis[(E)-3-chlorobenzylidene]-1-methylpiperidin-4-one (22f)
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Carbon spectrum of 3,5-bis[(E)-3-chlorobenzylidene]-1-methylpiperidin-4-one (22f)
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Compound 22g 
Proton spectrum of 3,5-bis[(E)-4-chlorobenzylidene]-1-methylpiperidin-4-one (22g)
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Carbon spectrum of 3,5-bis[(E)-4-chlorobenzylidene]-1-methylpiperidin-4-one (22g)
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Compound 22h 
Proton spectrum of 3,5-bis[(E)-2,4-dichlorobenzylidene]-1-methylpiperidin-4-one (22h)
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Carbon spectrum of 3,5-bis[(E)-2,4-dichlorobenzylidene]-1-methylpiperidin-4-one (22h)
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Compound 22i 
Proton spectrum of 3,5-bis[(E)-3,4-dichlorobenzylidene]-1-methylpiperidin-4-one (22i)
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Carbon spectrum of 3,5-bis[(E)-3,4-dichlorobenzylidene]-1-methylpiperidin-4-one (22i)
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Compound 22j 
Proton spectrum of 2,2'-((1E,1'E)-(1-methyl-4-oxopiperidine-3,5-diylidene)bis(methaneylylidene))dibenzoic acid (22j)
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Compound 22k 
Proton spectrum of 4,4'-((1E,1'E)-(1-methyl-4-oxopiperidine-3,5-diylidene)bis(methaneylylidene))dibenzoic acid (22k)
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Compound 22l 
Proton spectrum of 3,5-bis[(E)-4-methylbenzylidene]-1-methylpiperidin-4-one (22l)
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Carbon spectrum of 3,5-bis[(E)-4-methylbenzylidene]-1-methylpiperidin-4-one (22l)
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Compound 22m 
Proton spectrum of 3,5-bis[(E)-3-trifluoromethylbenzylidene]-1-methylpiperidin-4-one (22m)
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Carbon spectrum of 3,5-bis[(E)-3-trifluoromethylbenzylidene]-1-methylpiperidin-4-one (22m)
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Compound 22n 
Proton spectrum of 3,5-bis[(E)-4-trifluoromethylbenzylidene]-1-methylpiperidin-4-one (22n)
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Compound 22o 
Proton spectrum of 3,5-bis[(E)-3-trifluoromethoxybenzylidene]-1-methylpiperidin-4-one (22o)
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Carbon spectrum of 3,5-bis[(E)-3-trifluoromethoxybenzylidene]-1-methylpiperidin-4-one (22o)
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Compound 22p 
Proton spectrum of 3,5-bis[(E)-4-trifluoromethoxybenzylidene]-1-methylpiperidin-4-one (22p)
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Carbon spectrum of 3,5-bis[(E)-4-trifluoromethoxybenzylidene]-1-methylpiperidin-4-one (22p) 
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Compound 22q 
Proton spectrum of 3,5-bis[(E)-2-iodobenzylidene]-1-methylpiperidin-4-one (22q)
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Carbon spectrum of 3,5-bis[(E)-2-iodobenzylidene]-1-methylpiperidin-4-one (22q)
N
CH3
OI I
220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
A
b
so
lu
te
 In
te
n
si
ty
4
5
.5
6
5
6
.5
1
7
6
.7
8
7
7
.1
0
7
7
.4
0
1
0
0
.5
9
1
2
7
.9
3
1
2
9
.6
6
1
3
0
.1
1
1
3
3
.6
2
1
3
9
.0
7
1
3
9
.6
6
1
4
0
.4
9
1
8
5
.9
7
 
Appendix 1 Full spectra of synthesized dienones 
 
258 
 
Compound 22r 
Proton spectrum of 3,5-bis[(E)-3-iodobenzylidene]-1-methylpiperidin-4-one (22r)
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Carbon spectrum of 3,5-bis[(E)-3-iodobenzylidene]-1-methylpiperidin-4-one (22r)
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Compound 22s 
Proton spectrum of 3,5-bis[(E)-3-nitrobenzylidene]-1-methylpiperidin-4-one (22s)
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Carbon spectrum of 3,5-bis[(E)-3-nitrobenzylidene]-1-methylpiperidin-4-one (22s)
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Compound 22t 
Proton spectrum of 3,5-bis[(E)-4-nitrobenzylidene]-1-methylpiperidin-4-one (22t)
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Carbon spectrum of 3,5-bis[(E)-4-nitrobenzylidene]-1-methylpiperidin-4-one (22t)
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Compound 22u 
Proton spectrum of 2,5-bis[(E)-benzylidene]cyclopentan-1-one (22u)
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Carbon spectrum of 2,5-bis[(E)-benzylidene]cyclopentan-1-one (22u)
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Compound 22v 
Proton spectrum of 2,6-bis[(E)-benzylidene]cyclohexan-1-one (22v)
O
12 11 10 9 8 7 6 5 4 3 2 1 0 -1 -2
Chemical Shift (ppm)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
A
b
s
o
lu
te
 I
n
te
n
s
it
y
2.004.122.064.274.192.00
1
.7
9
2
.9
3
7
.2
5
7
.3
3
7
.4
0
7
.4
5
7
.8
0
Carbon spectrum of 2,6-bis[(E)-benzylidene]cyclohexan-1-one (22v)
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Compound 23a 
Proton spectrum of (3E,5E)-1-methyl-3,5-bis(pyridin-2-ylmethylene)piperidin-4-one (23a)
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Carbon spectrum of (3E,5E)-1-methyl-3,5-bis(pyridin-2-ylmethylene)piperidin-4-one (23a)
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Compound 23b 
Proton spectrum of (3E,5E)-1-methyl-3,5-bis(pyridin-3-ylmethylene)piperidin-4-one (23b)
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Carbon spectrum of (3E,5E)-1-methyl-3,5-bis(pyridin-3-ylmethylene)piperidin-4-one (23b)
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Compound 23c 
Proton spectrum of (3E,5E)-1-methyl-3,5-bis(pyridin-4-ylmethylene)piperidin-4-one (23c)
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Carbon spectrum of (3E,5E)-1-methyl-3,5-bis(pyridin-4-ylmethylene)piperidin-4-one (23c)
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Compound 23d 
Proton spectrum of (2E,5E)-2,5-bis(pyridin-2-ylmethylene)cyclopentan-1-one (23d)
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Carbon spectrum of (2E,5E)-2,5-bis(pyridin-2-ylmethylene)cyclopentan-1-one (23d)
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Compound 23e 
Proton spectrum of (2E,5E)-2,5-bis(pyridin-3-ylmethylene)cyclopentan-1-one (23e)
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Compound 23f 
Proton spectrum of (2E,5E)-2,5-bis(pyridin-4-ylmethylene)cyclopentan-1-one (23f)
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Carbon spectrum of (2E,5E)-2,5-bis(pyridin-4-ylmethylene)cyclopentan-1-one (23f)
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Compound 23g 
Proton spectrum of (2E,6E)-2,6-bis(pyridin-3-ylmethylene)cyclohexan-1-one (23g)
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Carbon spectrum of (2E,6E)-2,6-bis(pyridin-3-ylmethylene)cyclohexan-1-one (23g)
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Compound 23h 
Proton spectrum of (2E,6E)-2,6-bis(pyridin-4-ylmethylene)cyclohexan-1-one (23h)
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Carbon spectrum of (2E,6E)-2,6-bis(pyridin-4-ylmethylene)cyclohexan-1-one (23h)
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Compound 24a 
Proton spectrum of (3E,5E)-1-methyl-3,5-bis(thiophen-2-ylmethylene)piperidin-4-one (24a)
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Compound 24b 
Proton spectrum of (2E,5E)-2,5-bis(thiophen-2-ylmethylene)cyclopentan-1-one (24b)
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Carbon spectrum of (2E,5E)-2,5-bis(thiophen-2-ylmethylene)cyclopentan-1-one (24b)
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Compound 24c 
Proton spectrum of (2E,6E)-2,6-bis(thiophen-2-ylmethylene)cyclohexan-1-one (24c)
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Carbon spectrum of (2E,6E)-2,6-bis(thiophen-2-ylmethylene)cyclohexan-1-one (24c)
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Appendix 2 List of synthesized 1,4-diene-3-ones with their chemical 
names, structures and molecular weight  
Table 7. 1. Appendix. List of synthesized 1,4-diene-3-ones with detailed information about 
their chemical structures, chemical names and molecular weight. 
Compound 
numbers 
Compound structures Chemical names Molecular 
weight 
22a 
 
3,5-bis[(E)-(benzylidene)]-1-
methylpiperidin-4-one 
289.37 
22b 
 
3,5-bis[(E)-(2-
methoxybenzylidene)]-1-
methylpiperidin-4-one 
349.43 
22c 
 
3,5-bis[(E)-(3-
methoxybenzylidene)]-1-
methylpiperidin-4-one 
349.43 
22d 
 
3,5-bis[(E)-(4-
methoxybenzylidene)]-1-
methylpiperidin-4-one 
349.43 
22e 
 
3,5-bis[(E)-(2-chlorobenzylidene)]-
1-methylpiperidin-4-one 
358.26 
22f 
 
3,5-bis[(E)-(3-chlorobenzylidene)]-
1-methylpiperidin-4-one 
358.26 
22g 
 
3,5-bis[(E)-(4-chlorobenzylidene)]-
1-methylpiperidin-4-one 
358.26 
22h 
 
3,5-bis[(E)-(2,4-
dichlorobenzylidene)]-1-
methylpiperidin-4-one 
427.15 
22i 
 
3,5-bis[(E)-(3,4-
dichlorobenzylidene)]-1-
methylpiperidin-4-one 
427.15 
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22j 
 
2,2’-((1E,1’E)-(1-methyl-4-
oxopiperidine-3,5-
diylidene)bis(methaneylylidene))-
dibenzoic acid 
377.41 
22k 
 
4,4’-((1E,1’E)-(1-methyl-4-
oxopiperidine-3,5-
diylidene)bis(methaneylylidene))-
dibenzoic acid 
377.41 
22l 
 
3,5-bis[(E)-(4-
methylbenzylidene)]-1-
methylpiperidin-4-one 
317.43 
22m 
 
3,5-bis[(E)-(3-
trifluoromethylbenzylidene)]-1-
methylpiperidin-4-one 
425.37 
22n 
 
3,5-bis[(E)-(4-
trifluoromethylbenzylidene)]-1-
methylpiperidin-4-one 
425.37 
22o 
 
3,5-bis[(E)-(3-
trifluoromethyoxybenzylidene)]-
1-methylpiperidin-4-one 
457.30 
22p 
 
3,5-bis[(E)-(4-
trifluoromethyoxybenzylidene)]-
1-methylpiperidin-4-one 
457.30 
22q 
 
3,5-bis[(E)-(2-iodobenzylidene)]-
1-methylpiperidin-4-one 
540.84 
22r 
 
3,5-bis[(E)-(3-iodobenzylidene)]-
1-methylpiperidin-4-one 
540.84 
22s 
 
3,5-bis[(E)-(3-nitrobenzylidene)]-
1-methylpiperidin-4-one 
379.04 
22t 
 
3,5-bis[(E)-(4-nitrobenzylidene)]-
1-methylpiperidin-4-one 
379.04 
22u 
 
2,5-bis[(E)-
(benzylidene)]cyclopentan-1-one 
260.12 
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22v 
 
2,6-bis[(E)-
(benzylidene)]cyclohexan-1-one 
274.14 
23a 
 
(3E,5E)-1-methyl-3,5-bis(pyridin-
2-ylmethylene)piperidine-4-one 
291.35 
23b 
 
(3E,5E)-1-methyl-3,5-bis(pyridin-
3-ylmethylene)piperidine-4-one 
291.35 
23c 
 
(3E,5E)-1-methyl-3,5-bis(pyridin-
4-ylmethylene)piperidine-4-one 
291.35 
23d 
 
(2E,5E)-2,5-bis(pyridin-2-
ylmethylene)cyclopentan-1-one 
262.31 
23e 
 
(2E,5E)-2,5-bis(pyridin-3-
ylmethylene)cyclopentan-1-one 
262.31 
23f 
 
(2E,5E)-2,5-bis(pyridin-4-
ylmethylene)cyclopentan-1-one 
262.31 
23g 
 
(2E,6E)-2,6-bis(pyridin-3-
ylmethylene)cyclohexan-1-one 
276.33 
23h 
 
(2E,6E)-2,6-bis(pyridin-4-
ylmethylene)cyclohexan-1-one 
276.33 
24a 
 
(3E,5E)-1-methyl-3,5-
bis(thiophen-2-
ylmethylene)piperidin-4-one 
301.42 
24b 
 
(2E,5E)-2,5-bis(thiophen-2-
ylmethylene)cyclopentan-1-one 
272.38 
24c 
 
(2E,6E)-2,6-bis(thiophen-2-
ylmethylene)cyclohexan-1-one 
286.41 
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